Human Papillomavirus and Related Diseases Report

CHINA

Version posted at www.hpvcentre.net on 10 March 2023

Copyright and Permissions

©ICO/IARC Information Centre on HPV and Cancer (HPV Information Centre) 2023

All rights reserved. HPV Information Centre publications can be obtained from the HPV Information Centre Secretariat, Institut Català d'Oncologia, Avda. Gran Via de l'Hospitalet, 199-203 08908 L'Hospitalet del Llobregat (Barcelona) Spain. E-mail: hpvcentre@iconcologia.net. Requests for permission to reproduce or translate HPV Information Centre publications - whether for sale or for non-commercial distribution- should be addressed to the HPV Information Centre Secretariat, at the above address. Any digital or printed publication of the information provided in the web site should be accompanied by an acknowledgment of HPV Information Centre as the source.

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part the HPV Information Centre concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers products does not imply that they are endorsed or recommended the HPV Information Centre in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. All reasonable precautions have been taken by the HPV Information Centre to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the HPV Information Centre be liable for damages arising from its use.

Recommended citation:

Bruni L, Albero G, Serrano B, Mena M, Collado JJ, Gómez D, Muñoz J, Bosch FX, de Sanjosé S. ICO/IARC Information Centre on HPV and Cancer (HPV Information Centre). Human Papillomavirus and Related Diseases in China. Summary Report 10 March 2023. [Date Accessed]

ICO
Institut Català d'Oncologia

Executive summary

Human papillomavirus (HPV) infection is now a well-established cause of cervical cancer and there is growing evidence of HPV being a relevant factor in other anogenital cancers (anus, vulva, vagina and penis) and head and neck cancers. HPV types 16 and 18 are responsible for about 70% of all cervical cancer cases worldwide. HPV vaccines that prevent against HPV 16 and 18 infection are now available and have the potential to reduce the incidence of cervical and other anogenital cancers.

This report provides key information for China on cervical cancer, other anogenital cancers and head and neck cancers, HPV-related statistics, factors contributing to cervical cancer, cervical cancer screening practices, and HPV vaccine introduction. The report is intended to strengthen the guidance for health policy implementation of primary and secondary cervical cancer prevention strategies in the country.

Table 1: Key Statistics

Population			
Women at risk for cervical cancer (Female population aged >=15 yrs)			582.4 million
Burden of cervical cancer and other HPV-related cancers			
Annual number of cervical cancer cases			109741
Annual number of cervical cancer deaths			59060
Crude incidence rates per 100,000 population:		Male	Female
	Cervical cancer	-	15.6
	Anal cancer	0.34	0.33
	Vulva cancer	-	0.47
	Vaginal cancer	-	0.23
	Penile cancer	0.62	-
	Oropharyngeal cancer	0.59	0.17
	Oral cavity cancer	2.50	1.64
	Laryngeal cancer	3.49	0.46
Burden of cervical HPV infection			
Prevalence (%) of HPV 16 and/or HPV 18 among women with:			
	Normal cytology		3.8
	Low-grade cervical lesions (LSIL/CIN-1)		22.3
	High-grade cervical lesions (HSIL/CIN-2/CIN-3/CIS)		44.1
	Cervical cancer		69.1
Other factors contributing to cervical cancer			
Smoking prevalence (%) [95% UI], women			2.20 [1.70-2.70]
Total fertility rate (live births per women)			1.6
Oral contraceptive use (%)			1.20
HIV prevalence (%) [95% UI], women (15-49 years)			- [—]
Sexual behaviour			
Percentage of 15-year-old who have had sexual intercourse (men/women)			-/-
Range of median age at first sexual intercourse (men/women)			-/17.0-23.0
Cervical screening practices and recommendations			
Existence of official national recommendations			Yes
Starting year of current recommendations			2019
Active invitation to screening			No
Screening ages (years), primary screening test used, and screening interval or frequency of screenings			35-64 (cytology or HPV test and VIA, 3 years)
HPV vaccine in females			
HPV vaccination programme			-
Year of introduction			-
Year of estimation of HPV vaccination coverage			-
HPV coverage – first dose (%)			-
HPV coverage – last dose (%)			-

* Please see the specific sections for more information.

Contents

Executive summary iii

1 Introduction 2

2 Demographic and socioeconomic factors 4

3 Burden of HPV related cancers 5
3.1 HPV related cancers incidence . . . 5
3.2 HPV related cancers mortality . . . 7
3.3 Cervical cancer . . . 9
3.3.1 Cervical cancer incidence in China . . . 9
3.3.2 Cervical cancer incidence by histology in China . . . 13
3.3.3 Cervical cancer mortality in China . . . 15
3.3.4 Cervical cancer incidence and mortality comparison in China . . . 17
3.4 Anogenital cancers other than the cervix . . . 19
3.4.1 Anal cancer . . . 19
3.4.1.1 Anal cancer incidence in China . . . 19
3.4.1.2 Anal cancer mortality in China . . . 21
3.4.1.3 Anal cancer incidence and mortality comparison in China . . . 23
3.4.2 Vulva cancer . . . 24
3.4.2.1 Vulva cancer incidence in China . . . 24
3.4.2.2 Vulva cancer mortality in China . . . 26
3.4.2.3 Vulva cancer incidence and mortality comparison in China . . . 28
3.4.3 Vaginal cancer . . . 29
3.4.3.1 Vaginal cancer incidence in China . . . 29
3.4.3.2 Vaginal cancer mortality in China . . . 31
3.4.3.3 Vaginal cancer incidence and mortality comparison in China . . . 33
3.4.4 Penile cancer . . . 34
3.4.4.1 Penile cancer incidence in China . . . 34
3.4.4.2 Penile cancer mortality in China . . . 36
3.4.4.3 Penile cancer incidence and mortality comparison in China . . . 38
3.5 Head and neck cancers . . . 39
3.5.1 Oropharyngeal cancer . . . 39
3.5.1.1 Oropharyngeal cancer incidence in China . . . 39
3.5.1.2 Oropharyngeal cancer mortality in China . . . 41
3.5.1.3 Oropharyngeal cancer incidence and mortality comparison in China . . . 43
3.5.2 Oral cavity cancer . . . 44
3.5.2.1 Oral cavity cancer incidence in China . . . 44
3.5.2.2 Oral cavity cancer incidence and mortality comparison in China . . . 46
3.5.2.3 Oral cavity cancer incidence and mortality comparison in China . . . 48
3.5.3 Laryngeal cancer . . . 49
3.5.3.1 Laryngeal cancer incidence in China . . . 49
3.5.3.2 Laryngeal cancer incidence and mortality comparison in China . . . 51
3.5.3.3 Laryngeal cancer incidence and mortality comparison in China . . . 53

4 HPV related statistics 54
4.1 HPV burden in women with normal cervical cytology, cervical precancerous lesions or invasive cervical cancer . . . 54
4.1.1 HPV prevalence in women with normal cervical cytology . . . 55
4.1.2 HPV type distribution among women with normal cervical cytology, precancerous cervical lesions and cervical cancer . . . 58
4.1.3 HPV type distribution among HIV+ women with normal cervical cytology . . . 71

4.1.4 Terminology . . . 72
4.2 HPV burden in anogenital cancers other than cervix . . . 73
4.2.1 Anal cancer and precancerous anal lesions . . . 74
4.2.2 Vulvar cancer and precancerous vulvar lesions . . . 76
4.2.3 Vaginal cancer and precancerous vaginal lesions . . . 78
4.2.4 Penile cancer and precancerous penile lesions . . . 80
4.3 HPV burden in men . . . 82
4.4 HPV burden in the head and neck . . . 84
4.4.1 Burden of oral HPV infection in healthy population . . . 84
4.4.2 HPV burden in head and neck cancers . . . 85

5 Factors contributing to cervical cancer 87

6 Sexual and reproductive health behaviour indicators 88

7 HPV preventive strategies 91
7.1 Cervical cancer screening practices . . . 91
7.2 HPV vaccination . . . 93

8 Protective factors for cervical cancer 95

9 Annex 96
9.1 Incidence . . . 96
9.1.1 Cervical cancer incidence in China across Eastern Asia . . . 96
9.1.2 Anal cancer incidence in China across Eastern Asia . . . 99
9.1.3 Vulva cancer incidence in China across Eastern Asia . . . 104
9.1.4 Vaginal cancer incidence in China across Eastern Asia . . . 107
9.1.5 Penile cancer incidence in China across Eastern Asia . . . 110
9.1.6 Oropharyngeal cancer incidence in China across Eastern Asia . . . 113
9.1.7 Oral cavity cancer incidence in China across Eastern Asia . . . 118
9.1.8 Laryngeal cancer incidence in China across Eastern Asia . . . 123
9.2 Mortality . . . 128
9.2.1 Cervical cancer mortality in China across Eastern Asia . . . 128
9.2.2 Anal cancer mortality in China across Eastern Asia . . . 131
9.2.3 Vulva cancer mortality in China across Eastern Asia . . . 136
9.2.4 Vaginal cancer mortality in China across Eastern Asia . . . 139
9.2.5 Penile cancer mortality in China across Eastern Asia . . . 142
9.2.6 Oropharyngeal cancer mortality in China across Eastern Asia . . . 145
9.2.7 Oral cavity cancer mortality in China across Eastern Asia . . . 150
9.2.8 Laryngeal cancer mortality in China across Eastern Asia . . . 155

10 Glossary 160

List of Figures

1 China and Eastern Asia . . . 2
2 Population pyramid of China for 2022 . . . 4
3 Population trends in four selected age groups in China . . . 4
4 Comparison of HPV related cancers incidence to other cancers in men and women of all ages in China (estimates for 2020) . . . 5
5 Comparison of HPV related cancers incidence to other cancers among men and women 15-44 years of age in China (estimates for 2020) . . . 6
6 Comparison of HPV related cancers mortality to other cancers in men and women of all ages in China (estimates for 2020) . . . 7
7 Comparison of HPV related cancers mortality to other cancers among men and women 15-44 years of age in China (estimates for 2020) . . . 8
8 Age-specific incidence rates of cervical cancer in China (estimates for 2020) . . . 12
9 Annual number of new cases of cervical cancer in China (estimates for 2020) . . . 12
10 Time trends in cervical cancer incidence in China (cancer registry data) . . . 14
11 Age-specific mortality rates of cervical cancer in China (estimates for 2020) . . . 16
12 Annual number of deaths of cervical cancer in China (estimates for 2020) . . . 16
13 Comparison of age-specific cervical cancer incidence and mortality rates in China (estimates for 2020) . . . 17
14 Comparison of annual premature deaths and disability from cervical cancer in China to other cancers among women (estimates for 2019) . . . 18
15 Age-specific incidence rates of anal cancer in China (estimates for 2020) . . . 20
16 Annual number of new cases of anal cancer in China (estimates for 2020) . . . 20
17 Age-specific mortality rates of anal cancer in China (estimates for 2020) . . . 22
18 Annual number of deaths of of anal cancer in China (estimates for 2020) . . . 22
19 Comparison of age-specific anal cancer incidence and mortality rates among men in China (estimates for 2020) 23
20 Comparison of age-specific anal cancer incidence and mortality rates among women in China (estimates for 2020) 23
21 Age-specific incidence rates of vulva cancer in China (estimates for 2020) . . . 25
22 Annual number of new cases of vulva cancer in China (estimates for 2020) . . . 25
23 Age-specific mortality rates of vulva cancer in China (estimates for 2020) . . . 27
24 Annual number of deaths of vulva cancer in China (estimates for 2020) . . . 27
25 Comparison of age-specific vulva cancer incidence and mortality rates in China (estimates for 2020) . . . 28
26 Age-specific incidence rates of vaginal cancer in China (estimates for 2020) . . . 30
27 Annual number of new cases of vaginal cancer in China (estimates for 2020) . . . 30
28 Age-specific mortality rates of vaginal cancer in China (estimates for 2020) . . . 32
29 Annual number of deaths of vaginal cancer in China (estimates for 2020) . . . 32
30 Comparison of age-specific vaginal cancer incidence and mortality rates in China (estimates for 2020) . . . 33
31 Age-specific incidence rates of penile cancer in China (estimates for 2020) . . . 35
32 Annual number of new cases of penile cancer in China (estimates for 2020) . . . 35
33 Age-specific mortality rates of penile cancer in China (estimates for 2020) . . . 37
34 Annual number of deaths of penile cancer in China (estimates for 2020) . . . 37
35 Comparison of age-specific penile cancer incidence and mortality rates in China (estimates for 2020) . . . 38
36 Age-specific incidence rates of oropharyngeal cancer in China (estimates for 2020) . . . 40
37 Annual number of new cases of oropharyngeal cancer in China (estimates for 2020) . . . 40
38 Age-specific mortality rates of oropharyngeal cancer in China (estimates for 2020) . . . 42
39 Annual number of deaths of oropharyngeal cancer in China (estimates for 2020) . . . 42
40 Comparison of age-specific oropharyngeal cancer incidence and mortality rates among men in China (estimates for 2020) . . . 43
41 Comparison of age-specific oropharyngeal cancer incidence and mortality rates among women in China (estimates for 2020) . . . 43
42 Age-specific incidence rates of oral cavity cancer in China (estimates for 2020) . . . 45
43 Annual number of new cases of oral cavity cancer in China (estimates for 2020) . . . 45
44 Age-specific mortality rates of oral cavity cancer in China (estimates for 2020) . . . 47
45 Annual number of deaths of oral cavity cancer in China (estimates for 2020) . . . 47
46 Comparison of age-specific oral cavity cancer incidence and mortality rates among men in China (estimates for 2020) . . . 48
47 Comparison of age-specific oral cavity cancer incidence and mortality rates among women in China (estimates for 2020) . . . 48
48 Age-specific incidence rates of laryngeal cancer in China (estimates for 2020) . . . 50
49 Annual number of new cases of laryngeal cancer in China (estimates for 2020) . . . 50
50 Age-specific mortality rates of laryngeal cancer in China (estimates for 2020) . . . 52
51 Annual number of deaths of of laryngeal cancer in China (estimates for 2020) . . . 52
52 Comparison of age-specific laryngeal cancer incidence and mortality rates among men in China (estimates for 2020) . . . 53

53 Comparison of age-specific laryngeal cancer incidence and mortality rates among women in China (estimates for 2020) . . . 53
54 Crude age-specific HPV prevalence (%) and 95% confidence interval in women with normal cervical cytology in China . . . 55
55 HPV prevalence among women with normal cervical cytology in China, by study . . . 56
56 HPV 16 prevalence among women with normal cervical cytology in China, by study . . . 58
57 HPV 16 prevalence among women with low-grade cervical lesions in China, by study . . . 60
58 HPV 16 prevalence among women with high-grade cervical lesions in China, by study . . . 61
59 HPV 16 prevalence among women with invasive cervical cancer in China, by study . . . 62
60 Comparison of the ten most frequent HPV oncogenic types in China among women with and without cervical lesions . . . 63
61 Comparison of the ten most frequent HPV oncogenic types in China among women with invasive cervical cancer by histology . . . 65
62 Comparison of the ten most frequent HPV types in anal cancer cases in Asia and the World . . . 75
63 Comparison of the ten most frequent HPV types in AIN 2/3 cases in Asia and the World . . . 75
64 Comparison of the ten most frequent HPV types in cases of vulvar cancer in Asia and the World . . . 77
65 Comparison of the ten most frequent HPV types in VIN 2/3 cases in Asia and the World . . . 77
66 Comparison of the ten most frequent HPV types in cases of vaginal cancer in Asia and the World . . . 79
67 Comparison of the ten most frequent HPV types in VaIN 2/3 cases in Asia and the World . . . 79
68 Comparison of the ten most frequent HPV types in cases of penile cancer in Asia and the World . . . 81
69 Comparison of the ten most frequent HPV types in PeIN 2/3 cases in Asia and the World . . . 81
70 Estimated coverage* of cervical cancer screening in China . . . 92
71 HPV vaccination coverage in females by year in China . . . 93
72 HPV vaccination coverage in males by year in China . . . 94
73 Age-standardised incidence rates of cervical cancer of China (estimates for 2020) . . . 96
74 Annual number of new cases of cervical cancer by age group in China (estimates for 2020) . . . 97
75 Comparison of age-specific cervical cancer incidence rates in China, within the region, and the rest of world . . . 98
76 Age-standardised incidence rates of anal cancer of China (estimates for 2020) . . . 99
77 Annual number of new cases of anal cancer among men by age group in China (estimates for 2020) . . . 100
78 Annual number of new cases of anal cancer among women by age group in China (estimates for 2020) . . . 101
79 Comparison of age-specific anal cancer incidence rates among men by age in China, within the region, and the rest of world . . . 102
80 Comparison of age-specific anal cancer incidence rates among women by age in China, within the region, and the rest of world . . . 103
81 Age-standardised incidence rates of vulva cancer of China (estimates for 2020) . . . 104
82 Annual number of new cases of vulva cancer by age group in China (estimates for 2020) . . . 105
83 Comparison of age-specific vulva cancer incidence rates in China, within the region, and the rest of world . . . 106
84 Age-standardised incidence rates of vaginal cancer of China (estimates for 2020) . . . 107
85 Annual number of new cases of cervical cancer by age group in China (estimates for 2020) . . . 108
86 Comparison of age-specific vaginal cancer incidence rates in China, within the region, and the rest of world . . . 109
87 Age-standardised incidence rates of penile cancer of China (estimates for 2020) . . . 110
88 Annual number of new cases of penile cancer by age group in China (estimates for 2020) . . . 111
89 Comparison of age-specific penile cancer incidence rates in China, within the region, and the rest of world . . . 112
90 Age-standardised incidence rates of oropharyngeal cancer of China (estimates for 2020) . . . 113
91 Annual number of new cases of oropharyngeal cancer among men by age group in China (estimates for 2020) . . . 114
92 Annual number of new cases of oropharyngeal cancer among women by age group in China (estimates for 2020) 115
93 Comparison of age-specific oropharyngeal cancer incidence rates among men by age in China, within the region, and the rest of world . . . 116
94 Comparison of age-specific oropharyngeal cancer incidence rates among women by age in China, within the region, and the rest of world . . . 117
95 Age-standardised incidence rates of oral cavity cancer of China (estimates for 2020) . . . 118
96 Annual number of new cases of oral cavity cancer among men by age group in China (estimates for 2020) . . . 119
97 Annual number of new cases of oral cavity cancer among women by age group in China (estimates for 2020) . . . 120
98 Comparison of age-specific oral cavity cancer incidence rates among men by age in China, within the region, and the rest of world . . . 121
99 Comparison of age-specific oral cavity cancer incidence rates among women by age in China, within the region, and the rest of world . . . 122
100 Age-standardised incidence rates of laryngeal cancer of China (estimates for 2020) . . . 123
101 Annual number of new cases of laryngeal cancer among men by age group in China (estimates for 2020) . . . 124
102 Annual number of new cases of laryngeal cancer among women by age group in China (estimates for 2020) . . . 125
103 Comparison of age-specific laryngeal cancer incidence rates among men by age in China, within the region, and the rest of world . . . 126
104 Comparison of age-specific laryngeal cancer incidence rates among women by age in China, within the region, and the rest of world . . . 127
105 Age-standardised mortality rates of cervical cancer of China (estimates for 2020) . . . 128

106 Annual number of deaths of cervical cancer by age group in China (estimates for 2020) . . . 129
107 Comparison of age-specific cervical cancer mortality rates in China, within the region, and the rest of world . . 130
108 Age-standardised mortality rates of anal cancer of China (estimates for 2020) . . . 131
109 Annual number of deaths of anal cancer among men by age group in China (estimates for 2020) . . . 132
110 Annual number of deaths of anal cancer among women by age group in China (estimates for 2020) . . . 133
111 Comparison of age-specific anal cancer mortality rates among men by age in China, within the region, and the rest of world . . . 134
112 Comparison of age-specific anal cancer mortality rates among women by age in China, within the region, and the rest of world . . . 135
113 Age-standardised mortality rates of vulva cancer of China (estimates for 2020) . . . 136
114 Annual number of deaths of vulva cancer by age group in China (estimates for 2020) . . . 137
115 Comparison of age-specific vulva cancer mortality rates in China, within the region, and the rest of world . . . 138
116 Age-standardised mortality rates of vaginal cancer of China (estimates for 2020) . . . 139
117 Annual number of deaths of cervical cancer by age group in China (estimates for 2020) . . . 140
118 Comparison of age-specific vaginal cancer mortality rates in China, within the region, and the rest of world . . . 141
119 Age-standardised mortality rates of penile cancer of China (estimates for 2020) . . . 142
120 Annual number of new deaths of penile cancer by age group in China (estimates for 2020) . . . 143
121 Comparison of age-specific penile cancer mortality rates in China, within the region, and the rest of world . . . 144
122 Age-standardised mortality rates of oropharyngeal cancer of China (estimates for 2020) . . . 145
123 Annual number of deaths of oropharyngeal cancer among men by age group in China (estimates for 2020) . . . 146
124 Annual number of deaths of oropharyngeal cancer among women by age group in China (estimates for 2020) . . 147
125 Comparison of age-specific oropharyngeal cancer mortality rates among men by age in China, within the region, and the rest of world . . . 148
126 Comparison of age-specific oropharyngeal cancer mortality rates among women by age in China, within the region, and the rest of world . . . 149
127 Age-standardised mortality rates of oral cavity cancer of China (estimates for 2020) . . . 150
128 Annual number of deaths of oral cavity cancer among men by age group in China (estimates for 2020) . . . 151
129 Annual number of deaths of oral cavity cancer among women by age group in China (estimates for 2020) . . . 152
130 Comparison of age-specific oral cavity cancer mortality rates among men by age in China, within the region, and the rest of world . . . 153
131 Comparison of age-specific oral cavity cancer mortality rates among women by age in China, within the region, and the rest of world . . . 154
132 Age-standardised mortality rates of laryngeal cancer of China (estimates for 2020) . . . 155
133 Annual number of deaths of laryngeal cancer among men by age group in China (estimates for 2020) . . . 156
134 Annual number of deaths of laryngeal cancer among women by age group in China (estimates for 2020) . . . 157
135 Comparison of age-specific laryngeal cancer mortality rates among men by age in China, within the region, and the rest of world . . . 158
136 Comparison of age-specific laryngeal cancer mortality rates among women by age in China, within the region, and the rest of world . . . 159

List of Tables

1 Key Statistics . . . iv
2 Cervical cancer incidence in China (estimates for 2020) . . . 9
3 Cervical cancer incidence in China by cancer registry . . . 10
4 Age-standardised incidence rates of cervical cancer in China by histological type and cancer registry . . . 13
5 Cervical cancer mortality in China (estimates for 2020) . . . 15
6 Premature deaths and disability from cervical cancer in China, Asia and the rest of the world (estimates for 2019) 17
7 Anal cancer incidence in China (estimates for 2020) . . . 19
8 Anal cancer mortality in China (estimates for 2020) . . . 21
9 Vulva cancer incidence in China (estimates for 2020) . . . 24
10 Vulva cancer mortality in China (estimates for 2020) . . . 26
11 Vaginal cancer incidence in China (estimates for 2020) . . . 29
12 Vaginal cancer mortality in China (estimates for 2020) . . . 31
13 Penile cancer incidence in China (estimates for 2020) . . . 34
14 Penile cancer mortality in China (estimates for 2020) . . . 36
15 Oropharyngeal cancer incidence in China (estimates for 2020) . . . 39
16 Oropharyngeal cancer mortality in China (estimates for 2020) . . . 41
17 Oral cavity cancer incidence in China (estimates for 2020) . . . 44
18 Oral cavity cancer mortality in China (estimates for 2020) . . . 46
19 Laryngeal cancer incidence in China (estimates for 2020) . . . 49
20 Laryngeal cancer mortality in China (estimates for 2020) . . . 51
21 Prevalence of HPV16 and HPV18 by cytology in China . . . 58
22 Type-specific HPV prevalence in women with normal cervical cytology, precancerous cervical lesions and invasive cervical cancer in China . . . 67
23 Type-specific HPV prevalence among invasive cervical cancer cases in China by histology . . . 69
24 Studies on HPV prevalence among HIV+ women with normal cytology in China . . . 71
25 Studies on HPV prevalence among anal cancer cases in China (male and female) . . . 74
26 Studies on HPV prevalence among cases of AIN2/3 in China . . . 74
27 Studies on HPV prevalence among vulvar cancer cases in China . . . 76
28 Studies on HPV prevalence among VIN 2/3 cases in China . . . 76
29 Studies on HPV prevalence among vaginal cancer cases in China . . . 78
30 Studies on HPV prevalence among VaIN 2/3 cases in China . . . 78
31 Studies on HPV prevalence among penile cancer cases in China . . . 80
32 Studies on HPV prevalence among PeIN 2/3 cases in China . . . 80
33 Studies on HPV prevalence among men in China . . . 82
34 Studies on HPV prevalence among men from special subgroups in China . . . 82
35 Studies on oral HPV prevalence among healthy in China . . . 84
36 Studies on HPV prevalence among cases of oral cavity cancer in China . . . 85
37 Studies on HPV prevalence among cases of oropharyngeal cancer in China . . . 85
38 Studies on HPV prevalence among cases of hypopharyngeal or laryngeal cancer in China . . . 86
39 Factors contributing to cervical carcinogenesis (cofactors) in China . . . 87
40 Percentage of 15-year-olds who have had sexual intercourse in China . . . 88
41 Median age at first sex in China . . . 88
42 Marriage patterns in China . . . 89
43 Average number of sexual partners in China . . . 89
44 Lifetime prevalence of anal intercourse among women in China . . . 90
45 Main characteristics of cervical cancer screening in China . . . 91
46 National HPV Immunization programme in China . . . 93
47 Prevalence of male circumcision in China . . . 95
48 Prevalence of condom use in China . . . 95
49 Glossary . . . 160

1 Introduction

Figure 1: China and Eastern Asia



Information Centre aims to compile and centralise updated data and statistics on human papillomavirus (HPV) and related cancers. This report aims to summarise the data available to fully evaluate the burden of disease in China and to facilitate stakeholders and relevant bodies of decision makers to formulate recommendations on the prevention of cervical cancer and other HPV-related cancers. Data include relevant cancer statistic estimates, epidemiological determinants of cervical cancer such as demographics, socioeconomic factors, risk factors, burden of HPV infection in women and men, cervical screening and immunization practices. The report is structured into the following sections:

Section 2, Demographic and socioeconomic factors. This section summarises the socio-demographic profile of China. For analytical purposes, China is classified in the geographical region of Eastern Asia (Figure 1, lighter blue), which is composed of the following countries: Japan, Republic of Korea, China, Macao Special Administrative Region, Mongolia, Democratic People's Republic of Korea, and Taiwan. Throughout the report, China estimates will be complemented with corresponding regional estimates.

Section 3, Burden of HPV related cancers. This section describes the current burden of invasive cervical cancer and other HPV-related cancers in China ith estimates of prevalence, incidence, and mortality rates. Information in other HPV-related cancers includes other anogenital cancers (anus, vulva, vagina, and penis) and head and neck cancers (oral cavity, oropharyngeal, and larynx).

Section 4, HPV related statistics. This section reports on prevalence of HPV and HPV type-specific distribution in China, in women with normal cytology, precancerous lesions and invasive cervical cancer. In addition, the burden of HPV in other anogenital cancers (anus, vulva, vagina, and penis), head and neck cancers (oral cavity, oropharynx, and larynx) and men are presented.

Section 5, Factors contributing to cervical cancer. This section describes factors that can modify

the natural history of HPV and cervical carcinogenesis such as smoking, parity, oral contraceptive use, and co-infection with HIV.

Section 6, Sexual and reproductive health behaviour indicators. This section presents sexual and reproductive behaviour indicators that may be used as proxy measures of risk for HPV infection and anogenital cancers, such as age at first sexual intercourse, average number of sexual partners, and anal intercourse among others.

Section 7, HPV preventive strategies. This section presents preventive strategies that include basic characteristics and performance of cervical cancer screening status, status of HPV vaccine licensure introduction, and recommendations in national immunisation programmes.

Section 8, Protective factors for cervical cancer. This section presents male circumcision and the use of condoms.

2 Demographic and socioeconomic factors

Figure 2: Population pyramid of China for 2022



Data accessed on 30 Jul 2022
For statistical purposes, the data for China do not include Hong Kong and Macao, Special Administrative Regions (SAR) of China, and Taiwan Province of China.
Please refer to original source for methods of estimation.
Year of estimate: 2022
Data Sources:
United Nations, Department of Economic and Social Affairs, Population Division (2022). World Population Prospects 2022, Online Edition. [Accessed on July 30, 2022].

Figure 3: Population trends in four selected age groups in China



Data accessed on 30 Jul 2022
For statistical purposes, the data for China do not include Hong Kong and Macao, Special Administrative Regions (SAR) of China, and Taiwan Province of China.
Please refer to original source for methods of estimation.
Year of estimate: 2022
Data Sources:
United Nations, Department of Economic and Social Affairs, Population Division (2022). World Population Prospects 2022, Online Edition. [Accessed on July 30, 2022].

3 Burden of HPV related cancers

HPV is the cause of almost all cervical cancer cases and is responsible for an important fraction of other anogenital and head and neck cancer. Here, we present the most recent estimations on the burden of HPV-associated cancer.

3.1 HPV related cancers incidence

Figure 4: Comparison of HPV related cancers incidence to other cancers in men and women of all ages in China (estimates for 2020)



Data accessed on 27 Jan 2021
For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods
Non-melanoma skin cancer is not included
Rates per 100,000 men per year.
Rates per 100,000 women per year.
Data Sources:
Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2020). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: https://gco.iarc.fr/today, accessed [27 January 2021].

Figure 5: Comparison of HPV related cancers incidence to other cancers among men and women 15-44 years of age in China (estimates for 2020)



Data accessed on 27 Jan 2021

For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods
Non-melanoma skin cancer is not included
Rates per 100,000 men per year.
Rates per 100,000 women per year.

Data Sources:

Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2020). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: https://gco.iarc.fr/today, accessed [27 January 2021].

3.2 HPV related cancers mortality

Figure 6: Comparison of HPV related cancers mortality to other cancers in men and women of all ages in China (estimates for 2020)



Data accessed on 27 Jan 2021
For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods
Non-melanoma skin cancer is not included
Rates per 100,000 men per year.
Rates per 100,000 women per year.
Data Sources:
Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2020). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: https://gco.iarc.fr/today , accessed [27 January 2021].

Figure 7: Comparison of HPV related cancers mortality to other cancers among men and women 15-44 years of age in China (estimates for 2020)



Data accessed on 27 Jan 2021

For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods
Non-melanoma skin cancer is not included
Rates per 100,000 men per year.
Rates per 100,000 women per year.
Data Sources:
Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2020). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: https://gco.iarc.fr/today, accessed [27 January 2021].

3.3 Cervical cancer

Cancer of the cervix uteri is the 4^{th} most common cancer among women worldwide, with an estimated 604,127 new cases and 341,831 deaths in 2020. Worldwide, mortality rates of cervical cancer are substantially lower than incidence with a ratio of mortality to incidence to 57% (GLOBOCAN 2020). The majority of cases are squamous cell carcinoma followed by adenocarcinomas. *(Vaccine 2006, Vol. 24, Suppl 3; Vaccine 2008, Vol. 26, Suppl 10; Vaccine 2012, Vol. 30, Suppl 5; IARC Monographs 2007, Vol. 90)*

This section describes the current burden of invasive cervical cancer in China and in comparison to geographic region, including estimates of the annual number of new cases, deaths, incidence, and mortality rates.

3.3.1 Cervical cancer incidence in China

Key Stats.

About **109,741 new cervical cancer cases** are diagnosed **annually** in **China** (estimations for 2020).

Cervical cancer **ranks* as the 6th leading cause** of female cancer in **China**.

Cervical cancer is the **3rd most common** female cancer in **women aged 15 to 44 years in China**.

* Ranking of cervical cancer incidence to other cancers among all women according to highest incidence rates (ranking 1st) excluding non-melanoma skin cancer. Ranking is based on crude incidence rates (actual number of cervical cancer cases). Ranking using age-standardized rate (ASR) may differ.

Table 2: Cervical cancer incidence in China (estimates for 2020)

Indicator	China	Eastern Asia	World
Annual number of new cancer cases	109,741	129,567	604,127
Uncertainty intervals of new cancer cases [95% UI]	[106,978-112,576]	[126,381-132,833]	[582,031-627,062]
Crude incidence rate[b]	15.6	15.8	15.6
Age-standardized incidence rate[b]	10.7	10.8	13.3
Cumulative risk (%) at 75 years old[a]	1.08	1.08	1.39

Data accessed on 27 Jan 2021
For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods
[a] Cumulative risk (incidence) is the probability or risk of individuals getting from the disease during ages 0-74 years. For cancer, it is expressed as the % of new born children who would be expected to develop from a particular cancer before the age of 75 if they had the rates of cancer observed in the period in the absence of competing causes.
[b] Rates per 100,000 women per year.
Data Sources:
Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2020). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: https://gco.iarc.fr/today, accessed [27 January 2021].

Table 3: Cervical cancer incidence in China by cancer registry

Cancer registry	Period	N cases[a]	Crude rate[b]	ASR[b]
Beijing[1]	1993-1997	209	3.6	2.3
Changle[1]	1993-1997	0	0	0
Cixian[1]	1993-1997	0	0	0
Cixian County[2]	2003-2007	86	5.8	6.2
Guangzhou City[3]	2000-2002	298	5.7	4.6
Hong Kong[2]	2003-2007	2080	11.7	7.9
Jiashan[3]	1998-2002	33	3.5	2.4
Jiashan County[2]	2003-2007	40	4.2	2.6
Nangang District: Harbin City[3]	1998-2002	86	4.1	3
Harbin City, Nangang District[2]	2003-2007	277	11.3	8
Qidong City[1]	1993-1997	79	2.7	2.2
Qidong County[2]	2003-2007	194	6.8	4.7
Shanghai[3]	1998-2002	722	4.7	2.8
Shanghai City[2]	2003-2007	1038	6.8	4.2
Taiwan[1]	1997-1997	2855	27	24.9
Tianjin[1]	1993-1997	311	3.4	2.4
Wuhan[1]	1993-1997	433	4.5	3.9
Wuhan City[2]	2003-2007	983	8.8	6.5
Zhongshan[3]	1998-2002	133	4	3.5
Zhongshan City[2]	2004-2007	245	8.7	7.9
Beijing City[2]	2003-2007	1217	6.9	4.5
Haining County[2]	2003-2007	104	6.4	4.6
Jiaxing City[2]	2005-2007	48	6.4	4.3
Macao[2]	2003-2007	148	12	8.9
Yangcheng County[2]	2003-2007	749	78.2	71.8
Yanting County[2]	2003-2007	128	8.9	7.8
Anshan City[4]	2008-2012	1072	29.1	17
Beijing[4]	2008-2012	1595	8.3	5.5
Benxi[4]	2008-2011	386	20.1	15
Cixian County[4]	2008-2012	163	10.4	11.2
Guangzhou[4]	2010-2012	1682	14	10.1
Guanyun[4]	2008-2012	202	8.2	6.5
Haimen County[4]	2008-2012	492	19.2	12.3
Hangzhou City[4]	2008-2012	3184	18.8	12.6
Harbin City, Nangang District[4]	2008-2012	365	14.3	9.6
Hefei[4]	2010-2012	361	11.4	9.1
Hengdong[4]	2009-2012	317	22.6	17.2
Hong Kong[4]	2008-2012	2054	11	6.8
Huaiyin District, Huai'an[4]	2009-2012	105	6	4.1
Jiangmen[4]	2010-2012	127	13.3	9.5
Jianhu County[4]	2010-2012	266	22.4	15.6
Jiashan County[4]	2008-2012	108	11.2	6.8
Jiaxing City[4]	2008-2012	149	11.6	7.3
Lianyungang[4]	2008-2012	312	13.7	10.1
Linzhou County[4]	2008-2012	428	16.7	13.4
Liuzhou[4]	2009-2012	310	15.3	11

Continued on next page

Table 3 – continued from previous page

Cancer registry	Period	N cases[a]	Crude rate[b]	ASR[b]
Maanshan[4]	2008-2012	264	16.9	12.2
Qidong County[4]	2008-2012	286	10.1	6.4
Shanghai City[4]	2008-2012	1500	9.6	6.4
Shenyang[4]	2008-2012	1553	16.9	10.4
Shexian County[4]	2008-2012	334	34.5	27.2
Sheyang[4]	2008-2012	589	24.9	16.6
Tongling City[4]	2008-2012	120	11	8
Wuhan City[4]	2008-2012	1651	14.1	9.6
Wuxi[4]	2010-2012	714	19.7	12.8
Xianju[4]	2010-2012	130	18.1	12.4
Xiping[4]	2010-2012	163	12.9	10.5
Yanshi[4]	2010-2012	75	8.3	6.7
Yanting County[4]	2008-2012	150	10.3	8.4
Yueyanglou[4]	2009-2012	283	27.6	26.8
Zhongshan City[4]	2010-2012	259	11.5	8.6
Zhuhai[4]	2010-2012	289	18.9	15

Data accessed on 5 Oct 2018

Please refer to original source (available at http://ci5.iarc.fr/CI5-XI/Default.aspx)

ASR: Age-standardized rate, Standardized rates have been estimated using the direct method and the World population as the reference.

[a] Accumulated number of cases during the period in the population covered by the corresponding registry.

[b] Rates per 100,000 women per year.

Data Sources:

[1] Parkin, D.M., Whelan, S.L., Ferlay, J., Teppo, L., and Thomas, D.B., eds (2002). Cancer Incidence in Five Continents, Vol. VIII. IARC Scientific Publications No. 155, Lyon, IARC.

[2] Forman D, Bray F, Brewster DH, Gombe Mbalawa C, Kohler B, Piñeros M, Steliarova-Foucher E, Swaminathan R and Ferlay J eds (2013). Cancer Incidence in Five Continents, Vol. X (electronic version) Lyon, IARC. http://ci5.iarc.fr

[3] Curado. M. P., Edwards, B., Shin. H.R., Storm. H., Ferlay. J., Heanue. M. and Boyle. P., eds (2007). Cancer Incidence in Five Continents, Vol. IX. IARC Scientific Publications No. 160, Lyon, IARC.

[4] Bray F, Colombet M, Mery L, Piñeros M, Znaor A, Zanetti R and Ferlay J, editors (2017). Cancer Incidence in Five Continents, Vol. XI (electronic version). Lyon: International Agency for Research on Cancer. Available from: http://ci5.iarc.fr, accessed [05 October 2018].

Figure 8: Age-specific incidence rates of cervical cancer in China (estimates for 2020)



Data accessed on 27 Jan 2021
For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods
[a] Rates per 100,000 women per year.
Data Sources:
Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2020). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: https://gco.iarc.fr/today, accessed [27 January 2021].

Figure 9: Annual number of new cases of cervical cancer in China (estimates for 2020)



Data accessed on 27 Jan 2021
For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods
Data Sources:
Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2020). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: https://gco.iarc.fr/today, accessed [27 January 2021].

- For age-standardised incidence rates of cervical cancer of China (estimates for 2020) please refer to Figure 73
- For annual number of new cases of cervical cancer by age group in China (estimates for 2020) please refer to Figure 74
- For comparison of age-specific cervical cancer incidence rates in China, within the region, and the rest of world please refer to Figure 75

3.3.2 Cervical cancer incidence by histology in China

Table 4: Age-standardised incidence rates of cervical cancer in China by histological type and cancer registry

Cancer registry[1]	Period	Squamo	Adeno	Other	Unspec.
Anshan City	2008-2012	13.9	1.4	0.1	0.9
Beijing	2008-2012	4.1	0.7	0.1	0.1
Benxi	2008-2011	10.8	1.8	0.3	-
Cixian County	2008-2012	9.9	0.3	-	-
Guangzhou	2010-2012	7.5	1.1	0.3	0.2
Guanyun	2008-2012	3.4	0.3	-	-
Haimen County	2008-2012	7.4	0.9	0.2	3.5
Hangzhou City	2008-2012	7.1	0.9	0.2	0.3
Harbin City, Nangang District	2008-2012	7.3	0.8	0.1	0.2
Hefei	2010-2012	5.5	0.7	0.1	0.2
Hengdong	2009-2012	9.3	0.7	0.2	0.3
Hong Kong	2008-2012	4.9	1.3	0.4	0.1
Huaiyin District, Huai'an	2009-2012	3.6	-	-	-
Jiangmen	2010-2012	5.9	1.1	0.2	1.4
Jianhu County	2010-2012	8	0.6	0.1	-
Jiashan County	2008-2012	5.8	0.7	-	-
Jiaxing City	2008-2012	3.6	0.7	-	0.2
Lianyungang	2008-2012	5.5	1.1	0.1	-
Linzhou County	2008-2012	10.1	1.1	-	-
Liuzhou	2009-2012	8.7	1	0.1	0.2
Maanshan	2008-2012	9.5	1	0.1	0.4
Qidong County	2008-2012	3.1	0.4	0	2.5
Shanghai City	2008-2012	4.2	0.9	0.2	0
Shenyang	2008-2012	6.4	0.9	0.2	0.4
Shexian County	2008-2012	22.6	0.2	-	-
Sheyang	2008-2012	10.1	3.3	-	-
Tongling City	2008-2012	6.8	0.6	-	0.2
Wuhan City	2008-2012	-	-	-	-
Wuxi	2010-2012	11.1	1.1	0.2	0.1
Xianju	2010-2012	7.5	0.9	-	0.3
Xiping	2010-2012	9	1.1	0.1	0.2
Yanshi	2010-2012	2.9	2.1	-	0.3
Yanting County	2008-2012	6.8	0.6	0.5	-
Yueyanglou	2009-2012	21.2	2	0.1	0.4
Zhongshan City	2010-2012	7.1	0.9	0.2	0.2
Zhuhai	2010-2012	11.5	1.3	0.2	-

Data accessed on 5 Oct 2018
Rates per 100,000 women per year.
Standarized rates have been estimated using the direct method and the World population as the references.
Adeno: adenocarcinoma; Other: Other carcinoma; Squamous: Squamous cell carcinoma; Unspec: Unspecified carcinoma;
Data Sources:
[1] Bray F, Colombet M, Mery L, Piñeros M, Znaor A, Zanetti R and Ferlay J, editors (2017). Cancer Incidence in Five Continents, Vol. XI (electronic version). Lyon: International Agency for Research on Cancer. Available from: http://ci5.iarc.fr, accessed [05 October 2018].

Figure 10: Time trends in cervical cancer incidence in China (cancer registry data)



Data accessed on 28 Aug 2018

The following regional cancer registries provided data and contributed to their national estimate: Shanghai, Jiashan, Zhongshan, Harbin

[a] Estimated annual percentage change based on the trend variable from the net drift for 15 years, from 1988-2002.

Data Sources:

Ferlay J, Colombet M and Bray F. Cancer Incidence in Five Continents, CI5plus: IARC CancerBase No. 9 [Internet]. Lyon, France: International Agency for Research on Cancer; 2018. Available from: http://ci5.iarc.fr

Vaccarella S, Lortet-Tieulent J, Plummer M, Franceschi S, Bray F. Worldwide trends in cervical cancer incidence: Impact of screening against changes in disease risk factors. eur J Cancer 2013;49:3262-73.

3.3.3 Cervical cancer mortality in China

Key Stats.

About **59,060 cervical cancer deaths occur annually in China** are diagnosed **annually** (estimations for 2020).

Cervical cancer **ranks* as the 7th leading cause of cancer deaths** of female cancer deaths in **China**.

Cervical cancer is the **3rd leading cause of cancer deaths** in **women aged 15 to 44 years in China**.

* Ranking of cervical cancer incidence to other cancers among all women according to highest incidence rates (ranking 1st) excluding non-melanoma skin cancer. Ranking is based on crude incidence rates (actual number of cervical cancer cases). Ranking using age-standardized rate (ASR) may differ.

Table 5: Cervical cancer mortality in China (estimates for 2020)

Indicator	China	Eastern Asia	World
Annual number of deaths	59,060	66,436	341,831
Uncertainty intervals of mortality cancer cases [95% UI]	[56,090-62,187]	[63,240-69,794]	[324,231-360,386]
Crude mortality rate[b]	8.37	8.08	8.84
Age-standardized mortality rate[b]	5.27	4.95	7.25
Cumulative risk (%) at 75 years old[a]	0.61	0.57	0.82

Data accessed on 27 Jan 2021
For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods
[a] Cumulative risk (mortality) is the probability or risk of individuals dying from the disease during ages 0-74 years. For cancer, it is expressed as the % of new born children who would be expected to die from a particular cancer before the age of 75 if they had the rates of cancer observed in the period in the absence of competing causes.
[b] Rates per 100,000 women per year.
Data Sources:
Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2020). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: https://gco.iarc.fr/today, accessed [27 January 2021].

Figure 11: Age-specific mortality rates of cervical cancer in China (estimates for 2020)



Data accessed on 27 Jan 2021
For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods
[a] Rates per 100,000 women per year.
Data Sources:
Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2020). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: https://gco.iarc.fr/today, accessed [27 January 2021].

Figure 12: Annual number of deaths of cervical cancer in China (estimates for 2020)



Data accessed on 27 Jan 2021
For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods
Data Sources:
Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2020). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: https://gco.iarc.fr/today, accessed [27 January 2021].

- For age-standardised mortality rates of cervical cancer of China (estimates for 2020) please refer to Figure 105
- For annual number of deaths of cervical cancer by age group in China (estimates for 2020) please refer to Figure 106
- For comparison of age-specific cervical cancer mortality rates in China, within the region, and the rest of world please refer to Figure 107

3.3.4 Cervical cancer incidence and mortality comparison in China

Figure 13: Comparison of age-specific cervical cancer incidence and mortality rates in China (estimates for 2020)



Data accessed on 27 Jan 2021
For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods
[a] Rates per 100,000 women per year.
Data Sources:
Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2020). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: https://gco.iarc.fr/today, accessed [27 January 2021].

Table 6: Premature deaths and disability from cervical cancer in China, Asia and the rest of the world (estimates for 2019)

	China		Asia		World	
Indicator	**Number**	**Rate**	**Number**	**Rate**	**Number**	**Rate**
DALYs (95% UI)[a]	1,622,242 (892,585-2,090,864)	233 (128-300)	4,693,918 (3,779,579-5,446,237)	210 (169-243)	8,955,013 (7,547,733-9,978,462)	232 (196-259)
YLLs (95% UI)[b]	1,573,974 (864,835-2,047,675)	226 (124-294)	4,565,684 (3,682,645-5,330,317)	204 (165-238)	8,712,962 (7,365,279-9,728,886)	226 (191-252)
YLDs (95% UI)[c]	48,268 (24,565-69,669)	7 (4-10)	128,234 (88,980-176,159)	6 (4-8)	242,051 (171,644-326,024)	6 (4-8)

Data accessed on 29 Apr 2021
Rate per 100,000 women
[a] DALYs (95% UI): estimated disability adjusted life years (95% uncertainty interval)
[b] YLLs (95% UI): years of life lost (95% uncertainty interval)
[c] YLDs (95% UI): estimated years lived with disability (95% uncertainty interval)
Data Sources:
GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020 Oct 17;396(10258):1204-1222

Figure 14: Comparison of annual premature deaths and disability from cervical cancer in China to other cancers among women (estimates for 2019)



Data accessed on 29 Apr 2021

YLLs: years of life lost

YLDs: years lived with disability

Data Sources:

GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020 Oct 17;396(10258):1204-1222

3.4 Anogenital cancers other than the cervix

Data on HPV role in anogenital cancers other than cervix are limited, but there is an increasing body of evidence strongly linking HPV DNA with cancers of anus, vulva, vagina, and penis. Although these cancers are much less frequent compared to cervical cancer, their association with HPV make them potentially preventable and subject to similar preventative strategies as those for cervical cancer. (Vaccine 2006, Vol. 24, Suppl 3; Vaccine 2008, Vol. 26, Suppl 10; Vaccine 2012, Vol. 30, Suppl 5; IARC Monographs 2007, Vol. 90).

3.4.1 Anal cancer

Anal cancer is rare in the general population with an average worldwide incidence of 1 per 100,000, but is reported to be increasing in more developed regions. Globally, there are an estimated 29,000 new cases in 2018 every year (de Martel C et al. Lancet Glob Health 2020;8(2):e180-e190). Women have higher incidences of anal cancer than men. Incidence is particularly high among populations of men who have sex with men (MSM), women with history of cervical or vulvar cancer, and immunosuppressed populations, including those who are HIV-infected and patients with a history of organ transplantation. These cancers are predominantly squamous cell carcinoma, adenocarcinomas, or basaloid and cloacogenic carcinomas.

3.4.1.1 Anal cancer incidence in China

Table 7: Anal cancer incidence in China (estimates for 2020)

Indicator	China	Eastern Asia	World
MEN			
Annual number of new cancer cases	2,498	3,151	21,706
Uncertainty intervals of new cancer cases [95% UI]	[2,134-2,925]	[2,680-3,704]	[18,432-25,561]
Crude incidence rate[b]	0.34	0.37	0.55
Age-standardized incidence rate[b]	0.23	0.24	0.49
Cumulative risk (%) at 75 years old[a]	0.03	0.03	0.06
WOMEN			
Annual number of new cancer cases	2,351	3,241	29,159
Uncertainty intervals of new cancer cases [95% UI]	[1,982-2,789]	[2,727-3,852]	[25,656-33,140]
Crude incidence rate[c]	0.33	0.39	0.75
Age-standardized incidence rate[c]	0.20	0.22	0.58
Cumulative risk (%) at 75 years old[a]	0.02	0.02	0.07

Data accessed on 27 Jan 2021
For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods
[a] Cumulative risk (incidence) is the probability or risk of individuals getting from the disease during ages 0-74 years. For cancer, it is expressed as the % of new born children who would be expected to develop from a particular cancer before the age of 75 if they had the rates of cancer observed in the period in the absence of competing causes.
[b] Rates per 100,000 men per year.
[c] Rates per 100,000 women per year.
Data Sources:
Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2020). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: https://gco.iarc.fr/today, accessed [27 January 2021].

Figure 15: Age-specific incidence rates of anal cancer in China (estimates for 2020)



Data accessed on 27 Jan 2021

For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods

[a] Rates per 100,000 men per year.

[b] Rates per 100,000 women per year.

Data Sources:

Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2020). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: https://gco.iarc.fr/today, accessed [27 January 2021].

Figure 16: Annual number of new cases of anal cancer in China (estimates for 2020)



Data accessed on 27 Jan 2021

For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods

Data Sources:

Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2020). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: https://gco.iarc.fr/today, accessed [27 January 2021].

3.4.1.2 Anal cancer mortality in China

Table 8: Anal cancer mortality in China (estimates for 2020)

Indicator	China	Eastern Asia	World
MEN			
Annual number of new cancer cases	1,331	1,642	9,416
Uncertainty intervals of new cancer cases [95% UI]	[1,038-1,707]	[1,298-2,078]	[7,282-12,175]
Crude incidence rate[b]	0.18	0.19	0.24
Age-standardized incidence rate[b]	0.12	0.12	0.21
Cumulative risk (%) at 75 years old[a]	0.01	0.01	0.02
WOMEN			
Annual number of new cancer cases	1,080	1,454	9,877
Uncertainty intervals of new cancer cases [95% UI]	[803-1,452]	[1,117-1,893]	[7,795-12,516]
Crude incidence rate[c]	0.15	0.18	0.26
Age-standardized incidence rate[c]	0.09	0.09	0.19
Cumulative risk (%) at 75 years old[a]	0.01	0.01	0.02

Data accessed on 27 Jan 2021

For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods

[a] Cumulative risk (mortality) is the probability or risk of individuals dying from the disease during ages 0-74 years. For cancer, it is expressed as the % of new born children who would be expected to die from a particular cancer before the age of 75 if they had the rates of cancer observed in the period in the absence of competing causes.

[b] Rates per 100,000 men per year.

[c] Rates per 100,000 women per year.

Data Sources:

Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2020). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: https://gco.iarc.fr/today, accessed [27 January 2021].

Figure 17: Age-specific mortality rates of anal cancer in China (estimates for 2020)



Data accessed on 27 Jan 2021

For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods

[a] Rates per 100,000 men per year.

[b] Rates per 100,000 women per year.

Data Sources:

Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2020). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: https://gco.iarc.fr/today, accessed [27 January 2021].

Figure 18: Annual number of deaths of of anal cancer in China (estimates for 2020)



Data accessed on 27 Jan 2021

For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods

Data Sources:

Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2020). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: https://gco.iarc.fr/today, accessed [27 January 2021].

3.4.1.3 Anal cancer incidence and mortality comparison in China

Figure 19: Comparison of age-specific anal cancer incidence and mortality rates among men in China (estimates for 2020)



Data accessed on 27 Jan 2021
For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods
[a] Rates per 100,000 men per year.
Data Sources:
Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2020). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: https://gco.iarc.fr/today, accessed [27 January 2021].

Figure 20: Comparison of age-specific anal cancer incidence and mortality rates among women in China (estimates for 2020)



Data accessed on 27 Jan 2021
For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods
[a] Rates per 100,000 women per year.
Data Sources:
Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2020). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: https://gco.iarc.fr/today, accessed [27 January 2021].

3.4.2 Vulva cancer

Cancer of the vulva is rare among women worldwide, with an estimated 44,000 new cases in 2018, representing 6% of all gynaecologic cancers (de Martel C et al. Lancet Glob Health 2020;8(2):e180-e190). Worldwide, about 60% of all vulvar cancer cases occur in more developed countries. Vulvar cancer has two distinct histological patterns with two different risk factor profiles: (1) basaloid/warty types (2) keratinising types. Basaloid/warty lesions are more common in young women, are very often associated with HPV DNA detection (75-100%), and have a similar risk factor profile as cervical cancer. Keratinising vulvar carcinomas represent the majority of the vulvar lesions (>60%), they occur more often in older women and are more rarely associated with HPV (IARC Monograph Vol 100B).

3.4.2.1 Vulva cancer incidence in China

Table 9: Vulva cancer incidence in China (estimates for 2020)

Indicator	China	Eastern Asia	World
Annual number of new cancer cases	3,323	4,999	45,240
Uncertainty intervals [95% UI]	[2,888-3,823]	[4,421-5,652]	[40,656-50,342]
Crude incidence rate[b]	0.47	0.61	1.17
Age-standardized incidence rate[b]	0.29	0.33	0.85
Cumulative risk (%) at 75 years old[a]	0.03	0.03	0.09

Data accessed on 27 Jan 2021
For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods
[a] Cumulative risk (incidence) is the probability or risk of individuals getting from the disease during ages 0-74 years. For cancer, it is expressed as the % of new born children who would be expected to develop from a particular cancer before the age of 75 if they had the rates of cancer observed in the period in the absence of competing causes.
[b] Rates per 100,000 women per year.
Data Sources:
Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2020). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: https://gco.iarc.fr/today, accessed [27 January 2021].

Figure 21: Age-specific incidence rates of vulva cancer in China (estimates for 2020)



Data accessed on 27 Jan 2021
For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods
[a] Rates per 100,000 women per year.
Data Sources:
Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2020). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: https://gco.iarc.fr/today, accessed [27 January 2021].

Figure 22: Annual number of new cases of vulva cancer in China (estimates for 2020)



Data accessed on 27 Jan 2021
For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods
Data Sources:
Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2020). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: https://gco.iarc.fr/today, accessed [27 January 2021].

3.4.2.2 Vulva cancer mortality in China

Table 10: Vulva cancer mortality in China (estimates for 2020)

Indicator	China	Eastern Asia	World
Annual number of deaths	1,228	1,662	17,427
Uncertainty intervals [95% UI]	[937-1,609]	[1,304-2,118]	[14,497-20,950]
Crude mortality rate[b]	0.17	0.20	0.45
Age-standardized mortality rate[b]	0.10	0.10	0.30
Cumulative risk (%) at 75 years old[a]	0.01	0.01	0.03

Data accessed on 27 Jan 2021

For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods

[a] Cumulative risk (mortality) is the probability or risk of individuals dying from the disease during ages 0-74 years. For cancer, it is expressed as the % of new born children who would be expected to die from a particular cancer before the age of 75 if they had the rates of cancer observed in the period in the absence of competing causes.

[b] Rates per 100,000 women per year.

Data Sources:

Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2020). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: https://gco.iarc.fr/today, accessed [27 January 2021].

Figure 23: Age-specific mortality rates of vulva cancer in China (estimates for 2020)



Data accessed on 27 Jan 2021
For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods
[a] Rates per 100,000 women per year.
Data Sources:
Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2020). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: https://gco.iarc.fr/today, accessed [27 January 2021].

Figure 24: Annual number of deaths of vulva cancer in China (estimates for 2020)



Data accessed on 27 Jan 2021
For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods
[a] Rates per 100,000 women per year.
Data Sources:
Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2020). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: https://gco.iarc.fr/today, accessed [27 January 2021].

3.4.2.3 Vulva cancer incidence and mortality comparison in China

Figure 25: Comparison of age-specific vulva cancer incidence and mortality rates in China (estimates for 2020)



Data accessed on 27 Jan 2021
For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods
[a] Rates per 100,000 women per year.
Data Sources:
Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2020). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: https://gco.iarc.fr/today, accessed [27 January 2021].

3.4.3 Vaginal cancer

Cancer of the vagina is a rare cancer, with an estimated 18,000 new cases in 2018, representing 3% of all gynaecologic cancers (de Martel C et al. Lancet Glob Health 2020;8(2):e180-e190). Similar to cervical cancer, the majority of vaginal cancer cases (68%) occur in less developed countries. Most vaginal cancers are squamous cell carcinoma (90%) generally attributable to HPV, followed by clear cell adenocarcinomas and melanoma. Vaginal cancers are primarily reported in developed countries. Metastatic cervical cancer can be misclassified as cancer of the vagina. Invasive vaginal cancer is diagnosed primarily in old women (>= 65 years) and the diagnosis is rare in women under 45 years whereas the peak incidence of carcinoma in situ is observed between ages 55 and 70 (Vaccine 2008, Vol. 26, Suppl 10).

3.4.3.1 Vaginal cancer incidence in China

Table 11: Vaginal cancer incidence in China (estimates for 2020)

Indicator	China	Eastern Asia	World
Annual number of new cancer cases	1,640	2,226	17,908
Uncertainty intervals [95% UI]	[1,335-2,015]	[1,804-2,747]	[14,678-21,848]
Crude incidence rate[b]	0.23	0.27	0.46
Age-standardized incidence rate[b]	0.16	0.17	0.36
Cumulative risk (%) at 75 years old[a]	0.02	0.02	0.04

Data accessed on 27 Jan 2021
For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods
[a] Cumulative risk (incidence) is the probability or risk of individuals getting from the disease during ages 0-74 years. For cancer, it is expressed as the % of new born children who would be expected to develop from a particular cancer before the age of 75 if they had the rates of cancer observed in the period in the absence of competing causes.
[b] Rates per 100,000 women per year.
Data Sources:
Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2020). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: https://gco.iarc.fr/today, accessed [27 January 2021].

Figure 26: Age-specific incidence rates of vaginal cancer in China (estimates for 2020)



Data accessed on 27 Jan 2021
For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods
[a] Rates per 100,000 women per year.
Data Sources:
Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2020). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: https://gco.iarc.fr/today, accessed [27 January 2021].

Figure 27: Annual number of new cases of vaginal cancer in China (estimates for 2020)



Data accessed on 27 Jan 2021
For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods
Data Sources:
Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2020). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: https://gco.iarc.fr/today, accessed [27 January 2021].

3.4.3.2 Vaginal cancer mortality in China

Table 12: Vaginal cancer mortality in China (estimates for 2020)

Indicator	China	Eastern Asia	World
Annual number of deaths	682	923	7,995
Uncertainty intervals [95% UI]	[465-999]	[657-1,296]	[5,983-10,684]
Crude mortality rate[b]	0.10	0.11	0.21
Age-standardized mortality rate[b]	0.06	0.06	0.16
Cumulative risk (%) at 75 years old[a]	0.01	0.01	0.02

Data accessed on 27 Jan 2021

For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods

[a] Cumulative risk (mortality) is the probability or risk of individuals dying from the disease during ages 0-74 years. For cancer, it is expressed as the % of new born children who would be expected to die from a particular cancer before the age of 75 if they had the rates of cancer observed in the period in the absence of competing causes.

[b] Rates per 100,000 women per year.

Data Sources:

Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2020). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: https://gco.iarc.fr/today, accessed [27 January 2021].

Figure 28: Age-specific mortality rates of vaginal cancer in China (estimates for 2020)



Data accessed on 27 Jan 2021
For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods
[a] Rates per 100,000 women per year.
Data Sources:
Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2020). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: https://gco.iarc.fr/today, accessed [27 January 2021].

Figure 29: Annual number of deaths of vaginal cancer in China (estimates for 2020)



Data accessed on 27 Jan 2021
For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods
Data Sources:
Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2020). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: https://gco.iarc.fr/today, accessed [27 January 2021].

3.4.3.3 Vaginal cancer incidence and mortality comparison in China

Figure 30: Comparison of age-specific vaginal cancer incidence and mortality rates in China (estimates for 2020)



Data accessed on 27 Jan 2021

For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods

[a] Rates per 100,000 women per year.

Data Sources:

Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2020). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: https://gco.iarc.fr/today, accessed [27 January 2021].

3.4.4 Penile cancer

The annual burden of penile cancer has been estimated to be 34,000 cases in 2018 worldwide with incidence rates strongly correlating with those of cervical cancer (de Martel C et al. Lancet Glob Health 2020;8(2):e180-e190). Penile cancer is rare and most commonly affects men aged 50-70 years. Incidence rates are higher in less developed countries than in more developed countries, accounting for up to 10% of male cancers in some parts of Africa, South America and Asia. Precursor cancerous penile lesions (PeIN) are rare.

Cancers of the penis are primarily of squamous cell carcinomas (SCC) (95%) and the most common penile SCC histologic sub-types are keratinising (49%), mixed warty-basaloid (17%), verrucous (8%) warty (6%), and basaloid (4%). HPV is most commonly detected in basaloid and warty tumours but is less common in keratinising and verrucous tumours. Approximately 60-100% of PeIN lesions are HPV DNA positive.

3.4.4.1 Penile cancer incidence in China

Table 13: Penile cancer incidence in China (estimates for 2020)

Indicator	China	Eastern Asia	World
Annual number of new cancer cases	4,628	5,369	36,068
Uncertainty intervals [95% UI]	[4,092-5,234]	[4,727-6,098]	[30,963-42,015]
Crude incidence rate[b]	0.62	0.63	0.92
Age-standardized incidence rate[b]	0.42	0.40	0.80
Cumulative risk (%) at 75 years old[a]	0.05	0.04	0.09

Data accessed on 27 Jan 2021
For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods
[a] Cumulative risk (incidence) is the probability or risk of individuals getting from the disease during ages 0-74 years. For cancer, it is expressed as the % of new born children who would be expected to develop from a particular cancer before the age of 75 if they had the rates of cancer observed in the period in the absence of competing causes.
[b] Rates per 100,000 men per year.
Data Sources:
Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2020). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: https://gco.iarc.fr/today, accessed [27 January 2021].

Figure 31: Age-specific incidence rates of penile cancer in China (estimates for 2020)



Data accessed on 27 Jan 2021
For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods
[a] Rates per 100,000 men per year.
Data Sources:
Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2020). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: https://gco.iarc.fr/today, accessed [27 January 2021].

Figure 32: Annual number of new cases of penile cancer in China (estimates for 2020)



Data accessed on 27 Jan 2021
For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods
Data Sources:
Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2020). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: https://gco.iarc.fr/today, accessed [27 January 2021].

3.4.4.2 Penile cancer mortality in China

Table 14: Penile cancer mortality in China (estimates for 2020)

Indicator	China	Eastern Asia	World
Annual number of deaths	1,565	1,788	13,211
Uncertainty intervals [95% UI]	[1,214-2,017]	[1,396-2,291]	[10,687-16,332]
Crude mortality rate[b]	0.21	0.21	0.34
Age-standardized mortality rate[b]	0.14	0.13	0.29
Cumulative risk (%) at 75 years old[a]	0.01	0.01	0.03

Data accessed on 27 Jan 2021

For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods

[a] Cumulative risk (mortality) is the probability or risk of individuals dying from the disease during ages 0-74 years. For cancer, it is expressed as the % of new born children who would be expected to die from a particular cancer before the age of 75 if they had the rates of cancer observed in the period in the absence of competing causes.

[b] Rates per 100,000 men per year.

Data Sources:

Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2020). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: https://gco.iarc.fr/today, accessed [27 January 2021].

Figure 33: Age-specific mortality rates of penile cancer in China (estimates for 2020)



Data accessed on 27 Jan 2021
For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods
[a] Rates per 100,000 men per year.
Data Sources:
Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2020). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: https://gco.iarc.fr/today, accessed [27 January 2021].

Figure 34: Annual number of deaths of penile cancer in China (estimates for 2020)



Data accessed on 27 Jan 2021
For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods
Data Sources:
Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2020). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: https://gco.iarc.fr/today, accessed [27 January 2021].

3.4.4.3 Penile cancer incidence and mortality comparison in China

Figure 35: Comparison of age-specific penile cancer incidence and mortality rates in China (estimates for 2020)



Data accessed on 27 Jan 2021
For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods
[a] Rates per 100,000 men per year.
Data Sources:
Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2020). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: https://gco.iarc.fr/today, accessed [27 January 2021].

3.5 Head and neck cancers

The majority of head and neck cancers are associated with high tobacco and alcohol consumption. However, increasing trends in the incidence at specific sites suggest that other aetiological factors are involved, and infection by certain high-risk types of HPV (i.e. HPV16) have been reported to be associated with head and neck cancers, in particular with oropharyngeal cancer. Current evidence suggests that HPV16 is associated with tonsil cancer (including Waldeyer ring cancer), base of tongue cancer and other oropharyngeal cancer sites. Associations with other head and neck cancer sites such as oral cancer are neither strong nor consistent when compared to molecular-epidemiological data on HPV and oropharyngeal cancer. Association with laryngeal cancer is still unclear (IARC Monograph Vol 100B)

3.5.1 Oropharyngeal cancer

3.5.1.1 Oropharyngeal cancer incidence in China

Table 15: Oropharyngeal cancer incidence in China (estimates for 2020)

Indicator	China	Eastern Asia	World
MEN			
Annual number of new cancer cases	4,372	8,377	79,045
Uncertainty intervals of new cancer cases [95% UI]	[3,850-4,964]	[7,528-9,322]	[72,769-85,862]
Crude incidence rate sa[b]	0.59	0.98	2.01
Age-standardized incidence rate sa[b]	0.39	0.63	1.79
Cumulative risk (%) at 75 years old[a]	0.04	0.07	0.22
WOMEN			
Annual number of new cancer cases	1,232	1,812	19,367
Uncertainty intervals of new cancer cases [95% UI]	[970-1,565]	[1,424-2,306]	[16,279-23,041]
Crude incidence rate sa[c]	0.17	0.22	0.50
Age-standardized incidence rate sa[c]	0.11	0.13	0.40
Cumulative risk (%) at 75 years old[a]	0.01	0.01	0.05

Data accessed on 27 Jan 2021
For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods
[a] Cumulative risk (incidence) is the probability or risk of individuals getting from the disease during ages 0-74 years. For cancer, it is expressed as the % of new born children who would be expected to develop from a particular cancer before the age of 75 if they had the rates of cancer observed in the period in the absence of competing causes.
[b] Rates per 100,000 men per year.
[c] Rates per 100,000 women per year.
Data Sources:
Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2020). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: https://gco.iarc.fr/today, accessed [27 January 2021].

Figure 36: Age-specific incidence rates of oropharyngeal cancer in China (estimates for 2020)



Data accessed on 27 Jan 2021
For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods
[a] Rates per 100,000 men per year.
[b] Rates per 100,000 women per year.
Data Sources:
Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2020). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: https://gco.iarc.fr/today, accessed [27 January 2021].

Figure 37: Annual number of new cases of oropharyngeal cancer in China (estimates for 2020)



Data accessed on 27 Jan 2021
For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods
Data Sources:
Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2020). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: https://gco.iarc.fr/today, accessed [27 January 2021].

3.5.1.2 Oropharyngeal cancer mortality in China

Table 16: Oropharyngeal cancer mortality in China (estimates for 2020)

Indicator	China	Eastern Asia	World
MEN			
Annual number of deaths	2,385	4,208	39,590
Uncertainty intervals of mortality cancer cases [95% UI]	[1,948-2,920]	[3,566-4,965]	[35,255-44,458]
Crude mortality rate sa[b]	0.32	0.49	1.01
Age-standardized mortality rate sa[b]	0.21	0.31	0.89
Cumulative risk (%) at 75 years old[a]	0.02	0.03	0.11
WOMEN			
Annual number of deaths	520	777	8,553
Uncertainty intervals of mortality cancer cases [95% UI]	[334-811]	[540-1,119]	[6,684-10,945]
Crude mortality rate sa[c]	0.07	0.09	0.22
Age-standardized mortality rate sa[c]	0.04	0.05	0.17
Cumulative risk (%) at 75 years old[a]	0.00	0.01	0.02

Data accessed on 27 Jan 2021
For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods
[a] Cumulative risk (mortality) is the probability or risk of individuals dying from the disease during ages 0-74 years. For cancer, it is expressed as the % of new born children who would be expected to die from a particular cancer before the age of 75 if they had the rates of cancer observed in the period in the absence of competing causes.
[b] Rates per 100,000 men per year.
[c] Rates per 100,000 women per year.
Data Sources:
Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2020). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: https://gco.iarc.fr/today, accessed [27 January 2021].

Figure 38: Age-specific mortality rates of oropharyngeal cancer in China (estimates for 2020)



Data accessed on 27 Jan 2021
For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods
[a] Rates per 100,000 men per year.
[b] Rates per 100,000 women per year.
Data Sources:
Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2020). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: https://gco.iarc.fr/today, accessed [27 January 2021].

Figure 39: Annual number of deaths of oropharyngeal cancer in China (estimates for 2020)



Data accessed on 27 Jan 2021
For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods
Data Sources:
Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2020). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: https://gco.iarc.fr/today, accessed [27 January 2021].

3.5.1.3 Oropharyngeal cancer incidence and mortality comparison in China

Figure 40: Comparison of age-specific oropharyngeal cancer incidence and mortality rates among men in China (estimates for 2020)



Data accessed on 27 Jan 2021
For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods
[a] Rates per 100,000 men per year.
Data Sources:
Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2020). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: https://gco.iarc.fr/today, accessed [27 January 2021].

Figure 41: Comparison of age-specific oropharyngeal cancer incidence and mortality rates among women in China (estimates for 2020)



Data accessed on 27 Jan 2021
For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods
[a] Rates per 100,000 women per year.
Data Sources:
Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2020). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: https://gco.iarc.fr/today, accessed [27 January 2021].

3.5.2 Oral cavity cancer

3.5.2.1 Oral cavity cancer incidence in China

Table 17: Oral cavity cancer incidence in China (estimates for 2020)

Indicator	China	Eastern Asia	World
MEN			
Annual number of new cancer cases	18,546	33,658	264,211
Uncertainty intervals of new cancer cases [95% UI]	[17,440-19,722]	[31,886-35,528]	[251,153-277,948]
Crude incidence rate sa[b]	2.50	3.93	6.72
Age-standardized incidence rate sa[b]	1.68	2.55	5.96
Cumulative risk (%) at 75 years old[a]	0.20	0.29	0.68
WOMEN			
Annual number of new cancer cases	11,571	17,500	113,502
Uncertainty intervals of new cancer cases [95% UI]	[10,718-12,492]	[16,363-18,716]	[105,599-121,997]
Crude incidence rate sa[c]	1.64	2.13	2.94
Age-standardized incidence rate sa[c]	1.00	1.19	2.28
Cumulative risk (%) at 75 years old[a]	0.12	0.13	0.26

Data accessed on 27 Jan 2021

For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods

[a] Cumulative risk (incidence) is the probability or risk of individuals getting from the disease during ages 0-74 years. For cancer, it is expressed as the % of new born children who would be expected to develop from a particular cancer before the age of 75 if they had the rates of cancer observed in the period in the absence of competing causes.

[b] Rates per 100,000 men per year.

[c] Rates per 100,000 women per year.

Data Sources:

Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2020). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: https://gco.iarc.fr/today, accessed [27 January 2021].

Figure 42: Age-specific incidence rates of oral cavity cancer in China (estimates for 2020)



Data accessed on 27 Jan 2021
For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods
[a] Rates per 100,000 men per year.
[b] Rates per 100,000 women per year.
Data Sources:
Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2020). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: https://gco.iarc.fr/today, accessed [27 January 2021].

Figure 43: Annual number of new cases of oral cavity cancer in China (estimates for 2020)



Data accessed on 27 Jan 2021
For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods
Data Sources:
Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2020). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: https://gco.iarc.fr/today, accessed [27 January 2021].

3.5.2.2 Oral cavity cancer incidence and mortality comparison in China

Table 18: Oral cavity cancer mortality in China (estimates for 2020)

Indicator	China	Eastern Asia	World
MEN			
Annual number of deaths	9,338	14,083	125,022
Uncertainty intervals of mortality cancer cases [95% UI]	[8,440-10,332]	[12,818-15,472]	[116,573-134,084]
Crude mortality rate sa[b]	1.26	1.65	3.18
Age-standardized mortality rate sa[b]	0.84	1.04	2.82
Cumulative risk (%) at 75 years old[a]	0.09	0.11	0.32
WOMEN			
Annual number of deaths	5,447	7,850	52,735
Uncertainty intervals of mortality cancer cases [95% UI]	[4,772-6,217]	[7,010-8,791]	[47,690-58,313]
Crude mortality rate sa[c]	0.77	0.95	1.36
Age-standardized mortality rate sa[c]	0.44	0.47	1.04
Cumulative risk (%) at 75 years old[a]	0.05	0.05	0.12

Data accessed on 27 Jan 2021
For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods
[a] Cumulative risk (mortality) is the probability or risk of individuals dying from the disease during ages 0-74 years. For cancer, it is expressed as the % of new born children who would be expected to die from a particular cancer before the age of 75 if they had the rates of cancer observed in the period in the absence of competing causes.
[b] Rates per 100,000 men per year.
[c] Rates per 100,000 women per year.
Data Sources:
Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2020). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: https://gco.iarc.fr/today, accessed [27 January 2021].

Figure 44: Age-specific mortality rates of oral cavity cancer in China (estimates for 2020)



Data accessed on 27 Jan 2021
For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods
[a] Rates per 100,000 men per year.
[b] Rates per 100,000 women per year.
Data Sources:
Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2020). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: https://gco.iarc.fr/today, accessed [27 January 2021].

Figure 45: Annual number of deaths of oral cavity cancer in China (estimates for 2020)



Data accessed on 27 Jan 2021
For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods
Data Sources:
Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2020). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: https://gco.iarc.fr/today, accessed [27 January 2021].

3.5.2.3 Oral cavity cancer incidence and mortality comparison in China

Figure 46: Comparison of age-specific oral cavity cancer incidence and mortality rates among men in China (estimates for 2020)



Data accessed on 27 Jan 2021
For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods
[a] Rates per 100,000 men per year.
Data Sources:
Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2020). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: https://gco.iarc.fr/today, accessed [27 January 2021].

Figure 47: Comparison of age-specific oral cavity cancer incidence and mortality rates among women in China (estimates for 2020)



Data accessed on 27 Jan 2021
For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods
[a] Rates per 100,000 women per year.
Data Sources:
Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2020). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: https://gco.iarc.fr/today, accessed [27 January 2021].

3.5.3 Laryngeal cancer

3.5.3.1 Laryngeal cancer incidence in China

Table 19: Laryngeal cancer incidence in China (estimates for 2020)

Indicator	China	Eastern Asia	World
MEN			
Annual number of new cancer cases	25,871	33,020	160,265
Uncertainty intervals of new cancer cases [95% UI]	[24,543-27,270]	[31,412-34,710]	[150,633-170,513]
Crude incidence rate sa[b]	3.49	3.86	4.08
Age-standardized incidence rate sa[b]	2.29	2.41	3.59
Cumulative risk (%) at 75 years old[a]	0.29	0.30	0.45
WOMEN			
Annual number of new cancer cases	3,264	3,831	24,350
Uncertainty intervals of new cancer cases [95% UI]	[2,810-3,792]	[3,281-4,474]	[20,845-28,444]
Crude incidence rate sa[c]	0.46	0.47	0.63
Age-standardized incidence rate sa[c]	0.27	0.26	0.49
Cumulative risk (%) at 75 years old[a]	0.03	0.03	0.06

Data accessed on 27 Jan 2021

For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods

[a] Cumulative risk (incidence) is the probability or risk of individuals getting from the disease during ages 0-74 years. For cancer, it is expressed as the % of new born children who would be expected to develop from a particular cancer before the age of 75 if they had the rates of cancer observed in the period in the absence of competing causes.

[b] Rates per 100,000 men per year.

[c] Rates per 100,000 women per year.

Data Sources:

Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2020). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: https://gco.iarc.fr/today, accessed [27 January 2021].

Figure 48: Age-specific incidence rates of laryngeal cancer in China (estimates for 2020)



Data accessed on 27 Jan 2021
For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods
[a] Rates per 100,000 men per year.
[b] Rates per 100,000 women per year.
Data Sources:
Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2020). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: https://gco.iarc.fr/today, accessed [27 January 2021].

Figure 49: Annual number of new cases of laryngeal cancer in China (estimates for 2020)



Data accessed on 27 Jan 2021
For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods
Data Sources:
Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2020). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: https://gco.iarc.fr/today, accessed [27 January 2021].

3.5.3.2 Laryngeal cancer incidence and mortality comparison in China

Table 20: Laryngeal cancer mortality in China (estimates for 2020)

Indicator	China	Eastern Asia	World
MEN			
Annual number of deaths	13,471	15,261	85,351
Uncertainty intervals of mortality cancer cases [95% UI]	[12,396-14,639]	[14,049-16,578]	[78,895-92,335]
Crude mortality rate sa[b]	1.82	1.78	2.17
Age-standardized mortality rate sa[b]	1.19	1.09	1.89
Cumulative risk (%) at 75 years old[a]	0.14	0.13	0.23
WOMEN			
Annual number of deaths	2,343	2,537	14,489
Uncertainty intervals of mortality cancer cases [95% UI]	[1,916-2,864]	[2,067-3,114]	[11,902-17,639]
Crude mortality rate sa[c]	0.33	0.31	0.37
Age-standardized mortality rate sa[c]	0.19	0.16	0.28
Cumulative risk (%) at 75 years old[a]	0.02	0.02	0.03

Data accessed on 27 Jan 2021

For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods

[a] Cumulative risk (mortality) is the probability or risk of individuals dying from the disease during ages 0-74 years. For cancer, it is expressed as the % of new born children who would be expected to die from a particular cancer before the age of 75 if they had the rates of cancer observed in the period in the absence of competing causes.

[b] Rates per 100,000 men per year.

[c] Rates per 100,000 women per year.

Data Sources:

Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2020). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: https://gco.iarc.fr/today, accessed [27 January 2021].

Figure 50: Age-specific mortality rates of laryngeal cancer in China (estimates for 2020)



Data accessed on 27 Jan 2021
For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods
[a] Rates per 100,000 men per year.
[b] Rates per 100,000 women per year.
Data Sources:
Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2020). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: https://gco.iarc.fr/today, accessed [27 January 2021].

Figure 51: Annual number of deaths of of laryngeal cancer in China (estimates for 2020)



Data accessed on 27 Jan 2021
For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods
Data Sources:
Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2020). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: https://gco.iarc.fr/today, accessed [27 January 2021].

3.5.3.3 Laryngeal cancer incidence and mortality comparison in China

Figure 52: Comparison of age-specific laryngeal cancer incidence and mortality rates among men in China (estimates for 2020)



Data accessed on 27 Jan 2021
For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods
[a] Rates per 100,000 men per year.
Data Sources:
Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2020). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: https://gco.iarc.fr/today, accessed [27 January 2021].

Figure 53: Comparison of age-specific laryngeal cancer incidence and mortality rates among women in China (estimates for 2020)



Data accessed on 27 Jan 2021
For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods
[a] Rates per 100,000 women per year.
Data Sources:
Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2020). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: https://gco.iarc.fr/today, accessed [27 January 2021].

4 HPV related statistics

HPV infection is commonly found in the anogenital tract of men and women with and without clinical lesions. The aetiological role of HPV infection among women with cervical cancer is well-established, and there is growing evidence of its central role in other anogenital sites. HPV is also responsible for other diseases such as recurrent juvenile respiratory papillomatosis and genital warts, both mainly caused by HPV types 6 and 11 (Lacey CJ, Vaccine 2006; 24(S3):35). For this section, the methodologies used to compile the information on HPV burden are derived from systematic reviews and meta-analyses of the literature. Due to the limitations of HPV DNA detection methods and study designs used, these data should be interpreted with caution and used only as a guide to assess the burden of HPV infection within the population. (Vaccine 2006, Vol. 24, Suppl 3; Vaccine 2008, Vol. 26, Suppl 10; Vaccine 2012,Vol. 30, Suppl 5; IARC Monographs 2007, Vol. 90).

4.1 HPV burden in women with normal cervical cytology, cervical precancerous lesions or invasive cervical cancer

The statistics shown in this section focus on HPV infection in the cervix uteri. HPV cervical infection results in cervical morphological lesions ranging from normalcy (cytologically normal women) to different stages of precancerous lesions (CIN-1, CIN-2, CIN-3/CIS) and invasive cervical cancer. HPV infection is measured by HPV DNA detection in cervical cells (fresh tissue, paraffin embedded or exfoliated cells). The prevalence of HPV increases with lesion severity. HPV causes virtually 100% of cervical cancer cases, and an underestimation of HPV prevalence in cervical cancer is most likely due to the limitations of study methodologies. Worldwide, HPV16 and 18 (the two vaccine-preventable types) contribute to over 70% of all cervical cancer cases, between 41% and 67% of high-grade cervical lesions and 16-32% of low-grade cervical lesions. After HPV16/18, the six most common HPV types are the same in all world regions, namely 31, 33, 35, 45, 52 and 58; these account for an additional 20% of cervical cancers worldwide (Clifford G, Vaccine 2006;24(S3):26).

Methods: Prevalence and type distribution of human papillomavirus in cervical carcinoma, low-grade cervical lesions, high-grade cervical lesions and normal cytology: systematic review and meta-analysis

A systematic review of the literature was conducted regarding the worldwide HPV-prevalence and type distribution for cervical carcinoma, low-grade cervical lesions, high-grade cervical lesions and normal cytology from 1990 to 'data as of' indicated in each section. The search terms for the review were 'HPV' AND cerv* using Pubmed. There were no limits in publication language. References cited in selected articles were also investigated. Inclusion criteria were: HPV DNA detection by means of PCR or HC2, a minimum of 20 cases for cervical carcinoma, 20 cases for low-grade cervical lesions, 20 cases for highgrade cervical lesions and 100 cases for normal cytology and a detailed description of HPV DNA detection and genotyping techniques used. The number of cases tested and HPV positive extracted for each study were pooled to estimate the prevalence of HPV DNA and the HPV type distribution globally and by geographical region. Binomial 95% confidence intervals were calculated for each HPV prevalence. For more details refer to the methods document.

4.1.1 HPV prevalence in women with normal cervical cytology

Figure 54: Crude age-specific HPV prevalence (%) and 95% confidence interval in women with normal cervical cytology in China



Data updated on 30 Jun 2015 (data as of 30 Jun 2014)

Data Sources:
Belinson J, Gynecol Oncol 2001; 83: 439 | Dai M, Br J Cancer 2006; 95: 96 | Li LK, Br J Cancer 2006; 95: 1593 | Wu RF, Int J Cancer 2007; 121: 1306
Based on systematic reviews and meta-analysis performed by ICO. The ICO HPV Information Centre has updated data until June 2014. Reference publications: 1) Bruni L, J Infect Dis 2010; 202: 1789. 2) De Sanjosé S, Lancet Infect Dis 2007; 7: 453

Figure 55: HPV prevalence among women with normal cervical cytology in China, by study



Wei 2014 (Shenyang (Liaoning Province))	18−81	67172	1.7 (1.6−1.8)
Chen 2012 (Chaozhou)[c]	35−60	48559	7.9 (7.7−8.1)
Wang 2012 (Shenyang (Liaoning Province))[c]	18−60	24041	45.6 (45.0−46.2)
Mai 2014[d]	>=18	22114	19.0 (18.5−19.5)
DU 2012 (Shenzhen)[c]	20−59	10017	16.3 (15.6−17.0)
Zhang 2013 (Shangai)[c]	17−89	10000	12.6 (11.9−13.2)
Belinson 2011 (Guangdong Province)	25−59	7525	7.9 (7.3−8.5)
Moy 2010[e]	30−54	7367	9.5 (8.9−10.2)
Zhao 2013 (Yangcheng, Xinmi and Tonggu)	25−65	7089	10.9 (10.2−11.7)
Belinson 2003[b]	27−56	6643	14.4 (13.6−15.3)
Zhang 2008 (Shangai)[c]	18−78	6405	29.1 (28.0−30.2)
Sun 2012 (Qujing (Yunnan Province))[c]	18−65	5936	8.3 (7.6−9.1)
Li 2010 (Beijing)	25−54	5530	6.6 (6.0−7.3)
Zhao 2014 (Jiangsi Province)	18−25	5416	13.3 (12.5−14.3)
Ye 2010 (Zhejiang Province)	20−79	4987	13.3 (12.4−14.3)
Wang 2013 (Shenzhen)[c]	>=15	4413	13.8 (12.8−14.8)
Wu 2013[g]	17−54	3737	8.9 (8.0−9.9)
Li 2013 (Hunan Province)	17−74	3115	14.5 (13.3−15.8)
Yuan 2011 (Shandong Province)	20−61	3112	9.6 (8.6−10.7)
Jin 2010 (Tibetan Autonomous Region)	19−65	2847	7.4 (6.5−8.4)
Chan 2009 (Hong Kong)[c]	19−83	2604	6.7 (5.8−7.7)
Chen 2013 (Urumqi)[c]	18−69	2269	20.3 (18.7−22.0)
Wu 2010 (Shenzhen (Guangdong Province))[c]	25−59	2000	16.5 (14.9−18.2)
Chan 2002 (Hong Kong)	19−83	1962	5.6 (4.6−6.7)
Belinson 2001[b]	35−45	1784	14.2 (12.6−15.9)
Lin 2008 (Guandong)[c]	20−68	1705	9.0 (7.8−10.5)
Yip 2010 (Macao)[c]	20−60	1600	8.8 (7.5−10.2)
Yeoh 2006 (Hong Kong)	−	1090	25.7 (23.2−28.4)
Zhang 2012[c,j]	20−64	1032	11.1 (9.4−13.2)
Wu 2007 (Shenzhen)	15−59	942	11.9 (10.0−14.1)
Sui 2013[c,f]	16−59	883	8.8 (7.1−10.9)
Ye 2010[c,h]	25−65	734	20.2 (17.4−23.2)
Li 2006 (Shenyang)	17−59	663	13.7 (11.3−16.6)
Dai 2006 (Shanxi)	19−59	601	10.6 (8.4−13.4)
He 2008 (Hangzhou)	−	480	15.2 (12.3−18.7)
Chui 2012 (Macau)[c]	20−66	402	29.9 (25.6−34.5)
Bian 2013 (Beijing)	20−55	379	20.8 (17.1−25.2)
Yu 2013[c,i]	20−60	373	12.6 (9.6−16.4)
Wu 2010 (Fujian Province)	20−70	314	19.4 (15.4−24.2)
Wang 2013 (Huzhou)	20−35	292	19.2 (15.1−24.1)
Hu 2011 (Jaingsu Province)	18−25	257	10.5 (7.3−14.9)
Ding 2014 (Beijing)	18−68	165	9.7 (6.1−15.2)
Sun 2010 (Liaoning Province)	−	165	21.8 (16.2−28.7)

Data updated on 30 Jun 2015 (data as of 30 Jun 2014)

The samples for HPV testing come from cervical specimens (fresh/fixed biopsies or exfoliated cells)
[a] Number of women tested
[b] Yangcheng and Xiangyuan (Shanxi)
[c] Women from the general population, including some with cytological cervical abnormalities
[d] Shantou City (Guandong Province)

[e] Shanxi, Jiangxi and Gansu Provinces
[f] Uyghur (Yutian County, Xingjian Province)
[g] Beijing, Shanghai, Shanxi, Henan, Xinjiang
[h] Lishui County (Zhejiang Province)
[i] Shiquan County (Shaanxi Province)
[j] Wufeng County (Hubei Province)

Data Sources:

Belinson J, Gynecol Oncol 2001; 83: 439 | Belinson JL, Am J Clin Pathol 2011; 135: 790 | Belinson JL, Int J Gynecol Cancer 2003; 13: 819 | Bian ML, Exp Ther Med 2013; 6: 1332 | Chan PK, J Infect Dis 2002; 185: 28 | Chan PK, J Med Virol 2009; 81: 1635 | Chen Q, PLoS ONE 2012; 7: e32149 | Chen Z, Exp Ther Med 2013; 6: 85 | Chui SH, Public Health 2012; 126: 600 | Dai M, Br J Cancer 2006; 95: 96 | Ding X, J Med Virol 2014; 86: 1937 | DU H, Zhonghua Liu Xing Bing Xue Za Zhi 2012; 33: 799 | He X, Eur J Epidemiol 2008; 23: 403 | Hu SY, Chin J Cancer Res 2011; 23: 25 | Jin Q, Chin Med J 2010; 123: 2004 | Li C, Cancer Epidemiol Biomarkers Prev 2010; 19: 2655 | Li H, Eur J Obstet Gynecol Reprod Biol 2013; 170: 202 | Li LK, Br J Cancer 2006; 95: 1593 | Lin M, Aust N Z J Obstet Gynaecol 2008; 48: 189 | Mai RQ, Asian Pac J Cancer Prev 2014; 15: 4945 | Moy LM, Int J Cancer 2010; 127: 646 | Sui S, Asian Pac J Cancer Prev 2013; 14: 5861 | Sun LL, Virol J 2012; 9: 153 | Sun ZR, Int J Gynaecol Obstet 2010; 109: 105 | Wang S, BMC Cancer 2012; 12: 160 | Wang X, Int J Gynaecol Obstet 2013; 120: 37 | Wang YY, Asian Pac J Cancer Prev 2013; 14: 7483 | Wei H, Int J Gynaecol Obstet 2014; 126: 28 | Wu D, Eur J Obstet Gynecol Reprod Biol 2010; 151: 86 | Wu EQ, Cancer Causes Control 2013; 24: 795 | Wu R, Int J Gynecol Cancer 2010; 20: 1411 | Wu RF, Int J Cancer 2007; 121: 1306 | Ye J, Int J Gynecol Cancer 2010; 20: 1374 | Ye J, Virol J 2010; 7: 66 | Yeoh GP, Acta Cytol 2006; 50: 627 | Yip YC, J Med Virol 2010; 82: 1724 | Yu XW, J Low Genit Tract Dis 2013; 17: 17 | Yuan X, Arch Gynecol Obstet 2011; 283: 1385 | Zhang L, Arch Gynecol Obstet 2012; 286: 695 | Zhang R, J Clin Virol 2013; 58: 144 | Zhang WY, Chin Med J 2008; 121: 1578 | Zhao FH, Cancer Prev Res (Phila) 2013; 6: 938 | Zhao FH, Int J Cancer 2014; 135: 2604

Based on systematic reviews and meta-analysis performed by ICO. The ICO HPV Information Centre has updated data until June 2014. Reference publications: 1) Bruni L, J Infect Dis 2010; 202: 1789. 2) De Sanjosé S, Lancet Infect Dis 2007; 7: 453

4.1.2 HPV type distribution among women with normal cervical cytology, precancerous cervical lesions and cervical cancer

Table 21: Prevalence of HPV16 and HPV18 by cytology in China

	No. tested	HPV 16/18 Prevalence % (95% CI)
Normal cytology[1,2]	48689	3.8 (3.6-4.0)
Low-grade lesions[3,4]	3716	22.3 (21.0-23.7)
High-grade lesions[5,6]	5979	44.1 (42.9-45.4)
Cervical cancer[7,8]	6435	69.1 (68.0-70.2)

Data updated on 19 May 2017 (data as of 30 Jun 2015 / 30 Nov 2014)

The samples for HPV testing come from cervical specimens (fresh/fixed biopsies or exfoliated cells)
[a] Number of women tested
[b] 95% Confidence Interval

Data Sources:

[1] Bian ML, Exp Ther Med 2013; 6: 1332 | Dai M, Br J Cancer 2006; 95: 96 | Ding X, J Med Virol 2014; 86: 1937 | Jin Q, Chin Med J 2010; 123: 2004 | Li H, Eur J Obstet Gynecol Reprod Biol 2013; 170: 202 | Li LK, Br J Cancer 2006; 95: 1593 | Mai RQ, Asian Pac J Cancer Prev 2014; 15: 4945 | Sun ZR, Int J Gynaecol Obstet 2010; 109: 105 | Wei H, Int J Gynaecol Obstet 2014; 126: 28 | Wu D, Eur J Obstet Gynecol Reprod Biol 2010; 151: 86 | Wu EQ, Cancer Causes Control 2013; 24: 795 | Wu RF, Int J Cancer 2007; 121: 1306 | Yuan X, Arch Gynecol Obstet 2011; 283: 1385 | Zhao FH, Int J Cancer 2014; 135: 2604 | Zhao R, Br J Cancer 2009; 101: 1635

[2] Based on systematic reviews and meta-analysis performed by ICO. The ICO HPV Information Centre has updated data until November 2014. Reference publications: 1) Bruni L, J Infect Dis 2010; 202: 1789. 2) De Sanjosé S, Lancet Infect Dis 2007; 7: 453

[3] Contributing studies: Chan PK, Int J Cancer 2006; 118: 243 | Chan PK, Int J Cancer 2012; 131: 692 | Chan PK, J Med Virol 1999; 59: 232 | Ding X, J Med Virol 2014; 86: 1937 | Guo J, Scand J Infect Dis 2010; 42: 72 | Hong D, Int J Gynecol Cancer 2008; 18: 104 | Jin Q, Chin Med J 2010; 123: 2004 | Li H, Eur J Obstet Gynecol Reprod Biol 2013; 170: 202 | Li J, J Clin Microbiol 2012; 50: 1079 | Liu SS, Tumour Biol 2008; 29: 105 | Liu X, Int J Gynecol Cancer 2010; 20: 147 | Sun B, Arch Virol 2014; 159: 1027 | Tao PP, Zhonghua Fu Chan Ke Za Zhi 2006; 41: 43 | Wu D, Eur J Obstet Gynecol Reprod Biol 2010; 151: 86 | Wu EQ, Cancer Causes Control 2013; 24: 795 | Yuan X, Arch Gynecol Obstet 2011; 283: 1385 | Zhang R, Cancer Epidemiol 2013; 37: 939 | Zhao FH, Int J Cancer 2014; 135: 2604 | Zhao Y, Pathol Int 2008; 58: 643

[4] Based on meta-analysis performed by IARC's Infections and Cancer Epidemiology Group up to November 2011, the ICO HPV Information Centre has updated data until June 2015. Reference publications: 1) Guan P, Int J Cancer 2012;131:2349 2) Clifford GM, Cancer Epidemiol Biomarkers Prev 2005;14:1157

[5] Contributing studies: Chan MK, Gynecol Oncol 1996; 60: 217 | Chan PK, Int J Cancer 2006; 118: 243 | Chan PK, Int J Cancer 2012; 131: 692 | Chan PK, J Med Virol 1999; 59: 232 | Ding X, J Med Virol 2014; 86: 1937 | Guo J, Scand J Infect Dis 2010; 42: 72 | Jin Q, Chin Med J 2010; 123: 2004 | Li H, Eur J Obstet Gynecol Reprod Biol 2013; 170: 202 | Li J, Int J Gynaecol Obstet 2011; 112: 131 | Li J, J Clin Microbiol 2012; 50: 1079 | Liu SS, Tumour Biol 2008; 29: 105 | Singh S, Int J Clin Exp Pathol 2015; 8: 11901 | Sun B, Arch Virol 2014; 159: 1027 | Tao PP, Zhonghua Fu Chan Ke Za Zhi 2006; 41: 43 | Wu CH, Sex Transm Dis 1994; 21: 309 | Wu EQ, Cancer Causes Control 2013; 24: 795 | Yuan X, Arch Gynecol Obstet 2011; 283: 1385 | Zhang R, Cancer Epidemiol 2013; 37: 939 | Zhao FH, Int J Cancer 2014; 135: 2604 | Zhao Y, Pathol Int 2008; 58: 643

[6] Based on meta-analysis performed by IARC's Infections and Cancer Epidemiology Group up to November 2011, the ICO HPV Information Centre has updated data until June 2015. Reference publications: 1) Guan P, Int J Cancer 2012;131:2349 2) Smith JS, Int J Cancer 2007;121:621 3) Clifford GM, Br J Cancer 2003;89:101.

[7] Contributing studies: Cai HB, Eur J Gynaecol Oncol 2008; 29: 72 | Cai HB, Oncology 2009; 76: 157 | Chan PK, Int J Cancer 2009; 125: 1671 | Chan PK, Int J Cancer 2012; 131: 692 | Chen W, Cancer Causes Control 2009; 20: 1705 | Ding X, J Med Virol 2014; 86: 1937 | Gao YE, Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao 2003; 35: 1029 | Hong D, Int J Gynecol Cancer 2008; 18: 104 | Huang S, Int J Cancer 1997; 70: 408 | Li H, Eur J Obstet Gynecol Reprod Biol 2013; 170: 202 | Lin QQ, Int J Cancer 1998; 75: 484 | Liu GB, J First Mil Med Univ 2005; 25: 1236 | Liu J, Gynecol Oncol 2004; 94: 803 | Liu SS, Tumour Biol 2008; 29: 105 | Liu X, Int J Gynecol Cancer 2010; 20: 147 | Lo KW, Gynecol Obstet Invest 2001; 51: 202 | Lo KW, Int J Cancer 2002; 100: 327 | Peng HQ, Int J Cancer 1991; 47: 711 | Qiu AD, Gynecol Oncol 2007; 104: 77 | Serrano B, Cancer Epidemiol 2014 | Shah W, Clin Oncol (R Coll Radiol) 2009; 21: 768 | Stephen AL, Int J Cancer 2000; 86: 695 | Tao PP, Zhonghua Fu Chan Ke Za Zhi 2006; 41: 43 | Wang L, J Med Virol 2015; 87: 516 | Wu EQ, BMC Cancer 2008; 8: 202 | Wu EQ, Int J Gynecol Cancer 2009; 19: 919 | Wu Y, J Med Virol 2008; 80: 1808 | Yu MY, Int J Cancer 2003; 105: 204 | Yuan X, Arch Gynecol Obstet 2011; 283: 1385 | Zhao Y, Pathol Int 2008; 58: 643

[8] Based on meta-analysis performed by IARC's Infections and Cancer Epidemiology Group up to November 2011, the ICO HPV Information Centre has updated data until June 2015. Reference publications: 1) Guan P, Int J Cancer 2012;131:2349 2) Li N, Int J Cancer 2011;128:927 3) Smith JS, Int J Cancer 2007;121:621 4) Clifford GM, Br J Cancer 2003;88:63 5) Clifford GM, Br J Cancer 2003;89:101.

Figure 56: HPV 16 prevalence among women with normal cervical cytology in China, by study



Data updated on 30 Jun 2015 (data as of 30 Jun 2014)

The samples for HPV testing come from cervical specimens (fresh/fixed biopsies or exfoliated cells)
[a] Number of women tested

Data Sources:
Bian ML, Exp Ther Med 2013; 6: 1332 | Dai M, Br J Cancer 2006; 95: 96 | Jin Q, Chin Med J 2010; 123: 2004 | Li H, Eur J Obstet Gynecol Reprod Biol 2013; 170: 202 | Li LK, Br J Cancer 2006; 95: 1593 | Mai RQ, Asian Pac J Cancer Prev 2014; 15: 4945 | Sun ZR, Int J Gynaecol Obstet 2010; 109: 105 | Wu D, Eur J Obstet Gynecol Reprod Biol 2010; 151: 86 | Wu EQ, Cancer Causes Control 2013; 24: 795 | Wu RF, Int J Cancer 2007; 121: 1306 | Yuan X, Arch Gynecol Obstet 2011; 283: 1385 | Zhao FH, Int J Cancer 2014; 135: 2604 | Zhao R, Br J Cancer 2009; 101: 1635
Based on systematic reviews and meta-analysis performed by ICO. The ICO HPV Information Centre has updated data until June 2014. Reference publications: 1) Bruni L, J Infect Dis 2010; 202: 1789. 2) De Sanjosé S, Lancet Infect Dis 2007; 7: 453

Figure 57: HPV 16 prevalence among women with low-grade cervical lesions in China, by study



Data updated on 27 Jan 2017 (data as of 30 Jun 2015)

The samples for HPV testing come from cervical specimens (fresh/fixed biopsies or exfoliated cells)
[a] Number of women tested
Data Sources:
Chan PK, Int J Cancer 2006; 118: 243 | Chan PK, Int J Cancer 2012; 131: 692 | Chan PK, J Med Virol 1999; 59: 232 | Ding X, J Med Virol 2014; 86: 1937 | Guo J, Scand J Infect Dis 2010; 42: 72 | Hong D, Int J Gynecol Cancer 2008; 18: 104 | Jin Q, Chin Med J 2010; 123: 2004 | Li H, Eur J Obstet Gynecol Reprod Biol 2013; 170: 202 | Li J, J Clin Microbiol 2012; 50: 1079 | Liu SS, Tumour Biol 2008; 29: 105 | Liu X, Int J Gynecol Cancer 2010; 20: 147 | Sun B, Arch Virol 2014; 159: 1027 | Tao PP, Zhonghua Fu Chan Ke Za Zhi 2006; 41: 43 | Wu D, Eur J Obstet Gynecol Reprod Biol 2010; 151: 86 | Wu EQ, Cancer Causes Control 2013; 24: 795 | Yuan X, Arch Gynecol Obstet 2011; 283: 1385 | Zhang R, Cancer Epidemiol 2013; 37: 939 | Zhao FH, Int J Cancer 2014; 135: 2604 | Zhao Y, Pathol Int 2008; 58: 643
Based on meta-analysis performed by IARC's Infections and Cancer Epidemiology Group up to November 2011, the ICO HPV Information Centre has updated data until June 2015. Reference publications: 1) Guan P, Int J Cancer 2012;131:2349 2) Clifford GM, Cancer Epidemiol Biomarkers Prev 2005;14:1157

Figure 58: HPV 16 prevalence among women with high-grade cervical lesions in China, by study



Data updated on 27 Jan 2017 (data as of 30 Jun 2015)

The samples for HPV testing come from cervical specimens (fresh/fixed biopsies or exfoliated cells)
[a] Number of women tested

Data Sources:

Chan MK, Gynecol Oncol 1996; 60: 217 | Chan PK, Int J Cancer 2006; 118: 243 | Chan PK, Int J Cancer 2012; 131: 692 | Chan PK, J Med Virol 1999; 59: 232 | Ding X, J Med Virol 2014; 86: 1937 | Guo J, Scand J Infect Dis 2010; 42: 72 | Jin Q, Chin Med J 2010; 123: 2004 | Li H, Eur J Obstet Gynecol Reprod Biol 2013; 170: 202 | Li J, Int J Gynaecol Obstet 2011; 112: 131 | Li J, J Clin Microbiol 2012; 50: 1079 | Liu SS, Tumour Biol 2008; 29: 105 | Singh S, Int J Clin Exp Pathol 2015; 8: 11901 | Sun B, Arch Virol 2014; 159: 1027 | Tao PP, Zhonghua Fu Chan Ke Za Zhi 2006; 41: 43 | Wu CH, Sex Transm Dis 1994; 21: 309 | Wu EQ, Cancer Causes Control 2013; 24: 795 | Yuan X, Arch Gynecol Obstet 2011; 283: 1385 | Zhang R, Cancer Epidemiol 2013; 37: 939 | Zhao FH, Int J Cancer 2014; 135: 2604 | Zhao Y, Pathol Int 2008; 58: 643

Based on meta-analysis performed by IARC's Infections and Cancer Epidemiology Group up to November 2011, the ICO HPV Information Centre has updated data until June 2015. Reference publications: 1) Guan P, Int J Cancer 2012;131:2349 2) Smith JS, Int J Cancer 2007;121:621 3) Clifford GM, Br J Cancer 2003;89:101.

Figure 59: HPV 16 prevalence among women with invasive cervical cancer in China, by study



Data updated on 19 May 2017 (data as of 30 Jun 2015)

The samples for HPV testing come from cervical specimens (fresh/fixed biopsies or exfoliated cells)
[a] Number of women tested
Data Sources:
Cai HB, Eur J Gynaecol Oncol 2008; 29: 72 | Cai HB, Oncology 2009; 76: 157 | Chan PK, Int J Cancer 2009; 125: 1671 | Chan PK, Int J Cancer 2012; 131: 692 | Chen W, Cancer Causes Control 2009; 20: 1705 | Ding X, J Med Virol 2014; 86: 1937 | Gao YE, Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao 2003; 35: 1029 | Hong D, Int J Gynecol Cancer 2008; 18: 104 | Huang S, Int J Cancer 1997; 70: 408 | Li H, Eur J Obstet Gynecol Reprod Biol 2013; 170: 202 | Lin QQ, Int J Cancer 1998; 75: 484 | Liu GB, J First Mil Med Univ 2005; 25: 1236 | Liu J, Gynecol Oncol 2004; 94: 803 | Liu SS, Tumour Biol 2008; 29: 105 | Liu X, Int J Gynecol Cancer 2010; 20: 147 | Lo KW, Gynecol Obstet Invest 2001; 51: 202 | Lo KW, Int J Cancer 2002; 100: 327 | Peng HQ, Int J Cancer 1991; 47: 711 | Qiu AD, Gynecol Oncol 2007; 104: 77 | Serrano B, Cancer Epidemiol 2014 | Shah W, Clin Oncol (R Coll Radiol) 2009; 21: 768 | Stephen AL, Int J Cancer 2000; 86: 695 | Tao PP, Zhonghua Fu Chan Ke Za Zhi 2006; 41: 43 | Wang L, J Med Virol 2015; 87: 516 | Wu EQ, BMC Cancer 2008; 8: 202 | Wu EQ, Int J Gynecol Cancer 2009; 19: 919 | Wu Y, J Med Virol 2008; 80: 1808 | Yu MY, Int J Cancer 2003; 105: 204 | Yuan X, Arch Gynecol Obstet 2011; 283: 1385 | Zhao Y, Pathol Int 2008; 58: 643
Based on meta-analysis performed by IARC's Infections and Cancer Epidemiology Group up to November 2011, the ICO HPV Information Centre has updated data until June 2015. Reference publications: 1) Guan P, Int J Cancer 2012;131:2349 2) Li N, Int J Cancer 2011;128:927 3) Smith JS, Int J Cancer 2007;121:621 4) Clifford GM, Br J Cancer 2003;88:63 5) Clifford GM, Br J Cancer 2003;89:101.

Figure 60: Comparison of the ten most frequent HPV oncogenic types in China among women with and without cervical lesions



Data updated on 30 Jun 2015 (data as of 30 Jun 2015)

Data Sources:

[1] Contributing studies: Cai HB, Eur J Gynaecol Oncol 2008; 29: 72 | Cai HB, Oncology 2009; 76: 157 | Chan PK, Int J Cancer 2009; 125: 1671 | Chan PK, Int J Cancer 2012; 131: 692 | Chen W, Cancer Causes Control 2009; 20: 1705 | Ding X, J Med Virol 2014; 86: 1937 | Gao YE, Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao 2003; 35: 1029 | Hong D, Int J Gynecol Cancer 2008; 18: 104 | Huang S, Int J Cancer 1997; 70: 408 | Li H, Eur J Obstet Gynecol Reprod Biol 2013; 170: 202 | Lin QQ, Int J Cancer 1998; 75: 484 | Liu GB, J First Mil Med Univ 2005; 25: 1236 | Liu J, Gynecol Oncol 2004; 94: 803 | Liu SS, Tumour Biol 2008; 29: 105 | Liu X, Int J Gynecol Cancer 2010; 20: 147 | Lo KW, Gynecol Obstet Invest 2001; 51: 202 | Lo KW, Int J Cancer 2002; 100: 327 | Peng HQ, Int J Cancer 1991; 47: 711 | Qiu AD, Gynecol Oncol 2007; 104: 77 | Serrano B, Cancer Epidemiol 2014 | Shah W, Clin Oncol (R Coll Radiol) 2009; 21: 768 | Stephen AL, Int J Cancer 2000; 86: 695 | Tao PP, Zhonghua Fu Chan Ke Za Zhi 2006; 41: 43 | Wang L, J Med Virol 2015; 87: 516 | Wu EQ, BMC Cancer 2008; 8: 202 | Wu EQ, Int J Gynecol Cancer 2009; 19: 919 | Wu Y, J Med Virol 2008; 80: 1808 | Yu MY, Int J Cancer 2003; 105: 204 | Yuan X, Arch Gynecol Obstet 2011; 283: 1385 | Zhao Y, Pathol Int 2008; 58: 643

[2] Based on meta-analysis performed by IARC's Infections and Cancer Epidemiology Group up to November 2011, the ICO HPV Information Centre has updated data until June 2015. Reference publications: 1) Guan P, Int J Cancer 2012;131:2349 2) Li N, Int J Cancer 2011;128:927 3) Smith JS, Int J Cancer 2007;121:621 4) Clifford GM, Br J Cancer 2003;88:63 5) Clifford GM, Br J Cancer 2003;89:101.

[3] Contributing studies: Chan MK, Gynecol Oncol 1996; 60: 217 | Chan PK, Int J Cancer 2006; 118: 243 | Chan PK, Int J Cancer 2012; 131: 692 | Chan PK, J Med Virol 1999; 59: 232 | Ding X, J Med Virol 2014; 86: 1937 | Guo J, Scand J Infect Dis 2010; 42: 72 | Jin Q, Chin Med J 2010; 123: 2004 | Li H, Eur J Obstet Gynecol Reprod Biol 2013; 170: 202 | Li J, Int J Gynaecol Obstet 2011; 112: 131 | Li J, J Clin Microbiol 2012; 50: 1079 | Liu SS, Tumour Biol 2008; 29: 105 | Singh S, Int J Clin Exp Pathol 2015; 8: 11901 | Sun B, Arch Virol 2014; 159: 1027 | Tao PP, Zhonghua Fu Chan Ke Za Zhi 2006; 41: 43 | Wu CH, Sex Transm Dis 1994; 21: 309 | Wu EQ, Cancer Causes Control 2013; 24: 795 | Yuan X, Arch Gynecol Obstet 2011; 283: 1385 | Zhang R, Cancer Epidemiol 2013; 37: 939 | Zhao FH, Int J Cancer 2014; 135: 2604 | Zhao Y, Pathol Int 2008; 58: 643

[4] Based on meta-analysis performed by IARC's Infections and Cancer Epidemiology Group up to November 2011, the ICO HPV Information Centre has updated data until June 2015. Reference publications: 1) Guan P, Int J Cancer 2012;131:2349 2) Smith JS, Int J Cancer 2007;121:621 3) Clifford GM, Br J Cancer 2003;89:101.

[5] Contributing studies: Chan PK, Int J Cancer 2006; 118: 243 | Chan PK, Int J Cancer 2012; 131: 692 | Chan PK, J Med Virol 1999; 59: 232 | Ding X, J Med Virol 2014; 86: 1937 | Guo J, Scand J Infect Dis 2010; 42: 72 | Hong D, Int J Gynecol Cancer 2008; 18: 104 | Jin Q, Chin Med J 2010; 123: 2004 | Li H, Eur J Obstet Gynecol Reprod Biol 2013; 170: 202 | Li J, J Clin Microbiol 2012; 50: 1079 | Liu SS, Tumour Biol 2008; 29: 105 | Liu X, Int J Gynecol Cancer 2010; 20: 147 | Sun B, Arch Virol 2014; 159: 1027 | Tao PP, Zhonghua Fu Chan Ke Za Zhi 2006; 41: 43 | Wu D, Eur J Obstet Gynecol Reprod Biol 2010; 151: 86 | Wu EQ, Cancer Causes Control 2013; 24: 795 | Yuan X, Arch Gynecol Obstet 2011; 283: 1385 | Zhang R, Cancer Epidemiol 2013; 37: 939 | Zhao FH, Int J Cancer 2014; 135: 2604 | Zhao Y, Pathol Int 2008; 58: 643

[6] Based on meta-analysis performed by IARC's Infections and Cancer Epidemiology Group up to November 2011, the ICO HPV Information Centre has updated data until June 2015. Reference publications: 1) Guan P, Int J Cancer 2012;131:2349 2) Clifford GM, Cancer Epidemiol Biomarkers Prev 2005;14:1157

[7] Bian ML, Exp Ther Med 2013; 6: 1332 | Dai M, Br J Cancer 2006; 95: 96 | Ding X, J Med Virol 2014; 86: 1937 | Jin Q, Chin Med J 2010; 123: 2004 | Li H, Eur J Obstet Gynecol Reprod Biol 2013; 170: 202 | Li LK, Br J Cancer 2006; 95: 1593 | Mai RQ, Asian Pac J Cancer Prev 2014; 15: 4945 | Sun ZR, Int J Gynaecol Obstet 2010; 109: 105 | Wei H, Int J Gynaecol Obstet 2014; 126: 28 | Wu D, Eur J Obstet Gynecol Reprod Biol 2010; 151: 86 | Wu EQ, Cancer Causes Control 2013; 24: 795 | Wu RF, Int J Cancer 2007; 121: 1306 | Yuan X, Arch Gynecol Obstet 2011; 283: 1385 | Zhao FH, Int J Cancer 2014; 135: 2604 | Zhao R, Br J Cancer 2009; 101: 1635

[8] Based on systematic reviews and meta-analysis performed by ICO. The ICO HPV Information Centre has updated data until November 2014. Reference publications: 1) Bruni L, J Infect Dis 2010; 202: 1789. 2) De Sanjosé S, Lancet Infect Dis 2007; 7: 453

Figure 61: Comparison of the ten most frequent HPV oncogenic types in China among women with invasive cervical cancer by histology



Data updated on 30 Jun 2015 (data as of 30 Jun 2015)

* No data available. No more types than shown were tested or were positive

Data Sources:

[1] Contributing studies: Cai HB, Eur J Gynaecol Oncol 2008; 29: 72 | Cai HB, Oncology 2009; 76: 157 | Chan PK, Int J Cancer 2009; 125: 1671 | Chan PK, Int J Cancer 2012; 131: 692 | Chen W, Cancer Causes Control 2009; 20: 1705 | Ding X, J Med Virol 2014; 86: 1937 | Gao YE, Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao 2003; 35: 1029 | Hong D, Int J Gynecol Cancer 2008; 18: 104 | Huang S, Int J Cancer 1997; 70: 408 | Li H, Eur J Obstet Gynecol Reprod Biol 2013; 170: 202 | Lin QQ, Int J Cancer 1998; 75: 484 | Liu GB, J First Mil Med Univ 2005; 25: 1236 | Liu J, Gynecol Oncol 2004; 94: 803 | Liu SS, Tumour Biol 2008; 29: 105 | Liu X, Int J Gynecol Cancer 2010; 20: 147 | Lo KW, Gynecol Obstet Invest 2001; 51: 202 | Lo KW, Int J Cancer 2002; 100: 327 | Peng HQ, Int J Cancer 1991; 47: 711 | Qiu AD, Gynecol Oncol 2007; 104: 77 | Serrano B, Cancer Epidemiol 2014 | Shah W, Clin Oncol (R Coll Radiol) 2009; 21: 768 | Stephen AL, Int J Cancer 2000; 86: 695 | Tao PP, Zhonghua Fu Chan Ke Za Zhi 2006; 41: 43 | Wang L, J Med Virol 2015; 87: 516 | Wu EQ, BMC Cancer 2008; 8: 202 | Wu EQ, Int J Gynecol Cancer 2009; 19: 919 | Wu Y, J Med Virol 2008; 80: 1808 | Yu MY, Int J Cancer 2003; 105: 204 | Yuan X, Arch Gynecol Obstet 2011; 283: 1385 | Zhao Y, Pathol Int 2008;

58: 643

[2] Based on meta-analysis performed by IARC's Infections and Cancer Epidemiology Group up to November 2011, the ICO HPV Information Centre has updated data until June 2014. Reference publications: 1) Guan P, Int J Cancer 2012;131:2349 2) Li N, Int J Cancer 2011;128:927 3) Smith JS, Int J Cancer 2007;121:621 4) Clifford GM, Br J Cancer 2003;88:63 5) Clifford GM, Br J Cancer 2003;89:101.

[3] Based on meta-analysis performed by IARC's Infections and Cancer Epidemiology Group up to November 2011, the ICO HPV Information Centre has updated data until June 2015. Reference publications: 1) Guan P, Int J Cancer 2012;131:2349 2) Li N, Int J Cancer 2011;128:927 3) Smith JS, Int J Cancer 2007;121:621 4) Clifford GM, Br J Cancer 2003;88:63 5) Clifford GM, Br J Cancer 2003;89:101.

Table 22: Type-specific HPV prevalence in women with normal cervical cytology, precancerous cervical lesions and invasive cervical cancer in China

	Normal cytology[1,2]		Low-grade lesions[3,4]		High-grade lesions[5,6]		Cervical cancer[7,8]	
HPV Type	No. tested	HPV Prev % (95% CI)	No. tested	HPV Prev % (95% CI)	No. tested	HPV Prev % (95% CI)	No. tested	HPV Prev % (95% CI)
ONCOGENIC HPV TYPES								
High-risk HPV types								
16	48689	2.7 (2.6-2.9)	3716	15.9 (14.8-17.1)	5979	37.1 (35.8-38.3)	6435	59.5 (58.3-60.7)
18	45577	1.1 (1.0-1.2)	3716	6.4 (5.6-7.2)	5979	7.0 (6.4-7.6)	6343	9.6 (8.9-10.4)
31	45198	0.8 (0.7-0.9)	3716	3.5 (3.0-4.2)	5979	5.2 (4.7-5.8)	5484	2.8 (2.4-3.2)
33	45198	1.1 (1.0-1.2)	3716	6.2 (5.4-7.0)	5979	7.0 (6.4-7.6)	5468	3.5 (3.0-4.0)
35	45198	0.3 (0.2-0.3)	3716	0.8 (0.5-1.1)	5900	0.5 (0.3-0.7)	2983	0.6 (0.4-0.9)
39	45198	0.7 (0.6-0.8)	3515	4.9 (4.2-5.7)	5744	2.6 (2.2-3.1)	4782	1.5 (1.2-1.9)
45	45198	0.4 (0.3-0.4)	3716	0.9 (0.7-1.3)	5900	1.7 (1.4-2.1)	2846	1.9 (1.4-2.4)
51	45198	0.5 (0.4-0.5)	3716	5.2 (4.6-6.0)	5900	3.9 (3.4-4.4)	2516	0.4 (0.2-0.8)
52	48310	2.8 (2.6-2.9)	3716	16.0 (14.8-17.2)	5900	17.6 (16.6-18.6)	6120	6.5 (5.9-7.1)
56	45198	0.4 (0.4-0.5)	3243	4.7 (4.0-5.4)	5287	2.1 (1.8-2.6)	3852	1.1 (0.8-1.5)
58	48310	1.7 (1.6-1.9)	3716	12.6 (11.6-13.8)	5900	15.7 (14.8-16.6)	6343	8.2 (7.6-8.9)
59	45198	0.4 (0.3-0.4)	3716	3.1 (2.6-3.7)	5900	2.7 (2.3-3.1)	4926	2.6 (2.2-3.1)
Probable/possible carcinogen								
26	5943	0.1 (0.0-0.2)	2107	1.4 (1.0-2.0)	3738	1.2 (0.9-1.6)	2131	0.2 (0.1-0.5)
30	2206	0.3 (0.1-0.6)	246	0.0 (0.0-1.5)	188	0.0 (0.0-2.0)	801	0.0 (0.0-0.5)
34	11359	0.1 (0.1-0.2)	2143	0.5 (0.3-0.9)	3644	0.1 (0.1-0.3)	1438	0.0 (0.0-0.3)
53	45198	1.2 (1.1-1.3)	3459	5.2 (4.5-6.0)	5604	3.7 (3.2-4.2)	2345	0.6 (0.3-0.9)
66	45198	0.6 (0.5-0.7)	3515	5.8 (5.1-6.6)	5744	2.4 (2.1-2.9)	2816	0.5 (0.3-0.9)
67	5943	0.1 (0.1-0.2)	2013	0.5 (0.3-1.0)	3670	0.7 (0.5-1.1)	2173	0.5 (0.3-0.8)
68	48310	1.0 (0.9-1.1)	3515	5.3 (4.6-6.1)	5744	2.8 (2.4-3.3)	2816	1.0 (0.7-1.4)
69	5943	0.0 (0.0-0.1)	2112	0.3 (0.2-0.7)	3789	0.1 (0.0-0.3)	1830	0.2 (0.1-0.6)
70	11359	0.1 (0.1-0.2)	2314	1.1 (0.8-1.6)	3784	0.8 (0.6-1.1)	2257	0.3 (0.2-0.6)
73	11227	0.1 (0.0-0.1)	2013	0.8 (0.5-1.3)	3670	0.8 (0.6-1.2)	1979	0.1 (0.0-0.4)
82	11227	0.1 (0.0-0.1)	2013	1.3 (0.9-1.9)	3670	2.5 (2.1-3.1)	1957	0.1 (0.0-0.4)
85	2206	0.0 (0.0-0.2)	1733	0.3 (0.1-0.7)	3253	0.0 (0.0-0.1)	-	-
97	-	-	-	-	-	-	-	-
LOW RISK HPV TYPES								
6	115217	0.8 (0.7-0.8)	3485	2.2 (1.8-2.8)	5771	1.4 (1.1-1.8)	3668	0.5 (0.4-0.8)
11	115217	0.6 (0.6-0.7)	3450	3.0 (2.5-3.6)	5839	2.3 (1.9-2.7)	3633	0.3 (0.2-0.5)
32	2206	0.0 (0.0-0.2)	-	-	-	-	575	0.0 (0.0-0.7)
40	11359	0.1 (0.1-0.2)	1299	1.0 (0.6-1.7)	2019	0.1 (0.1-0.4)	1730	0.0 (0.0-0.2)
42	112370	0.2 (0.2-0.3)	1815	1.5 (1.1-2.2)	3522	0.9 (0.6-1.2)	2167	0.5 (0.3-0.8)
43	108319	0.1 (0.1-0.2)	661	0.6 (0.2-1.5)	1269	0.0 (0.0-0.3)	1094	0.1 (0.0-0.5)
44	112370	0.1 (0.1-0.1)	1672	1.9 (1.3-2.6)	3065	1.3 (1.0-1.8)	1732	0.3 (0.2-0.8)
54	11359	0.6 (0.5-0.8)	1299	3.0 (2.2-4.1)	2019	3.4 (2.7-4.3)	1730	0.2 (0.1-0.6)
55	-	-	-	-	-	-	-	-
57	5943	0.0 (0.0-0.1)	152	1.3 (0.4-4.7)	256	2.7 (1.3-5.5)	660	0.0 (0.0-0.6)
61	5943	0.1 (0.1-0.3)	998	2.2 (1.5-3.3)	1905	2.5 (1.9-3.3)	3366	1.2 (0.8-1.6)
62	3737	0.3 (0.2-0.6)	846	7.8 (6.2-9.8)	1649	3.9 (3.1-4.9)	1723	0.4 (0.2-0.8)
64	-	-	-	-	-	-	-	-
71	5943	0.0 (0.0-0.1)	1015	0.2 (0.1-0.7)	1901	0.7 (0.4-1.2)	1462	0.2 (0.1-0.6)
72	5943	0.0 (0.0-0.1)	921	0.1 (0.0-0.6)	1833	0.4 (0.2-0.9)	1539	0.1 (0.0-0.5)
74	5416	0.4 (0.3-0.6)	207	0.5 (0.1-2.7)	46	0.0 (0.0-7.7)	554	0.0 (0.0-0.7)
81	101670	0.7 (0.6-0.7)	1222	5.0 (3.9-6.4)	2412	2.6 (2.0-3.3)	1789	0.4 (0.2-0.9)
83	11227	0.1 (0.1-0.2)	998	1.0 (0.5-1.8)	1905	0.4 (0.2-0.8)	1462	0.0 (0.0-0.3)
84	5943	0.1 (0.0-0.2)	998	2.2 (1.5-3.3)	1905	1.8 (1.3-2.5)	1462	0.2 (0.1-0.6)
86	2206	0.0 (0.0-0.2)	-	-	-	-	-	-
87	-	-	-	-	-	-	-	-
89	5943	0.2 (0.1-0.3)	769	1.0 (0.5-2.0)	1577	1.1 (0.7-1.7)	1346	0.3 (0.1-0.8)
90	2206	0.5 (0.3-0.9)	-	-	-	-	467	0.0 (0.0-0.8)
91	-	-	-	-	-	-	477	0.0 (0.0-0.8)

Data updated on 30 Jun 2015 (data as of 30 Jun 2015 / 30 Nov 2014)

The samples for HPV testing come from cervical specimens (fresh/fixed biopsies or exfoliated cells)

Data Sources:

[1] Bian ML, Exp Ther Med 2013; 6: 1332 | Dai M, Br J Cancer 2006; 95: 96 | Ding X, J Med Virol 2014; 86: 1937 | Jin Q, Chin Med J 2010; 123: 2004 | Li H, Eur J Obstet Gynecol Reprod Biol 2013; 170: 202 | Li LK, Br J Cancer 2006; 95: 1593 | Mai RQ, Asian Pac J Cancer Prev 2014; 15: 4945 | Sun ZR, Int J Gynaecol Obstet 2010; 109: 105 | Wei H, Int J Gynaecol Obstet 2014; 126: 28 | Wu D, Eur J Obstet Gynecol Reprod Biol 2010; 151: 86 | Wu EQ, Cancer Causes Control 2013; 24: 795 | Wu RF, Int J Cancer 2007; 121: 1306 | Yuan X, Arch Gynecol Obstet 2011; 283: 1385 | Zhao FH, Int J Cancer 2014; 135: 2604 | Zhao R, Br J Cancer 2009; 101: 1635

[2] Based on systematic reviews and meta-analysis performed by ICO. The ICO HPV Information Centre has updated data until November 2014. Reference publications: 1) Bruni L, J Infect Dis 2010; 202: 1789. 2) De Sanjosé S, Lancet Infect Dis 2007; 7: 453

[3] Contributing studies: Chan PK, Int J Cancer 2006; 118: 243 | Chan PK, Int J Cancer 2012; 131: 692 | Chan PK, J Med Virol 1999; 59: 232 | Ding X, J Med Virol 2014; 86: 1937 | Guo J, Scand J Infect Dis 2010; 42: 72 | Hong D, Int J Gynecol Cancer 2008; 18: 104 | Jin Q, Chin Med J 2010; 123: 2004 | Li H, Eur J Obstet Gynecol Reprod Biol 2013; 170: 202 | Li J, J Clin Microbiol 2012; 50: 1079 | Liu SS, Tumour Biol 2008; 29: 105 | Liu X, Int J Gynecol Cancer 2010; 20: 147 | Sun B, Arch Virol 2014; 159: 1027 | Tao PP, Zhonghua Fu Chan Ke Za Zhi 2006; 41: 43 | Wu D, Eur J Obstet Gynecol Reprod Biol 2010; 151: 86 | Wu EQ, Cancer Causes Control 2013; 24: 795 | Yuan X, Arch Gynecol Obstet 2011; 283: 1385 | Zhang R, Cancer

Epidemiol 2013; 37: 939 | Zhao FH, Int J Cancer 2014; 135: 2604 | Zhao Y, Pathol Int 2008; 58: 643

[4] Based on meta-analysis performed by IARC's Infections and Cancer Epidemiology Group up to November 2011, the ICO HPV Information Centre has updated data until June 2015. Reference publications: 1) Guan P, Int J Cancer 2012;131:2349 2) Clifford GM, Cancer Epidemiol Biomarkers Prev 2005;14:1157

[5] Contributing studies: Chan MK, Gynecol Oncol 1996; 60: 217 | Chan PK, Int J Cancer 2006; 118: 243 | Chan PK, Int J Cancer 2012; 131: 692 | Chan PK, J Med Virol 1999; 59: 232 | Ding X, J Med Virol 2014; 86: 1937 | Guo J, Scand J Infect Dis 2010; 42: 72 | Jin Q, Chin Med J 2010; 123: 2004 | Li H, Eur J Obstet Gynecol Reprod Biol 2013; 170: 202 | Li J, Int J Gynaecol Obstet 2011; 112: 131 | Li J, J Clin Microbiol 2012; 50: 1079 | Liu SS, Tumour Biol 2008; 29: 105 | Singh S, Int J Clin Exp Pathol 2015; 8: 11901 | Sun B, Arch Virol 2014; 159: 1027 | Tao PP, Zhonghua Fu Chan Ke Za Zhi 2006; 41: 43 | Wu CH, Sex Transm Dis 1994; 21: 309 | Wu EQ, Cancer Causes Control 2013; 24: 795 | Yuan X, Arch Gynecol Obstet 2011; 283: 1385 | Zhang R, Cancer Epidemiol 2013; 37: 939 | Zhao FH, Int J Cancer 2014; 135: 2604 | Zhao Y, Pathol Int 2008; 58: 643

[6] Based on meta-analysis performed by IARC's Infections and Cancer Epidemiology Group up to November 2011, the ICO HPV Information Centre has updated data until June 2015. Reference publications: 1) Guan P, Int J Cancer 2012;131:2349 2) Smith JS, Int J Cancer 2007;121:621 3) Clifford GM, Br J Cancer 2003;89:101.

[7] Contributing studies: Cai HB, Eur J Gynaecol Oncol 2008; 29: 72 | Cai HB, Oncology 2009; 76: 157 | Chan PK, Int J Cancer 2009; 125: 1671 | Chan PK, Int J Cancer 2012; 131: 692 | Chen W, Cancer Causes Control 2009; 20: 1705 | Ding X, J Med Virol 2014; 86: 1937 | Gao YE, Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao 2003; 35: 1029 | Hong D, Int J Gynecol Cancer 2008; 18: 104 | Huang S, Int J Cancer 1997; 70: 408 | Li H, Eur J Obstet Gynecol Reprod Biol 2013; 170: 202 | Lin QQ, Int J Cancer 1998; 75: 484 | Liu GB, J First Mil Med Univ 2005; 25: 1236 | Liu J, Gynecol Oncol 2004; 94: 803 | Liu SS, Tumour Biol 2008; 29: 105 | Liu X, Int J Gynecol Cancer 2010; 20: 147 | Lo KW, Gynecol Obstet Invest 2001; 51: 202 | Lo KW, Int J Cancer 2002; 100: 327 | Peng HQ, Int J Cancer 1991; 47: 711 | Qiu AD, Gynecol Oncol 2007; 104: 77 | Serrano B, Cancer Epidemiol 2014 | Shah W, Clin Oncol (R Coll Radiol) 2009; 21: 768 | Stephen AL, Int J Cancer 2000; 86: 695 | Tao PP, Zhonghua Fu Chan Ke Za Zhi 2006; 41: 43 | Wang L, J Med Virol 2015; 87: 516 | Wu EQ, BMC Cancer 2008; 8: 202 | Wu EQ, Int J Gynecol Cancer 2009; 19: 919 | Wu Y, J Med Virol 2008; 80: 1808 | Yu MY, Int J Cancer 2003; 105: 204 | Yuan X, Arch Gynecol Obstet 2011; 283: 1385 | Zhao Y, Pathol Int 2008; 58: 643

[8] Based on meta-analysis performed by IARC's Infections and Cancer Epidemiology Group up to November 2011, the ICO HPV Information Centre has updated data until June 2015. Reference publications: 1) Guan P, Int J Cancer 2012;131:2349 2) Li N, Int J Cancer 2011;128:927 3) Smith JS, Int J Cancer 2007;121:621 4) Clifford GM, Br J Cancer 2003;88:63 5) Clifford GM, Br J Cancer 2003;89:101.

Table 23: Type-specific HPV prevalence among invasive cervical cancer cases in China by histology

	Any Histology		Squamous cell carcinoma		Adenocarcinoma		Unespecified	
HPV Type	No. tested	HPV Prev % (95% CI)	No. tested	HPV Prev % (95% CI)	No. tested	HPV Prev % (95% CI)	No. tested	HPV Prev % (95% CI)
ONCOGENIC HPV TYPES								
High-risk HPV types								
16	6435	59.5 (58.3-60.7)	4528	58.1 (56.7-59.6)	228	45.2 (38.8-51.7)	1679	65.3 (63.0-67.6)
18	6343	9.6 (8.9-10.4)	4436	8.1 (7.3-9.0)	228	36.4 (30.4-42.8)	1679	10.1 (8.7-11.6)
31	5484	2.8 (2.4-3.2)	3705	2.9 (2.4-3.4)	150	0.7 (0.1-3.7)	1629	2.7 (2.0-3.6)
33	5468	3.5 (3.0-4.0)	3689	3.8 (3.2-4.5)	150	0.7 (0.1-3.7)	1629	2.9 (2.2-3.9)
35	2983	0.6 (0.4-0.9)	1598	0.8 (0.5-1.4)	133	0.0 (0.0-2.8)	1252	0.3 (0.1-0.8)
39	4782	1.5 (1.2-1.9)	3417	1.8 (1.4-2.3)	133	1.5 (0.4-5.3)	1232	0.7 (0.4-1.4)
45	2846	1.9 (1.4-2.4)	1559	1.4 (0.9-2.1)	133	0.8 (0.1-4.1)	1154	2.6 (1.8-3.7)
51	2516	0.4 (0.2-0.8)	1451	0.6 (0.3-1.2)	133	0.0 (0.0-2.8)	932	0.2 (0.1-0.8)
52	6120	6.5 (5.9-7.1)	4328	7.4 (6.7-8.2)	228	3.5 (1.8-6.8)	1564	4.2 (3.3-5.3)
56	3852	1.1 (0.8-1.5)	2787	1.5 (1.1-2.0)	133	0.0 (0.0-2.8)	932	0.1 (0.0-0.6)
58	6343	8.2 (7.6-8.9)	4436	8.0 (7.2-8.8)	228	3.1 (1.5-6.2)	1679	9.6 (8.3-11.2)
59	4926	2.6 (2.2-3.1)	3529	2.3 (1.9-2.8)	133	1.5 (0.4-5.3)	1264	3.5 (2.6-4.6)
Probable/possible carcinogen								
26	2131	0.2 (0.1-0.5)	-	-	-	-	-	-
30	801	0.0 (0.0-0.5)	213	0.0 (0.0-1.8)	-	-	588	0.0 (0.0-0.6)
34	1438	0.0 (0.0-0.3)	668	0.0 (0.0-0.6)	105	0.0 (0.0-3.5)	665	0.0 (0.0-0.6)
53	2345	0.6 (0.3-0.9)	-	-	-	-	-	-
66	2816	0.5 (0.3-0.9)	1451	0.6 (0.3-1.1)	133	0.0 (0.0-2.8)	1232	0.6 (0.3-1.2)
67	2173	0.5 (0.3-0.8)	1103	0.7 (0.4-1.4)	105	0.0 (0.0-3.5)	965	0.2 (0.1-0.8)
68	2816	1.0 (0.7-1.4)	1451	1.3 (0.8-2.0)	133	0.8 (0.1-4.1)	1232	0.6 (0.3-1.2)
69	1830	0.2 (0.1-0.6)	-	-	-	-	-	-
70	2257	0.3 (0.2-0.6)	-	-	-	-	-	-
73	1979	0.1 (0.0-0.4)	-	-	-	-	-	-
82	1957	0.1 (0.0-0.4)	1081	0.1 (0.0-0.5)	105	0.0 (0.0-3.5)	771	0.1 (0.0-0.7)
85	-	-	-	-	-	-	-	-
97	-	-	-	-	-	-	-	-
LOW RISK HPV TYPES								
6	3668	0.5 (0.4-0.8)	-	-	-	-	-	-
11	3633	0.3 (0.2-0.5)	-	-	-	-	-	-
32	575	0.0 (0.0-0.7)	-	-	-	-	-	-
40	1730	0.0 (0.0-0.2)	-	-	-	-	-	-
42	2167	0.5 (0.3-0.8)	1357	0.7 (0.4-1.4)	105	0.0 (0.0-3.5)	705	0.0 (0.0-0.5)
43	1094	0.1 (0.0-0.5)	-	-	-	-	-	-
44	1732	0.3 (0.2-0.8)	922	0.5 (0.2-1.3)	105	0.0 (0.0-3.5)	705	0.1 (0.0-0.8)
54	1730	0.2 (0.1-0.6)	-	-	-	-	-	-
55	-	-	-	-	-	-	-	-
57	660	0.0 (0.0-0.6)	-	-	-	-	-	-
61	3366	1.2 (0.8-1.6)	-	-	-	-	-	-
62	1723	0.4 (0.2-0.8)	-	-	-	-	-	-
64	-	-	-	-	-	-	-	-
71	1462	0.2 (0.1-0.6)	-	-	-	-	-	-
72	1539	0.1 (0.0-0.5)	-	-	-	-	-	-
74	554	0.0 (0.0-0.7)	-	-	-	-	-	-
81	1789	0.4 (0.2-0.9)	-	-	-	-	-	-
83	1462	0.0 (0.0-0.3)	-	-	-	-	-	-
84	1462	0.2 (0.1-0.6)	-	-	-	-	-	-
86	-	-	-	-	-	-	-	-
87	-	-	-	-	-	-	-	-
89	1346	0.3 (0.1-0.8)	-	-	-	-	-	-
90	467	0.0 (0.0-0.8)	-	-	-	-	-	-
91	477	0.0 (0.0-0.8)	-	-	-	-	-	-

Data updated on 19 May 2017 (data as of 30 Jun 2015)

The samples for HPV testing come from cervical specimens (fresh/fixed biopsies or exfoliated cells)
[a] Number of women tested
[b] 95% Confidence Interval
Data Sources:
Contributing studies: Cai HB, Eur J Gynaecol Oncol 2008; 29: 72 | Cai HB, Oncology 2009; 76: 157 | Chan PK, Int J Cancer 2009; 125: 1671 | Chan PK, Int J Cancer 2012; 131: 692 | Chen W, Cancer Causes Control 2009; 20: 1705 | Ding X, J Med Virol 2014; 86: 1937 | Gao YE, Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao 2003; 35: 1029 | Hong D, Int J Gynecol Cancer 2008; 18: 104 | Huang S, Int J Cancer 1997; 70: 408 | Li H, Eur J Obstet Gynecol Reprod Biol 2013; 170: 202 | Lin QQ, Int J Cancer 1998; 75: 484 | Liu GB, J First Mil Med Univ 2005; 25: 1236 | Liu J, Gynecol Oncol 2004; 94: 803 | Liu SS, Tumour Biol 2008; 29: 105 | Liu X, Int J Gynecol Cancer 2010; 20: 147 | Lo KW, Gynecol Obstet Invest 2001; 51: 202 | Lo KW, Int J Cancer 2002; 100: 327 | Peng HQ, Int J Cancer 1991; 47: 711 | Qiu AD, Gynecol Oncol 2007; 104: 77 | Serrano B, Cancer Epidemiol 2014 | Shah W, Clin Oncol (R Coll Radiol) 2009; 21: 768 | Stephen AL, Int J Cancer 2000; 86: 695 | Tao PP, Zhonghua Fu Chan Ke Za Zhi 2006; 41: 43 | Wang L, J Med Virol 2015; 87: 516 | Wu EQ, BMC Cancer 2008; 8: 202 | Wu EQ, Int J Gynecol Cancer 2009; 19: 919 | Wu Y, J Med Virol 2008; 80: 1808 | Yu MY, Int J Cancer 2003; 105: 204 | Yuan X, Arch Gynecol Obstet 2011; 283: 1385 | Zhao Y, Pathol Int 2008; 58: 643
Based on meta-analysis performed by IARC's Infections and Cancer Epidemiology Group up to November 2011, the ICO HPV Information Centre has updated data until June 2015. Reference publications: 1) Guan P, Int J Cancer 2012;131:2349 2) Li N, Int J Cancer 2011;128:927 3) Smith JS, Int J Cancer 2007;121:621 4) Clifford GM, Br J Cancer 2003;88:63 5) Clifford GM, Br J Cancer 2003;89:101.

4.1.3 HPV type distribution among HIV+ women with normal cervical cytology

Table 24: Studies on HPV prevalence among HIV+ women with normal cytology in China

Study	HPV detection method and targeted HPV types	HPV Prevalence			
		No. Tested[a]	%	(95% CI)[b]	Prevalence of 5 most frequent HPVs, HPV type (%)
-	-	-	-	-	

Data updated on 31 Dec 2011 (data as of 31 Dec 2011)

DBH: Dot Blot Hybridization; EIA: Enzyme ImmunoAssay; HC2: Hybrid Capture 2; PCR: Polymerase Chain Reaction; TS: Type Specific
[a] Number of women tested
[b] 95% Confidence Interval
Data Sources:
Systematic review and meta-analysis were performed by the ICO HPV Information Centre up to December 2011. Selected studies had to include at least 20 HIV positive women who had both normal cervical cytology and HPV test results (PCR or HC2).

4.1.4 Terminology

Cytologically normal women
No abnormal cells are observed on the surface of their cervix upon cytology.

Cervical Intraepithelial Neoplasia (CIN) / Squamous Intraepithelial Lesions (SIL)
SIL and CIN are two commonly used terms to describe precancerous lesions or the abnormal growth of squamous cells observed in the cervix. SIL is an abnormal result derived from cervical cytological screening or Pap smear testing. CIN is a histological diagnosis made upon analysis of cervical tissue obtained by biopsy or surgical excision. The condition is graded as CIN 1, 2 or 3, according to the thickness of the abnormal epithelium (1/3, 2/3 or the entire thickness).

Low-grade cervical lesions (LSIL/CIN-1)
Low-grade cervical lesions are defined by early changes in size, shape, and number of abnormal cells formed on the surface of the cervix and may be referred to as mild dysplasia, LSIL, or CIN-1.

High-grade cervical lesions (HSIL/ CIN-2 / CIN-3 / CIS)
High-grade cervical lesions are defined by a large number of precancerous cells on the surface of the cervix that are distinctly different from normal cells. They have the potential to become cancerous cells and invade deeper tissues of the cervix. These lesions may be referred to as moderate or severe dysplasia, HSIL, CIN-2, CIN-3 or cervical carcinoma in situ (CIS).

Carcinoma in situ (CIS)
Preinvasive malignancy limited to the epithelium without invasion of the basement membrane. CIN 3 encompasses the squamous carcinoma in situ.

Invasive cervical cancer (ICC) / Cervical cancer
If the high-grade precancerous cells invade the basement membrane is called ICC. ICC stages range from stage I (cancer is in the cervix or uterus only) to stage IV (the cancer has spread to distant organs, such as the liver).

Invasive squamous cell carcinoma
Invasive carcinoma composed of cells resembling those of squamous epithelium.

Adenocarcinoma
Invasive tumour with glandular and squamous elements intermingled.

4.2 HPV burden in anogenital cancers other than cervix

Methods: Prevalence and type distribution of human papillomavirus in carcinoma of the vulva, vagina, anus and penis: systematic review and meta-analysis

A systematic review of the literature was conducted on the worldwide HPV-prevalence and type distribution for anogenital carcinomas other than cervix from January 1986 to 'data as of' indicated in each section. The search terms for the review were 'HPV' AND (anus OR anal) OR (penile) OR vagin* OR vulv* using Pubmed. There were no limits in publication language. References cited in selected articles were also investigated. Inclusion criteria were: HPV DNA detection by means of PCR, a minimum of 10 cases by lesion and a detailed description of HPV DNA detection and genotyping techniques used. The number of cases tested and HPV positive cases were extracted for each study to estimate the prevalence of HPV DNA and the HPV type distribution. Binomial 95% confidence intervals were calculated for each HPV prevalence.

4.2.1 Anal cancer and precancerous anal lesions

Anal cancer is similar to cervical cancer with respect to overall HPV DNA positivity, with approximately 100% of anal squamous cell carcinoma cases associated with HPV infection worldwide (de Martel C et al. Lancet Glob Health 2020;8(2):e180-e190). HPV16 is the most common type detected, representing 73% of all HPV-positive tumours. HPV18 is the second most common type detected and is found in approximately 5% of cases. HPV DNA is also detected in the majority of precancerous anal lesions (AIN) (91.5% in AIN1 and 93.9% in AIN2/3) (De Vuyst H et al. Int J Cancer 2009; 124: 1626-36). In this section, the burden of HPV among cases of anal cancers and precancerous anal lesions in China are presented.

Table 25: Studies on HPV prevalence among anal cancer cases in China (male and female)

Study	HPV detection method and targeted HPV types	HPV Prevalence			
		No. Tested	%	(95% CI)[a]	Prevalence of 5 most frequent HPVs, HPV type (%)
No data available	-	-	-	-	

Data updated on 30 Jun 2015 (data as of 30 Jun 2015)

DBH: Dot Blot Hybridization; EIA: Enzyme ImmunoAssay; HC2: Hybrid Capture 2; ISH: In Situ Hybridization; LBA: Line-Blot Assay; LiPA: Line Probe Assay; PCR: Polymerase Chain Reaction; RFLP: Restriction Fragment Length Polymorphism; RLBH: Reverse Line Blot Hybridization; RT-PCR: Real Time Polymerase Chain Reaction; SBH: Southern Blot Hybridization; SPF: Short Primer Fragment; TS: Type Specific;
[a] 95% Confidence Interval
Data Sources:
Based on systematic reviews (up to 2008) performed by ICO for the IARC Monograph on the Evaluation of Carcinogenic Risks to Humans volume 100B and IARC's Infections and Cancer Epidemiology Group. The ICO HPV Information Centre has updated data until June 2015. Reference publications: 1) Bouvard V, Lancet Oncol 2009;10:321 2) De Vuyst H, Int J Cancer 2009;124:1626

Table 26: Studies on HPV prevalence among cases of AIN2/3 in China

Study	HPV detection method and targeted HPV types	HPV Prevalence			
		No. Tested	%	(95% CI)[a]	Prevalence of 5 most frequent HPVs, HPV type (%)
No data available	-	-	-	-	

Data updated on 30 Jun 2015 (data as of 30 Jun 2015)

DBH: Dot Blot Hybridization; EIA: Enzyme ImmunoAssay; HC2: Hybrid Capture 2; ISH: In Situ Hybridization; LBA: Line-Blot Assay; LiPA: Line Probe Assay; PCR: Polymerase Chain Reaction; RFLP: Restriction Fragment Length Polymorphism; RLBH: Reverse Line Blot Hybridization; RT-PCR: Real Time Polymerase Chain Reaction; SBH: Southern Blot Hybridization; SPF: Short Primer Fragment; TS: Type Specific;
AIN 2/3: Anal intraepithelial neoplasia of grade 2/3
[a] 95% Confidence Interval
Data Sources:
Based on systematic reviews (up to 2008) performed by ICO for the IARC Monograph on the Evaluation of Carcinogenic Risks to Humans volume 100B and IARC's Infections and Cancer Epidemiology Group. The ICO HPV Information Centre has updated data until June 2015. Reference publications: 1) Bouvard V, Lancet Oncol 2009;10:321 2) De Vuyst H, Int J Cancer 2009;124:1626

Figure 62: Comparison of the ten most frequent HPV types in anal cancer cases in Asia and the World



Data updated on 9 Feb 2017 (data as of 30 Jun 2014)

[a] Includes cases from Bangladesh,India and South Korea

[b] Includes cases from Europe (Bosnia-Herzegovina, Czech Republic, France, Germany, Poland, Portugal, Slovenia, Spain and United Kingdom); America (Chile, Colombia, Ecuador, Guatemala, Honduras, Mexico, Paraguay and United States); Africa (Mali, Nigeria and Senegal); Asia (Bangladesh,India and South Korea)

Data Sources:

Data from Alemany L, Int J Cancer 2015; 136: 98. This study has gathered the largest international series of anal cancer cases and precancerous lesions worldwide using a standard protocol with a highly sensitive HPV DNA detection assay.

Figure 63: Comparison of the ten most frequent HPV types in AIN 2/3 cases in Asia and the World



Data updated on 7 Feb 2017 (data as of 30 Jun 2014)

AIN 2/3: Anal intraepithelial neoplasia of grade 2/3

[a] Includes cases from Europe (Bosnia-Herzegovina, Czech Republic, France, Germany, Poland, Portugal, Slovenia, Spain and United Kingdom); America (Chile, Colombia, Ecuador, Guatemala, Honduras, Mexico, Paraguay)

Data Sources:

Data from Alemany L, Int J Cancer 2015; 136: 98. This study has gathered the largest international series of anal cancer cases and precancerous lesions worldwide using a standard protocol with a highly sensitive HPV DNA detection assay.

4.2.2 Vulvar cancer and precancerous vulvar lesions

HPV attribution for vulvar cancer is 48% among age 15-54 years, 28% among age 55-64 years, and 15% among age 65+ worldwide (de Martel C et al. Lancet Glob Health 2020;8(2):e180-e190). Vulvar cancer has two distinct histological patterns with two different risk factor profiles: (1) basaloid/warty types (2) keratinising types. Basaloid/warty lesions are more common in young women, are frequently found adjacent to VIN, are very often associated with HPV DNA detection (86%), and have a similar risk factor profile as cervical cancer. Keratinising vulvar carcinomas represent the majority of the vulvar lesions (>60%). These lesions develop from non HPV-related chronic vulvar dermatoses, especially lichen sclerosus and/or squamous hyperplasia, their immediate cancer precursor lesion is differentiated VIN, they occur more often in older women, and are rarely associated with HPV (6%) or with any of the other risk factors typical of cervical cancer. HPV prevalence is frequently detected among cases of high-grade VIN (VIN2/3) (85.3%). HPV 16 is the most common type detected followed by HPV 33 (De Vuyst H et al. Int J Cancer 2009; 124: 1626-36). In this section, the HPV burden among cases of vulvar cancer cases and precancerous vulvar lesions in China are presented.

Table 27: Studies on HPV prevalence among vulvar cancer cases in China

Study	HPV detection method and targeted HPV types	No. Tested	HPV Prevalence		Prevalence of 5 most frequent HPVs, HPV type (%)
			%	(95% CI)[a]	
No data available	-	-	-	-	

Data updated on 30 Jun 2015 (data as of 30 Jun 2015)

DBH: Dot Blot Hybridization; EIA: Enzyme ImmunoAssay; HC2: Hybrid Capture 2; ISH: In Situ Hybridization; LBA: Line-Blot Assay; LiPA: Line Probe Assay; PCR: Polymerase Chain Reaction; RFLP: Restriction Fragment Length Polymorphism; RLBH: Reverse Line Blot Hybridization; RT-PCR: Real Time Polymerase Chain Reaction; SBH: Southern Blot Hybridization; SPF: Short Primer Fragment; TS: Type Specific;
[a] 95% Confidence Interval
Data Sources:
Based on systematic reviews (up to 2008) performed by ICO for the IARC Monograph on the Evaluation of Carcinogenic Risks to Humans volume 100B and IARC's Infections and Cancer Epidemiology Group. The ICO HPV Information Centre has updated data until June 2015. Reference publications: 1) Bouvard V, Lancet Oncol 2009;10:321 2) De Vuyst H, Int J Cancer 2009;124:1626

Table 28: Studies on HPV prevalence among VIN 2/3 cases in China

Study	HPV detection method and targeted HPV types	No. Tested	HPV Prevalence		Prevalence of 5 most frequent HPVs, HPV type (%)
			%	(95% CI)[a]	
No data available	-	-	-	-	

Data updated on 30 Jun 2015 (data as of 30 Jun 2015)

DBH: Dot Blot Hybridization; EIA: Enzyme ImmunoAssay; HC2: Hybrid Capture 2; ISH: In Situ Hybridization; LBA: Line-Blot Assay; LiPA: Line Probe Assay; PCR: Polymerase Chain Reaction; RFLP: Restriction Fragment Length Polymorphism; RLBH: Reverse Line Blot Hybridization; RT-PCR: Real Time Polymerase Chain Reaction; SBH: Southern Blot Hybridization; SPF: Short Primer Fragment; TS: Type Specific;
VIN 2/3: Vulvar intraepithelial neoplasia of grade 2/3
[a] 95% Confidence Interval
Data Sources:
Based on systematic reviews (up to 2008) performed by ICO for the IARC Monograph on the Evaluation of Carcinogenic Risks to Humans volume 100B and IARC's Infections and Cancer Epidemiology Group. The ICO HPV Information Centre has updated data until June 2015. Reference publications: 1) Bouvard V, Lancet Oncol 2009;10:321 2) De Vuyst H, Int J Cancer 2009;124:1626

Figure 64: Comparison of the ten most frequent HPV types in cases of vulvar cancer in Asia and the World



Data updated on 30 Jun 2015 (data as of 30 Jun 2015)

[a] Includes cases from Bangladesh, India, Israel, South Korea, Kuwait, Lebanon, Philippines, Taiwan and Turkey.
[b] Includes cases from America (Argentina, Brazil, Chile, Colombia, Ecuador, Guatemala, Honduras, Mexico, Paraguay, Uruguay, United States of America and Venezuela); Africa (Mali, Mozambique, Nigeria, and Senegal); Oceania (Australia and New Zealand); Europe (Austria, Belarus, Bosnia-Herzegovina, Czech Republic, France, Germany, Greece, Italy, Poland, Portugal, Spain and United Kingdom); and in Asia (Bangladesh, India, Israel, South Korea, Kuwait, Lebanon, Philippines, Taiwan and Turkey)
Data Sources:
Data from de Sanjosé S, Eur J Cancer 2013; 49: 3450. This study has gathered the largest international series of vulva cancer cases and precancerous lesions worldwide using a standard protocol with a highly sensitive HPV DNA detection assay.

Figure 65: Comparison of the ten most frequent HPV types in VIN 2/3 cases in Asia and the World



Data updated on 30 Jun 2014 (data as of 30 Jun 2014)

VIN 2/3: Vulvar intraepithelial neoplasia of grade 2/3
[a] Includes cases from Bangladesh, India, Israel, South Korea, Kuwait, Lebanon, Philippines, Taiwan and Turkey.
[b] Includes cases from America (Argentina, Brazil, Chile, Colombia, Ecuador, Guatemala, Honduras, Mexico, Paraguay, Uruguay and Venezuela); Oceania (Australia and New Zealand); Europe (Austria, Belarus, Bosnia-Herzegovina, Czech Republic, France, Germany, Greece, Italy, Poland, Portugal, Spain and United Kingdom); and in Asia (Bangladesh, India, Israel, South Korea, Kuwait, Lebanon, Philippines, Taiwan and Turkey)
Data Sources:
Data from de Sanjosé S, Eur J Cancer 2013; 49: 3450. This study has gathered the largest international series of vulva cancer cases and precancerous lesions worldwide using a standard protocol with a highly sensitive HPV DNA detection assay.

4.2.3 Vaginal cancer and precancerous vaginal lesions

Vaginal and cervical cancers share similar risk factors and it is generally accepted that both carcinomas share the same aetiology of HPV infection although there is limited evidence available. Women with vaginal cancer are more likely to have a history of other ano-genital cancers, particularly of the cervix, and these two carcinomas are frequently diagnosed simultaneously. HPV DNA is detected among 78% of invasive vaginal carcinomas and 91% of high-grade vaginal neoplasias (VaIN2/3). HPV16 is the most common type in high-grade vaginal neoplasias and it is detected in at least 78% of HPV-positive carcinomas (de Martel C et al. Lancet Glob Health 2020;8(2):e180-e190; De Vuyst H et al. Int J Cancer 2009; 124:1626-36). In this section, the HPV burden among cases of vaginal cancer cases and precancerous vaginal lesions in China are presented.

Table 29: Studies on HPV prevalence among vaginal cancer cases in China

Study	HPV detection method and targeted HPV types	HPV Prevalence			
		No. Tested	%	(95% CI)[a]	Prevalence of 5 most frequent HPVs, HPV type (%)
No data available	-	-	-	-	

Data updated on 30 Jun 2015 (data as of 30 Jun 2015)

DBH: Dot Blot Hybridization; EIA: Enzyme ImmunoAssay; HC2: Hybrid Capture 2; ISH: In Situ Hybridization; LBA: Line-Blot Assay; LiPA: Line Probe Assay; PCR: Polymerase Chain Reaction; RFLP: Restriction Fragment Length Polymorphism; RLBH: Reverse Line Blot Hybridization; RT-PCR: Real Time Polymerase Chain Reaction; SBH: Southern Blot Hybridization; SPF: Short Primer Fragment; TS: Type Specific;
[a] 95% Confidence Interval
Data Sources:
Based on systematic reviews (up to 2008) performed by ICO for the IARC Monograph on the Evaluation of Carcinogenic Risks to Humans volume 100B and IARC's Infections and Cancer Epidemiology Group. The ICO HPV Information Centre has updated data until June 2015. Reference publications: 1) Bouvard V, Lancet Oncol 2009;10:321 2) De Vuyst H, Int J Cancer 2009;124:1626

Table 30: Studies on HPV prevalence among VaIN 2/3 cases in China

Study	HPV detection method and targeted HPV types	HPV Prevalence			
		No. Tested	%	(95% CI)[a]	Prevalence of 5 most frequent HPVs, HPV type (%)
No data available	-	-	-	-	

Data updated on 30 Jun 2015 (data as of 30 Jun 2015)

DBH: Dot Blot Hybridization; EIA: Enzyme ImmunoAssay; HC2: Hybrid Capture 2; ISH: In Situ Hybridization; LBA: Line-Blot Assay; LiPA: Line Probe Assay; PCR: Polymerase Chain Reaction; RFLP: Restriction Fragment Length Polymorphism; RLBH: Reverse Line Blot Hybridization; RT-PCR: Real Time Polymerase Chain Reaction; SBH: Southern Blot Hybridization; SPF: Short Primer Fragment; TS: Type Specific;
VAIN 2/3: Vaginal intraepithelial neoplasia of grade 2/3
[a] 95% Confidence Interval
Data Sources:
Based on systematic reviews (up to 2008) performed by ICO for the IARC Monograph on the Evaluation of Carcinogenic Risks to Humans volume 100B and IARC's Infections and Cancer Epidemiology Group. The ICO HPV Information Centre has updated data until June 2015. Reference publications: 1) Bouvard V, Lancet Oncol 2009;10:321 2) De Vuyst H, Int J Cancer 2009;124:1626

Figure 66: Comparison of the ten most frequent HPV types in cases of vaginal cancer in Asia and the World



Data updated on 30 Jun 2015 (data as of 30 Jun 2015)

[a] Includes cases from Bangladesh, India, Israel, South Korea, Kuwait, Philippines, Taiwan and Turkey

[b] Includes cases from Europe (Austria, Belarus, Czech Republic, France, Germany, Greece, Poland, Spain and United Kingdom); America (Argentina, Brazil, Chile, Colombia, Ecuador, Guatemala, Mexico, Paraguay, Uruguay, United states of America and Venezuela); Africa (Mozambique, Nigeria); Asia (Bangladesh, India, Israel, South Korea, Kuwait, Philippines, Taiwan and Turkey); and Oceania (Australia)

Data Sources:

Data from Alemany L, Eur J Cancer 2014; 50: 2846. This study has gathered the largest international series of vaginal cancer cases and precancerous lesions worldwide using a standard protocol with a highly sensitive HPV DNA detection assay.

Figure 67: Comparison of the ten most frequent HPV types in VaIN 2/3 cases in Asia and the World



Data updated on 30 Jun 2014 (data as of 30 Jun 2014)

VAIN 2/3: Vaginal intraepithelial neoplasia of grade 2/3

[a] Includes cases from Australia, Bangladesh, India, Israel, South Korea, Kuwait, Philippines, Taiwan and Turkey.

[b] Includes cases from Europe (Austria, Belarus, Czech Republic, France, Germany, Greece, Poland, Spain and United Kingdom); America (Argentina, Brazil, Chile, Colombia, Ecuador, Guatemala, Mexico, Paraguay, Uruguay, United states of America and Venezuela); Asia (Bangladesh, India, Israel, South Korea, Kuwait, Philippines, Taiwan and Turkey); and Oceania (Australia)

Data Sources:

Data from Alemany L, Eur J Cancer 2014; 50: 2846. This study has gathered the largest international series of vaginal cancer cases and precancerous lesions worldwide using a standard protocol with a highly sensitive HPV DNA detection assay.

4.2.4 Penile cancer and precancerous penile lesions

HPV DNA is detectable in approximately 51% of all penile cancers (de Martel C et al. Lancet Glob Health 2020;8(2):e180-e190). Among HPV-related penile tumours, HPV16 is the most common type detected, followed by HPV18 and HPV types 6/11 (Miralles C et al. J Clin Pathol 2009;62:870-8). Over 95% of invasive penile cancers are SCC and the most common penile SCC histologic sub-types are keratinising (49%), mixed warty-basaloid (17%), verrucous (8%), warty (6%), and basaloid (4%). HPV is commonly detected in basaloid and warty tumours but is less common in keratinising and verrucous tumours. In this section, the HPV burden among cases of penile cancer cases and precancerous penile lesions in China are presented.

Table 31: Studies on HPV prevalence among penile cancer cases in China

Study	HPV detection method and targeted HPV types	HPV Prevalence			
		No. Tested	%	(95% CI)[a]	Prevalence of 5 most frequent HPVs, HPV type (%)
Chan 1994	PCR Type specific for HPV16/18	41	19.5	(10.2-34.0)	HPV 16 (9.8), HPV 18 (9.8)

Data updated on 5 Mar 2015 (data as of 30 Jun 2014)

DBH: Dot Blot Hybridization; EIA: Enzyme ImmunoAssay; HC2: Hybrid Capture 2; ISH: In Situ Hybridization; LBA: Line-Blot Assay; LiPA: Line Probe Assay; PCR: Polymerase Chain Reaction; RFLP: Restriction Fragment Length Polymorphism; RLBH: Reverse Line Blot Hybridization; RT-PCR: Real Time Polymerase Chain Reaction; SBH: Southern Blot Hybridization; SPF: Short Primer Fragment; TS: Type Specific;
[a] 95% Confidence Interval
Data Sources:
Chan KW, J Clin Pathol 1994; 47: 823
The ICO HPV Information Centre has updated data until June 2014. Reference publications (up to 2008): 1) Bouvard V, Lancet Oncol 2009;10:321 2) Miralles-Guri C,J Clin Pathol 2009;62:870

Table 32: Studies on HPV prevalence among PeIN 2/3 cases in China

Study	HPV detection method and targeted HPV types	HPV Prevalence			
		No. Tested	%	(95% CI)[a]	Prevalence of 5 most frequent HPVs, HPV type (%)
No data available	-	-	-	-	

Data updated on 10 Feb 2015 (data as of 30 Jun 2014)

PeIN 2/3: Penile intraepithelial neoplasia of grade 2/3
DBH: Dot Blot Hybridization; EIA: Enzyme ImmunoAssay; HC2: Hybrid Capture 2; ISH: In Situ Hybridization; LBA: Line-Blot Assay; LiPA: Line Probe Assay; PCR: Polymerase Chain Reaction; RFLP: Restriction Fragment Length Polymorphism; RLBH: Reverse Line Blot Hybridization; RT-PCR: Real Time Polymerase Chain Reaction; SBH: Southern Blot Hybridization; SPF: Short Primer Fragment; TS: Type Specific;
[a] 95% Confidence Interval
Data Sources:
The ICO HPV Information Centre has updated data until June 2014. Reference publication (up to 2008): Bouvard V, Lancet Oncol 2009;10:321

Figure 68: Comparison of the ten most frequent HPV types in cases of penile cancer in Asia and the World



Data updated on 9 Feb 2017 (data as of 30 Jun 2015)

[a] Includes cases from Bangladesh, India, South Korea, Lebanon, Philippinesy
[b] Includes cases from Australia, Bangladesh, India, South Korea, Lebanon, Philippines, Chile, Colombia, Ecuador, Guatemala, Honduras, Mexico, Paraguay, Venezuela and United States, Mozambique, Nigeria, Senegal, Czech Republic, France, Greece, Poland, Portugal, Spain and United Kingdom.
Data Sources:
Alemany L, Eur Urol 2016; 69: 953

Figure 69: Comparison of the ten most frequent HPV types in PeIN 2/3 cases in Asia and the World



Data updated on 9 Feb 2017 (data as of 30 Jun 2015)

PeIN 2/3: Penile intraepithelial neoplasia of grade 2/3
[a] Includes cases from Australia, Bangladesh, India, South Korea, Lebanon, Philippines, Chile, Colombia, Ecuador, Guatemala, Honduras, Mexico, Paraguay, Venezuela, Mozambique, Nigeria, Senegal, Czech Republic, France, Greece, Poland, Portugal, Spain and United Kingdom.
Data Sources:
Gan LL, Asian Pac J Cancer Prev 2014; 15: 5861 | Lee LA, Medicine (Baltimore) 2015; 94: e2069 | Tang X, J Oral Pathol Med 2003; 32: 393 | Wen S, Anticancer Res 1997; 17: 307 | Zhang ZY, Int J Oral Maxillofac Surg 2004; 33: 71
Based on systematic reviews and meta-analysis performed by ICO. Reference publications: 1) Ndiaye C, Lancet Oncol 2014; 15: 1319 2) Kreimer AR, Cancer Epidemiol Biomarkers Prev 2005; 14: 467

4.3 HPV burden in men

The information to date regarding anogenital HPV infection is primarily derived from cross-sectional studies of selected populations such as general population, university students, military recruits, and studies that examined husbands of control women, as well as from prospective studies. Special subgroups include mainly studies that examined STD (sexually transmitted diseases) clinic attendees, MSM (men who have sex with men), HIV positive men, and partners of women with HPV lesions, CIN (cervical intraepithelial neoplasia), cervical cancer or cervical carcinoma in situ. Globally, prevalence of external genital HPV infection in men is higher than cervical HPV infection in women, but persistence is less likely. As with genital HPV prevalence, high numbers of sexual partners increase the acquisition of oncogenic HPV infections (Vaccine 2012, Vol. 30, Suppl 5). In this section, the HPV burden among men in China is presented.

Methods

HPV burden in men was based on published systematic reviews and meta-analyses (Dunne EF, J Infect Dis 2006; 194: 1044, Smith JS, J Adolesc Health 2011; 48: 540, Olesen TB, Sex Transm Infect 2014; 90: 455, and Hebnes JB, J Sex Med 2014; 11: 2630) up to October 31, 2015. The search terms for the review were human papillomavirus, men, polymerase chain reaction (PCR), hybrid capture (HC), and viral DNA. References cited in selected articles were also investigated. Inclusion criteria were: HPV DNA detection by means of PCR or HC (ISH if data are not available for the country), and a detailed description of HPV DNA detection and genotyping techniques used. The number of cases tested and HPV positive cases were extracted for each study to estimate the anogenital prevalence of HPV DNA. Binomial 95% confidence intervals were calculated for each anogenital HPV prevalence.

Table 33: Studies on HPV prevalence among men in China

Study	Anatomic sites samples	HPV detection method	Population	Age (years)	No. Tested	HPV Prevalence	
						%	(95% CI)[a]
Liu 2015	Coronal sulcus, shaft, glans, and scrotum	PCR-SPF1/GP6+	Population-based esophageal cancer cohort study	25-65	2228	16.9	(15.3-18.5)

Data updated on 31 Oct 2015 (data as of 31 Oct 2015)

HC2: Hybrid Capture 2; ISH: In Situ Hybridization; PCR: Polymerase Chain Reaction; RT-PCR: Real Time Polymerase Chain Reaction; SPF: Short Primer Fragment; TS: Type Specific; MSM: Men who have sex with men; MSW:Men who have sex with women; STD: sexually transmitted diseases

[a] 95% Confidence Interval

Data Sources:

Liu F, Sci Rep 2015; 5: 27

Based on published systematic reviews, the ICO HPV Information Centre has updated data until October 2015. Reference publications: 1) Dunne EF, J Infect Dis 2006; 194: 1044 2) Smith JS, J Adolesc Health 2011; 48: 540 3) Olesen TB, Sex Transm Infect 2014; 90: 455 4) Hebnes JB, J Sex Med 2014; 11: 2630.

Table 34: Studies on HPV prevalence among men from special subgroups in China

Study	Anatomic sites samples	HPV detection method	Population	Age (years)	No. Tested	HPV Prevalence	
						%	(95% CI)[a]
Gao 2010	Anal canal	PCR-TellgenplexTM HPV DNA Test	HIV+ MSM	>=18 (70% <30 years)	50	96.0	(86.3-99.5)
Gao 2010	Anal canal	PCR-TellgenplexTM HPV DNA Test	HIV- MSM	>=18 (70% <30 years)	528	58.9	(54.6-63.1)
Li 2015	Anus	PCR-GenoArray	HIV+ MSM	18-60	193	99.0	(96.3-99.9)
Tang 2006	Urethral meatus	PCR-MY09/11	STD clinic attendees	18-70	305	13.8	(10.1-18.2)
Yang 2012	Anus	PCR-TellgenplexTM HPV DNA Test	HIV+ MSM	>=18	91	70.3	(59.8-79.5)
Zhang 2014	Anus	PCR-GenoArray	HIV- MSM, STD clinic attendees	IQR=25-34.8	380	33.7	(28.9-38.7)
Zhang 2014	Anus	PCR-GenoArray	HIV+ MSM STD clinic attendees	IQR=25-34.8	28	71.4	(51.3-86.8)

Data updated on 31 Oct 2015 (data as of 31 Oct 2015)

DBH: Dot Blot Hybridization; EIA: Enzyme ImmunoAssay; HC2: Hybrid Capture 2; LiPA: Line Probe Assay; PCR: Polymerase Chain Reaction; RFLP: Restriction Fragment Length Polymorphism; RLH: Reverse Line Hybridisation; RT-PCR: Real Time Polymerase Chain Reaction; SPF: Short Primer Fragment; TS: Type Specific; MSM: Men who have sex with men; MSW:Men who have sex with women; STD: sexually transmitted diseases

[a] 95% Confidence Interval

Data Sources:

Gao L, PLoS ONE 2010; 5: 125 | Li Z, PLoS One 2015; 10: 122 | Tang X, Biomed Environ Sci 2006; 19: 153 | Yang Y, PLoS ONE 2012; 7: 126 | Zhang DY, PLoS ONE 2014; 9: 134

Based on published systematic reviews, the ICO HPV Information Centre has updated data until October 2015. Reference publications: 1) Dunne EF, J Infect Dis 2006; 194: 1044 2) Smith JS, J Adolesc Health 2011; 48: 540 3) Olesen TB, Sex Transm Infect 2014; 90: 455 4) Hebnes JB, J Sex Med 2014; 11: 2630.

4.4 HPV burden in the head and neck

The last evaluation of the International Agency for Research in Cancer (IARC) on the carcinogenicity of HPV in humans concluded that (a) there is enough evidence for the carcinogenicity of HPV type 16 in the oral cavity, oropharynx (including tonsil cancer, base of tongue cancer and other oropharyngeal cancer sites), and (b) limited evidence for laryngeal cancer (IARC Monograph Vol 100B). There is increasing evidence that HPV-related oropharyngeal cancers constitute an epidemiological, molecular and clinical distinct form as compared to non HPV-related ones. Some studies indicate that the most likely explanation for the origin of this distinct form of head and neck cancers associated with HPV is a sexually acquired oral HPV infection that is not cleared, persists and evolves into a neoplastic lesion. Around 30% of oropharyngeal cancers (which mainly comprises the tonsils and base of tongue sites) are caused by HPV with HPV16 being the most frequent type (de Martel C et al. Int J Cancer 2017;141(4):664-670). Attributable fraction varies greatly worldwide, being highest in more developed countries (60% in Republic of Korea, 51% in North America, 50% in Eastern Europe, 46% in Japan, 42% in North-Western Europe, 41% in Australia/New Zealand, 24% in South Europe, 23% in China, 22% in India, and 13% in elsewhere) (de Martel C et al. Lancet Glob Health 2020;8(2):e180-e190). In this section, the HPV burden in the head and neck in China is presented.

4.4.1 Burden of oral HPV infection in healthy population

Table 35: Studies on oral HPV prevalence among healthy in China

Study	Specimen collection method / anatomic site	HPV detection method[a]	Population	% males	Age (years)[b]	No. tested[c]	HPV prevalence % (95% CI)	High-Risk HPV prevalence % (95% CI)	5 most frequent HPVs, HPV type (n)[d]
Hang 2014	Brush/swab / Oral mucosa	PCR-SPF1 GP6+	General population	47	25-65	5351	0.7 (0.4-1.1)	0.6 (0.4-1.0)	HPV3 (223); 10 (23); 57 (25); 16 (23); 75 (6)

Data updated on 19 Oct 2021 (data as of 19 May 2015)

(95% CI): 95% Confidence Interval
[a] TS: type-specific; RT-PCR: real-time PCR; qPCR: quantitative PCR
[b] NS: not specified
[c] number of cases tested for HPV DNA
[d] number of cases positive for the specific HPV-type
Data Sources:
Hang D, Cancer Epidemiol Biomarkers Prev 2014;23(10):2101-10
Systematic review and meta-analysis was performed by ICO HPV Information Centre until May 19, 2015. Reference publication: Mena M et al. J Infect Dis 2019;219(10):1574-1585.

4.4.2 HPV burden in head and neck cancers

Table 36: Studies on HPV prevalence among cases of oral cavity cancer in China

Study	HPV detection method and targeted HPV types	HPV Prevalence			
		No. Tested	%	(95% CI)[a]	Prevalence of 5 most frequent HPVs, HPV type (%)
MEN					
Zhang 2004	TS-PCR E6 for 16/18 Amplification with TS primers (16. 18)	48	81.3	(68.1-89.8)	-
WOMEN					
Zhang 2004	TS-PCR E6 for 16/18 Amplification with TS primers (16. 18)	25	60	(40.7-76.6)	-
BOTH OR UNSPECIFIED					
Gan 2014	PCR-GP5+/6+, PCR L1-Consensus primer (HPV 6, 16, 18)	200	27.5	(21.8-34.1)	-
Lee 2015	PCR-GP5+/6+, PCR-MY09/11, PCR L1-Consensus primer, (HPV 6, 11, 16, 18, 26, 31, 32, 33, 35, 39, 42, 43, 44, 45, 51, 52, 53, 54, 56, 58, 59, 61, 62, 66, 67, 68, 69, 70, 71, 72, 74, 81, 82, 83, 84)	1002	19.4	(17.0-21.9)	-
Tang 2003	TS-PCR E6 for 16/18/33 Sequencing	30	46.7	(30.2-63.9)	HPV 16 (36.7) HPV 18 (16.7)
Wen 1997	TS-PCR E6 for 16/18 Hybridization with TS probes (HPV16.18 E6)	45	31.1	(19.5-45.7)	HPV 18 (24.4) HPV 16 (20.0)
Zhang 2004	TS-PCR E6 for 16/18 Amplification with TS primers (16. 18)	73	74	(62.9-82.7)	HPV 16 (58.9) HPV 18 (24.7)

Data updated on 9 May 2016 (data as of 31 Dec 2015)

DBH: Dot Blot Hybridization; EIA: Enzyme ImmunoAssay; HC2: Hybrid Capture 2; ISH: In Situ Hybridization; LBA: Line-Blot Assay; LiPA: Line Probe Assay; PCR: Polymerase Chain Reaction; RFLP: Restriction Fragment Length Polymorphism; RLBH: Reverse Line Blot Hybridization; RT-PCR: Real Time Polymerase Chain Reaction; SBH: Southern Blot Hybridization; SPF: Short Primer Fragment; TS: Type Specific;
Only for European countries
[a] 95% Confidence Interval
Data Sources:
Gan LL, Asian Pac J Cancer Prev 2014; 15: 5861 | Lee LA, Medicine (Baltimore) 2015; 94: e2069 | Tang X, J Oral Pathol Med 2003; 32: 393 | Wen S, Anticancer Res 1997; 17: 307 | Zhang ZY, Int J Oral Maxillofac Surg 2004; 33: 71
Based on systematic reviews and meta-analysis performed by ICO. Reference publications: 1) Ndiaye C, Lancet Oncol 2014; 15: 1319 2) Kreimer AR, Cancer Epidemiol Biomarkers Prev 2005; 14: 467

Table 37: Studies on HPV prevalence among cases of oropharyngeal cancer in China

Study	HPV detection method and targeted HPV types	HPV Prevalence			
		No. Tested	%	(95% CI)[a]	Prevalence of 5 most frequent HPVs, HPV type (%)
MEN					
Li 2007	GP5+/GP6+ (L1). CP65/70ct-CP66/69ct (L1). FAP59/6415 (L1). A5/A10-A6/A8 (L1) and TS-PCR E6 for 16 Sequencing	21	14.3	(5.0-34.6)	HPV 16 (14.3)
WOMEN					
Li 2007	GP5+/GP6+ (L1). CP65/70ct-CP66/69ct (L1). FAP59/6415 (L1). A5/A10-A6/A8 (L1) and TS-PCR E6 for 16 Sequencing	10	60.0	(31.3-83.2)	HPV 16 (60.0)
BOTH OR UNSPECIFIED					
Li 2007	GP5+/GP6+ (L1). CP65/70ct-CP66/69ct (L1). FAP59/6415 (L1). A5/A10-A6/A8 (L1) and TS-PCR E6 for 16 Sequencing	31	29.0	(16.1-46.6)	HPV 16 (29.0)

Data updated on 9 May 2016 (data as of 31 Dec 2015)

DBH: Dot Blot Hybridization; EIA: Enzyme ImmunoAssay; HC2: Hybrid Capture 2; ISH: In Situ Hybridization; LBA: Line-Blot Assay; LiPA: Line Probe Assay; PCR: Polymerase Chain Reaction; RFLP: Restriction Fragment Length Polymorphism; RLBH: Reverse Line Blot Hybridization; RT-PCR: Real Time Polymerase Chain Reaction; SBH: Southern Blot Hybridization; SPF: Short Primer Fragment; TS: Type Specific
Only for European countries
[a] 95% Confidence Interval
Data Sources:
Li W, Pathology 2007; 39: 217
Based on systematic reviews and meta-analysis performed by ICO. Reference publications: 1) Ndiaye C, Lancet Oncol 2014; 15: 1319 2) Kreimer AR, Cancer Epidemiol Biomarkers Prev 2005; 14: 467

Table 38: Studies on HPV prevalence among cases of hypopharyngeal or laryngeal cancer in China

Study	HPV detection method and targeted HPV types	HPV Prevalence			
		No. Tested	%	(95% CI)[a]	Prevalence of 5 most frequent HPVs, HPV type (%)
MEN					
Liu 2010	GP5+/GP6+ (L1) and TS-PCR E6/E7 for 16 and E6 for 18 Amplification with TS primers (16. 18)	61	37.7	(26.6-50.3)	-
WOMEN					
Liu 2010	GP5+/GP6+ (L1) and TS-PCR E6/E7 for 16 and E6 for 18 Amplification with TS primers (16. 18)	23	34.8	(18.8-55.1)	-
BOTH OR UNSPECIFIED					
Liu 2010	GP5+/GP6+ (L1) and TS-PCR E6/E7 for 16 and E6 for 18 Amplification with TS primers (16. 18)	84	36.9	(27.4-47.6)	HPV 16 (34.5) HPV 18 (7.1)
Ma 1998	TS-PCR E6/E7 for 6/11/16/18/31/33/52b/58 SBH (6. 11. 16. 18. 31. 33. 52b. 58)	102	58.8	(49.1-67.9)	HPV 16 (29.4) HPV 6 (24.5) HPV 18 (21.6) HPV 11 (2.0) HPV 33 (1.0)

Data updated on 9 May 2016 (data as of 31 Dec 2015)

DBH: Dot Blot Hybridization; EIA: Enzyme ImmunoAssay; HC2: Hybrid Capture 2; ISH: In Situ Hybridization; LBA: Line-Blot Assay; LiPA: Line Probe Assay; PCR: Polymerase Chain Reaction; RFLP: Restriction Fragment Length Polymorphism; RLBH: Reverse Line Blot Hybridization; RT-PCR: Real Time Polymerase Chain Reaction; SBH: Southern Blot Hybridization; SPF: Short Primer Fragment; TS: Type Specific

Only for European countries

[a] 95% Confidence Interval

Data Sources:

Liu B, Neoplasma 2010; 57: 594 | Ma XL, J Med Virol 1998; 54: 186

Based on systematic reviews and meta-analysis performed by ICO. Reference publications: 1) Ndiaye C, Lancet Oncol 2014; 15: 1319 2) Kreimer AR, Cancer Epidemiol Biomarkers Prev 2005; 14: 467

5 Factors contributing to cervical cancer

HPV is a necessary cause of cervical cancer, but it is not a sufficient cause. Other cofactors are necessary for progression from cervical HPV infection to cancer. Tobacco smoking, high parity, long-term hormonal contraceptive use, and co-infection with HIV have been identified as established cofactors. Co-infection with Chlamydia trachomatis and herpes simplex virus type-2, immunosuppression, and certain dietary deficiencies are other probable cofactors. Genetic and immunological host factors and viral factors other than type, such as variants of type, viral load and viral integration, are likely to be important but have not been clearly identified. (Muñoz N, Vaccine 2006; 24(S3): 1-10). In this section, the prevalence of smoking, parity (fertility), oral contraceptive use, and HIV in China are presented.

Table 39: Factors contributing to cervical carcinogenesis (cofactors) in China

INDICATOR		MALE	FEMALE	TOTAL
Smoking				
Smoking of any tobacco adjusted prevalence (%) [95% UI]	Current[a]	50.5 [40-62.5]	2.2 [1.7-2.7]	26.9 [21.3-33.2]
	Daily[b]	43.9 [34.3-53.4]	1.9 [1.4-2.3]	23.3 [18.2-28.4]
Cigarette smoking adjusted prevalence (%) [95% UI]	Current[c]	50.5 [40-62.5]	2.2 [1.7-2.7]	26.9 [21.3-33.2]
	Daily[d]	43.9 [34.3-53.4]	1.9 [1.4-2.3]	23.3 [18.2-28.4]
Parity				
Total fertility rate per woman		-	1.6	-
Age-specific fertility rate (per 1000 women)	15-19 yrs	-	-	-
	20-24 yrs	-	-	-
	25-29 yrs	-	-	-
	30-34 yrs	-	-	-
	35-39 yrs	-	-	-
	40-44 yrs	-	-	-
	45-49 yrs	-	-	-
Hormonal contraception				
Oral contraceptive use (%) among women who are married or in union		-	1.20	-
Injectable contraception use (%) among women who are married or in union		-	0	-
Implant contraceptive use (%) among women who are married or in union		-	0.20	-
HIV				
Estimated percent of adults aged 15-49 who are living with HIV [95% UI]		- [—]	- [—]	- [—]
Estimated percent of young adults aged 15-24 who are living with HIV [95% UI]		- [—]	- [—]	- [—]
HIV prevalence (%) among sex workers		-	0.2	0.2
HIV prevalence (%) among men who have sex with men[1]		6.9000001	-	6.9000001
Estimated number of people living with HIV [95% UI]		-	-	- [—]
Estimated number of adults (15+ yrs) living with HIV [95% UI]		- [—]	- [—]	- [—]
Estimated number of AIDS-related deaths [95% UI]		-	-	- [—]

Data accessed on 12 Nov 2019

Crude adjusted prevalence (%) estimates of tabacco use among people aged >= 15 years by country, for the year 2016.

[a] "Current" means smoking at the time of the survey, including both daily and non-daily or occasional smoking. "Tobacco smoking" means smoking any form of tobacco, including cigarettes, cigars, pipes, or any other smoked tobacco products and excluding smokeless products.

[b] "Daily" means smoking every day at the time of the survey. "Tobacco smoking" means smoking any form of tobacco, including cigarettes, cigars, pipes, or any other smoked tobacco products and excluding smokeless products.

[c] "Current" means smoking at the time of the survey, including both daily and non-daily or occasional smoking.

[d] "Daily" means smoking every day at the time of the survey.

Data with no response were excluded for 2,699 weighted sample of married women.

Year of estimate: 2016

Data Sources:

WHO global report on trends in prevalence of tobacco use 2000–2025, third edition. Geneva: World Health Organization; 2019. Available at https://www.who.int/publications/i/item/who-global-report-on-trends-in-prevalence-of-tobacco-use-2000-2025-third-edition

United Nations, Department of Economic and Social Affairs, Population Division (2019). World Contraceptive Use 2019 (POP/DB/CP/Rev2019). https://www.un.org/en/development/desa/population/publications/dataset/contraception/wcu2019.asp. Available at: [Accessed on November 18, 2019].

UNAIDS database [internet]. Available at: http://aidsinfo.unaids.org/ [Accessed on November 21, 2019]

[1] National HIV sentinel surveillance

6 Sexual and reproductive health behaviour indicators

Sexual intercourse is the primary route of transmission of genital HPV infection. Information about sexual and reproductive health behaviours is essential to the design of effective preventive strategies against anogenital cancers. In this section, we describe sexual and reproductive health indicators that may be used as proxy measures of risk for HPV infection and anogenital cancers. Several studies have reported that earlier sexual debut is a risk factor for HPV infection, although the reason for this relationship is still unclear. In this section, information on sexual and reproductive health behaviour in China are presented.

Table 40: Percentage of 15-year-olds who have had sexual intercourse in China

Indicator	Male	Female
Percentage of 15-year-old subjects who report sexual intercourse	-	-

Data accessed on 16 Mar 2017
Please refer to original source for methods of estimation
Year of estimation: 1997

Table 41: Median age at first sex in China

Study[1,a]	Year/period	Birth cohort N	MALE N	MALE Median age at first sex	FEMALE N	FEMALE Median age at first sex	TOTAL N	TOTAL Median age at first sex
Fang-Hui Zhao 2009[b]	2009	1985-1989	-	-	504	19.0	-	-
Fang-Hui Zhao 2009[b]	2009	1990-1994	-	-	42	17.0	-	-
Fang-Hui Zhao 2009[b]	2009	1960-1964	-	-	676	21.0	-	-
Fang-Hui Zhao 2009[c]	2009	1965-1969	-	-	462	22.0	-	-
Fang-Hui Zhao 2009[c]	2009	1955-1959	-	-	352	23.0	-	-
Fang-Hui Zhao 2009[c]	2009	1985-1989	-	-	272	19.0	-	-
Fang-Hui Zhao 2009[c]	2009	1975-1979	-	-	666	22.0	-	-
Fang-Hui Zhao 2009[b]	2009	1965-1969	-	-	686	20.0	-	-
Fang-Hui Zhao 2009[c]	2009	1950-1954	-	-	247	23.0	-	-
Fang-Hui Zhao 2009[c]	2009	1980-1984	-	-	595	22.0	-	-
Fang-Hui Zhao 2009[c]	2009	1950-1994	-	-	3756	22.0	-	-
Fang-Hui Zhao 2009[c]	2009	1990-1994	-	-	64	17.0	-	-
Fang-Hui Zhao 2009[b]	2009	1980-1984	-	-	888	21.0	-	-
Fang-Hui Zhao 2009[b]	2009	1975-1979	-	-	1054	20.0	-	-
Fang-Hui Zhao 2009[b]	2009	1950-1954	-	-	369	20.0	-	-
Fang-Hui Zhao 2009[b]	2009	1950-1994	-	-	5633	20.0	-	-
Fang-Hui Zhao 2009[c]	2009	1970-1974	-	-	645	22.0	-	-
Fang-Hui Zhao 2009[b]	2009	1955-1959	-	-	528	21.0	-	-
Fang-Hui Zhao 2009[c]	2009	1960-1964	-	-	447	22.0	-	-
Fang-Hui Zhao 2009[b]	2009	1970-1974	-	-	889	21.0	-	-

Data accessed on 16 Mar 2017
Please refer to original source for methods of estimation
[a] Data were collected anonimously using a short, nurse-administered questionnaire.
[b] Rural.
[c] Urban.
Data Sources:
[1] Zhao FH, Tiggelaar SM, Hua SY, Xu LN, Hong Y, Niyazi M, et al. A multi-center survey of age of sexual debut and sexual behavior in Chinese women: Suggestions for optimal age of human papillomavirus vaccination in China. Cancer Epidemiology 2012; 36: 384-390

Table 42: Marriage patterns in China

Indicator		Male	Female
Average age at first marriage[1]		26.2	24.4
Age-specific % of ever married[2]	15-19 years	1.39	2.18
	20-24 years	14.32	26.53
	25-29 years	57.83	73.52
	30-34 years	85.29	92.73
	35-39 years	93.49	97.5
	40-44 years	95.8	99.05
	45-49 years	96.92	99.53
	50-54 years	97.75	99.71
	55-59 years	97.84	99.78
	60-64 years	97.43	99.84
	65-69 years	97.04	99.79
	70-74 years	-	-
	+75	-	-

Data accessed on 20 Feb 2020

Please refer to original source for methods of estimation.

[a] 2016 Annual APC

[b] National statistics

Data Sources:

[1] The world bank: health nutrition and population statistics. Updated 20-Dec-2019. Accessed on February 20 2020. Available at http://data.worldbank.org/data-catalog/health-nutrition-and-population-statistics

[2] United Nations, Department of Economic and Social Affairs, Population Division (2019). World Marriage Data 2019 (POP/DB/Marr/Rev2019). Available at: https://population.un.org/MarriageData/Index.html#/home Accessed on February 24, 2020.

Table 43: Average number of sexual partners in China

Study	Period of estimate	Year/Period	Birth cohort	Male Mean(N)	Female Mean(N)	Total Mean(N)
-	-	-	-	-(-)	-(-)	-(-)

Data accessed on 8 Aug 2013

Please refer to original source for methods of estimation

Table 44: Lifetime prevalence of anal intercourse among women in China

			FEMALE		
Study	**Year/Period**	**Birth cohort**	**N surveyed**	**N sexual active**	**% among sexually active**
-	-	-	-	-	-

Data accessed on 8 Aug 2013
Please refer to original source for methods of estimation

7 HPV preventive strategies

It is established that well-organised cervical screening programmes or widespread good quality cytology can reduce cervical cancer incidence and mortality. The introduction of HPV vaccination could also effectively reduce the burden of cervical cancer in the coming decades. This section presents indicators on basic characteristics and performance of cervical cancer screening, status of HPV vaccine licensure and introduction in China.

7.1 Cervical cancer screening practices

Screening strategies differ between countries. Some countries have population-based programmes, where in each round of screening women in the target population are individually identified and invited to attend screening. This type of programme can be implemented nationwide or only in specific regions of the country. In opportunistic screening, invitations depend on the individual's decision or on encounters with health-care providers. The most frequent method for cervical cancer screening is cytology, and there are alternative methods such as HPV DNA tests and visual inspection with acetic acid (VIA). VIA is an alternative to cytology-based screening in low-resource settings (the 'see and treat' approach). HPV DNA testing is being introduced into some countries as an adjunct to cytology screening ('co-testing') or as the primary screening test to be followed by a secondary, more specific test, such as cytology.

Table 45: Main characteristics of cervical cancer screening in China

Region	Existence of official national recommendations	Starting year of current recommendations	Active invitation to screening	Screening ages (years), primary screening test used, and screening interval or frequency of screenings
China	Yes	2019	No	35-64 (cytology or HPV test and VIA, 3 years)

Data accessed on 31 Aug 2022

Data Sources:

Bruni L, Serrano B, Roura E, Alemany L, Cowan M, Herrero R, et al. Cervical cancer screening programmes and age-specific coverage estimates for 202 countries and territories worldwide: a review and synthetic analysis. Lancet Glob Health. 2022;10(8):e1115.

Figure 70: Estimated coverage* of cervical cancer screening in China



Data accessed on 31 Aug 2022

* Estimated coverage and 95% confidence interval in 2019

Data Sources:

Bruni L, Serrano B, Roura E, Alemany L, Cowan M, Herrero R, et al. Cervical cancer screening programmes and age-specific coverage estimates for 202 countries and territories worldwide: a review and synthetic analysis. Lancet Glob Health. 2022;10(8):e1115.

7.2 HPV vaccination

Table 46: National HPV Immunization programme in China

	Female	Male
HPV vaccination programme	Not Available/Not Introduced	Not Available/Not Introduced
Year of introduction	-	-
Year of estimation of HPV vaccination coverage	-	-
HPV coverage – first dose (%)	-	-
HPV coverage – last dose (%)	-	-

Data accessed on 24 Oct 2022

Data Sources:

Human papillomavirus (HPV) vaccination coverage. World Health Organization. 2022. Available from: https://immunizationdata.who.int/pages/coverage/hpv.html, accessed [24 Oct 2022]

Bruni L, Saura-Lázaro A, Montoliu A, Brotons M, Alemany L, Diallo MS, et al. HPV vaccination introduction worldwide and WHO and UNICEF estimates of national HPV immunization coverage 2010-2019. Prev Med. 2021;144(106399):106399.

Figure 71: HPV vaccination coverage in females by year in China



Data accessed on 24 Oct 2022

Data Sources:

Human papillomavirus (HPV) vaccination coverage. World Health Organization. 2022. Available from: https://immunizationdata.who.int/pages/coverage/hpv.html, accessed [24 Oct 2022]

Bruni L, Saura-Lázaro A, Montoliu A, Brotons M, Alemany L, Diallo MS, et al. HPV vaccination introduction worldwide and WHO and UNICEF estimates of national HPV immunization coverage 2010-2019. Prev Med. 2021;144(106399):106399.

Figure 72: HPV vaccination coverage in males by year in China

Data accessed on 24 Oct 2022

Data Sources:

Human papillomavirus (HPV) vaccination coverage. World Health Organization. 2022. Available from: https://immunizationdata.who.int/pages/coverage/hpv.html, accessed [24 Oct 2022]

Bruni L, Saura-Lázaro A, Montoliu A, Brotons M, Alemany L, Diallo MS, et al. HPV vaccination introduction worldwide and WHO and UNICEF estimates of national HPV immunization coverage 2010-2019. Prev Med. 2021;144(106399):106399.

8 Protective factors for cervical cancer

Male circumcision and the use of condoms have shown a significant protective effect against HPV transmission.

Table 47: Prevalence of male circumcision in China

Reference	Prevalence % (95% CI)	Methods
Drain 2006	<20	Data from Demographic and Health Surveys (DHS) and other publications to categorize the country-wide prevalence of male circumcision as <20%, 20-80%, or >80%.
Zeng 2014	11.6 (9.1-14.5)	N=570: Men who have sex with men
Wan 2014	2.8 (2.1-3.5)	N=2,241: Male children between the ages of 3 and 6 years
WHO 2007	<20	Data from Demographic and Health Surveys (DHS) and other publications to categorize the country-wide prevalence of male circumcision as <20%, 20-80%, or >80%.

Data accessed on 31 Aug 2015
Please refer to country-specific reference(s) for full methodologies.
Data Sources:
Drain PK, BMC Infect Dis 2006; 6: 172 | Wan S, Pediatrics 2014; 133: e624 | WHO 2007: Male circumcision: Global trends and determinants of prevalence, safety and acceptability | Zeng Y, Biomed Res Int 2014; 2014: 498987
Based on systematic reviews and meta-analysis performed by ICO. The ICO HPV Information Centre has updated data until August 2015. Reference publication: Albero G, Sex Transm Dis. 2012 Feb;39(2):104-13.

Table 48: Prevalence of condom use in China

Indicator	Age range	Year of estimate	Prevalence %[a]
Condom use	15-49	2017	24.6

Data accessed on 18 Nov 2019
Please refer to original source for methods of estimation.
Data with no response were excluded for 2,699 weighted sample of married women.
[a] Condom use: Proportion of male partners who are using condoms with their female partners of reproductive age to whom they are married or in union by country.
Data Sources:
2017 NFS
United Nations, Department of Economic and Social Affairs, Population Division (2019). World Contraceptive Use 2019 (POP/DB/CP/Rev2019). https://www.un.org/en/development/desa/population/publications/dataset/contraception/wcu2019.asp. Available at: [Accessed on November 18, 2019].

9 Annex

9.1 Incidence

9.1.1 Cervical cancer incidence in China across Eastern Asia

Figure 73: Age-standardised incidence rates of cervical cancer of China (estimates for 2020)



Data accessed on 27 Jan 2021
For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods
[a] Rates per 100,000 women per year.
Data Sources:
Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2020). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: https://gco.iarc.fr/today, accessed [27 January 2021].

Figure 74: Annual number of new cases of cervical cancer by age group in China (estimates for 2020)



Data accessed on 27 Jan 2021

For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods

[a] 16 cases for China and 18 cases for Eastern Asia in the 15-19 age group. 220 cases for China and 492 cases for Eastern Asia in the 20-24 age group.

Data Sources:

Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2020). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: https://gco.iarc.fr/today, accessed [27 January 2021].

Figure 75: Comparison of age-specific cervical cancer incidence rates in China, within the region, and the rest of world



Data accessed on 27 Jan 2021

For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods

[a] Rates per 100,000 women per year.

Data Sources:

Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2020). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: https://gco.iarc.fr/today, accessed [27 January 2021].

9.1.2 Anal cancer incidence in China across Eastern Asia

Figure 76: Age-standardised incidence rates of anal cancer of China (estimates for 2020)



Data accessed on 27 Jan 2021
For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods
[a] Rates per 100,000 men per year.
[b] Rates per 100,000 women per year.
Data Sources:
Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2020). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: https://gco.iarc.fr/today, accessed [27 January 2021].

Figure 77: Annual number of new cases of anal cancer among men by age group in China (estimates for 2020)



Data accessed on 27 Jan 2021

For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods

[a] 0 cases for China and 2 cases for Eastern Asia in the 15-19 age group. 0 cases for China and 0 cases for Eastern Asia in the 20-24 age group. 8 cases for China and 8 cases for Eastern Asia in the 25-29 age group.

Data Sources:

Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2020). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: https://gco.iarc.fr/today, accessed [27 January 2021].

Figure 78: Annual number of new cases of anal cancer among women by age group in China (estimates for 2020)



Data accessed on 27 Jan 2021

For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods

[a] 3 cases for China and 3 cases for Eastern Asia in the 15-19 age group. 9 cases for China and 10 cases for Eastern Asia in the 20-24 age group. 10 cases for China and 11 cases for Eastern Asia in the 25-29 age group.

Data Sources:

Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2020). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: https://gco.iarc.fr/today, accessed [27 January 2021].

Figure 79: Comparison of age-specific anal cancer incidence rates among men by age in China, within the region, and the rest of world



Data accessed on 27 Jan 2021

For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods

[a] Rates per 100,000 men per year.

Data Sources:

Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2020). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: https://gco.iarc.fr/today, accessed [27 January 2021].

Figure 80: Comparison of age-specific anal cancer incidence rates among women by age in China, within the region, and the rest of world



Data accessed on 27 Jan 2021

For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods

[a] Rates per 100,000 women per year.

Data Sources:

Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2020). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: https://gco.iarc.fr/today, accessed [27 January 2021].

9.1.3 Vulva cancer incidence in China across Eastern Asia

Figure 81: Age-standardised incidence rates of vulva cancer of China (estimates for 2020)



Data accessed on 27 Jan 2021
For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods
[a] Rates per 100,000 women per year.
Data Sources:
Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2020). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: https://gco.iarc.fr/today, accessed [27 January 2021].

Figure 82: Annual number of new cases of vulva cancer by age group in China (estimates for 2020)



Data accessed on 27 Jan 2021
For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods
[a] 0 cases for China and 1 cases for Eastern Asia in the 15-19 age group. 11 cases for China and 13 cases for Eastern Asia in the 20-24 age group.
Data Sources:
Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2020). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: https://gco.iarc.fr/today, accessed [27 January 2021].

Figure 83: Comparison of age-specific vulva cancer incidence rates in China, within the region, and the rest of world



Data accessed on 27 Jan 2021

For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods

[a] Rates per 100,000 women per year.

Data Sources:

Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2020). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: https://gco.iarc.fr/today, accessed [27 January 2021].

9.1.4 Vaginal cancer incidence in China across Eastern Asia

Figure 84: Age-standardised incidence rates of vaginal cancer of China (estimates for 2020)



Data accessed on 27 Jan 2021
For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods
[a] Rates per 100,000 women per year.
Data Sources:
Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2020). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: https://gco.iarc.fr/today, accessed [27 January 2021].

Figure 85: Annual number of new cases of cervical cancer by age group in China (estimates for 2020)



Data accessed on 27 Jan 2021

For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods

[a] 0 cases for China and 0 cases for Eastern Asia in the 15-19 age group. 3 cases for China and 5 cases for Eastern Asia in the 20-24 age group. 8 cases for China and 9 cases for Eastern Asia in the 25-29 age group.

Data Sources:

Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2020). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: https://gco.iarc.fr/today, accessed [27 January 2021].

Figure 86: Comparison of age-specific vaginal cancer incidence rates in China, within the region, and the rest of world



Data accessed on 27 Jan 2021
For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods
[a] Rates per 100,000 women per year.
Data Sources:
Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2020). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: https://gco.iarc.fr/today, accessed [27 January 2021].

9.1.5 Penile cancer incidence in China across Eastern Asia

Figure 87: Age-standardised incidence rates of penile cancer of China (estimates for 2020)



Data accessed on 27 Jan 2021

For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods

[a] Rates per 100,000 men per year.

Data Sources:

Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2020). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: https://gco.iarc.fr/today, accessed [27 January 2021].

Figure 88: Annual number of new cases of penile cancer by age group in China (estimates for 2020)



Data accessed on 27 Jan 2021

For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods

[a] 2 cases for China and 2 cases for Eastern Asia in the 15-19 age group. 3 cases for China and 3 cases for Eastern Asia in the 20-24 age group. 20 cases for China and 23 cases for Eastern Asia in the 25-29 age group.

Data Sources:

Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2020). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: https://gco.iarc.fr/today, accessed [27 January 2021].

Figure 89: Comparison of age-specific penile cancer incidence rates in China, within the region, and the rest of world



Data accessed on 27 Jan 2021

For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods

[a] Rates per 100,000 men per year.

Data Sources:

Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2020). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: https://gco.iarc.fr/today, accessed [27 January 2021].

9.1.6 Oropharyngeal cancer incidence in China across Eastern Asia

Figure 90: Age-standardised incidence rates of oropharyngeal cancer of China (estimates for 2020)



Data accessed on 27 Jan 2021

For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods

[a] Rates per 100,000 men per year.

[b] Rates per 100,000 women per year.

Data Sources:

Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2020). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: https://gco.iarc.fr/today, accessed [27 January 2021].

Figure 91: Annual number of new cases of oropharyngeal cancer among men by age group in China (estimates for 2020)



Data accessed on 27 Jan 2021

For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods

[a] 0 cases for China and 0 cases for Eastern Asia in the 15-19 age group. 6 cases for China and 6 cases for Eastern Asia in the 20-24 age group. 21 cases for China and 22 cases for Eastern Asia in the 25-29 age group. 34 cases for China and 68 cases for Eastern Asia in the 30-34 age group.

Data Sources:

Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2020). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: https://gco.iarc.fr/today, accessed [27 January 2021].

Figure 92: Annual number of new cases of oropharyngeal cancer among women by age group in China (estimates for 2020)



Data accessed on 27 Jan 2021

For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods

[a] 2 cases for China and 2 cases for Eastern Asia in the 15-19 age group. 1 cases for China and 1 cases for Eastern Asia in the 20-24 age group. 5 cases for China and 5 cases for Eastern Asia in the 25-29 age group.

Data Sources:

Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2020). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: https://gco.iarc.fr/today, accessed [27 January 2021].

Figure 93: Comparison of age-specific oropharyngeal cancer incidence rates among men by age in China, within the region, and the rest of world



Data accessed on 27 Jan 2021

For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods

[a] Rates per 100,000 men per year.

Data Sources:

Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2020). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: https://gco.iarc.fr/today, accessed [27 January 2021].

Figure 94: Comparison of age-specific oropharyngeal cancer incidence rates among women by age in China, within the region, and the rest of world



Data accessed on 27 Jan 2021

For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods

[a] Rates per 100,000 women per year.

Data Sources:

Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2020). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: https://gco.iarc.fr/today, accessed [27 January 2021].

9.1.7 Oral cavity cancer incidence in China across Eastern Asia

Figure 95: Age-standardised incidence rates of oral cavity cancer of China (estimates for 2020)



Data accessed on 27 Jan 2021

For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods

[a] Rates per 100,000 men per year.

[b] Rates per 100,000 women per year.

Data Sources:

Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2020). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: https://gco.iarc.fr/today, accessed [27 January 2021].

Figure 96: Annual number of new cases of oral cavity cancer among men by age group in China (estimates for 2020)



Data accessed on 27 Jan 2021

For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods

[a] 27 cases for China and 31 cases for Eastern Asia in the 15-19 age group. 56 cases for China and 89 cases for Eastern Asia in the 20-24 age group. 63 cases for China and 105 cases for Eastern Asia in the 25-29 age group.

Data Sources:

Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2020). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: https://gco.iarc.fr/today, accessed [27 January 2021].

Figure 97: Annual number of new cases of oral cavity cancer among women by age group in China (estimates for 2020)



Data accessed on 27 Jan 2021

For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods

[a] 33 cases for China and 39 cases for Eastern Asia in the 15-19 age group. 39 cases for China and 59 cases for Eastern Asia in the 20-24 age group. 97 cases for China and 137 cases for Eastern Asia in the 25-29 age group.

Data Sources:

Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2020). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: https://gco.iarc.fr/today, accessed [27 January 2021].

Figure 98: Comparison of age-specific oral cavity cancer incidence rates among men by age in China, within the region, and the rest of world



Data accessed on 27 Jan 2021

For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods

[a] Rates per 100,000 men per year.

Data Sources:

Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2020). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: https://gco.iarc.fr/today, accessed [27 January 2021].

Figure 99: Comparison of age-specific oral cavity cancer incidence rates among women by age in China, within the region, and the rest of world



Data accessed on 27 Jan 2021

For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods

[a] Rates per 100,000 women per year.

Data Sources:

Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2020). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: https://gco.iarc.fr/today, accessed [27 January 2021].

9.1.8 Laryngeal cancer incidence in China across Eastern Asia

Figure 100: Age-standardised incidence rates of laryngeal cancer of China (estimates for 2020)



Data accessed on 27 Jan 2021

For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods

[a] Rates per 100,000 men per year.

[b] Rates per 100,000 women per year.

Data Sources:

Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2020). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: https://gco.iarc.fr/today, accessed [27 January 2021].

Figure 101: Annual number of new cases of laryngeal cancer among men by age group in China (estimates for 2020)



Data accessed on 27 Jan 2021

For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods

[a] 0 cases for China and 0 cases for Eastern Asia in the 15-19 age group. 3 cases for China and 4 cases for Eastern Asia in the 20-24 age group. 16 cases for China and 16 cases for Eastern Asia in the 25-29 age group. 58 cases for China and 64 cases for Eastern Asia in the 30-34 age group. 116 cases for China and 137 cases for Eastern Asia in the 35-39 age group.

Data Sources:

Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2020). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: https://gco.iarc.fr/today, accessed [27 January 2021].

Figure 102: Annual number of new cases of laryngeal cancer among women by age group in China (estimates for 2020)



Data accessed on 27 Jan 2021

For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods

[a] 3 cases for China and 3 cases for Eastern Asia in the 15-19 age group. 6 cases for China and 7 cases for Eastern Asia in the 20-24 age group. 10 cases for China and 12 cases for Eastern Asia in the 25-29 age group. 10 cases for China and 11 cases for Eastern Asia in the 30-34 age group. 14 cases for China and 16 cases for Eastern Asia in the 35-39 age group.

Data Sources:

Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2020). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: https://gco.iarc.fr/today, accessed [27 January 2021].

Figure 103: Comparison of age-specific laryngeal cancer incidence rates among men by age in China, within the region, and the rest of world



Data accessed on 27 Jan 2021

For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods

[a] Rates per 100,000 men per year.

Data Sources:

Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2020). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: https://gco.iarc.fr/today, accessed [27 January 2021].

Figure 104: Comparison of age-specific laryngeal cancer incidence rates among women by age in China, within the region, and the rest of world



Data accessed on 27 Jan 2021

For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods

[a] Rates per 100,000 women per year.

Data Sources:

Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2020). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: https://gco.iarc.fr/today, accessed [27 January 2021].

9.2 Mortality

9.2.1 Cervical cancer mortality in China across Eastern Asia

Figure 105: Age-standardised mortality rates of cervical cancer of China (estimates for 2020)



Data accessed on 27 Jan 2021
For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods
[a] Rates per 100,000 women per year.
Data Sources:
Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2020). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: https://gco.iarc.fr/today, accessed [27 January 2021].

Figure 106: Annual number of deaths of cervical cancer by age group in China (estimates for 2020)



Data accessed on 27 Jan 2021

For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods

[a] 13 cases for China and 13 cases for Eastern Asia in the 15-19 age group. 53 cases for China and 60 cases for Eastern Asia in the 20-24 age group. 235 cases for China and 309 cases for Eastern Asia in the 25-29 age group.

Data Sources:

Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2020). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: https://gco.iarc.fr/today, accessed [27 January 2021].

Figure 107: Comparison of age-specific cervical cancer mortality rates in China, within the region, and the rest of world



Data accessed on 27 Jan 2021

For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods

[a] Rates per 100,000 women per year.

Data Sources:

Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2020). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: https://gco.iarc.fr/today, accessed [27 January 2021].

9.2.2 Anal cancer mortality in China across Eastern Asia

Figure 108: Age-standardised mortality rates of anal cancer of China (estimates for 2020)



Data accessed on 27 Jan 2021

For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods

[a] Rates per 100,000 men per year.

[b] Rates per 100,000 women per year.

* Rates are not available

Data Sources:

Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2020). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: https://gco.iarc.fr/today, accessed [27 January 2021].

Figure 109: Annual number of deaths of anal cancer among men by age group in China (estimates for 2020)



Data accessed on 27 Jan 2021

For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods

[a] 0 cases for China and 0 cases for Eastern Asia in the 15-19 age group. 0 cases for China and 0 cases for Eastern Asia in the 20-24 age group. 0 cases for China and 0 cases for Eastern Asia in the 25-29 age group. 3 cases for China and 4 cases for Eastern Asia in the 30-34 age group. 12 cases for China and 15 cases for Eastern Asia in the 35-39 age group.

Data Sources:

Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2020). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: https://gco.iarc.fr/today, accessed [27 January 2021].

Figure 110: Annual number of deaths of anal cancer among women by age group in China (estimates for 2020)



Data accessed on 27 Jan 2021

For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods

[a] 0 cases for China and 0 cases for Eastern Asia in the 15-19 age group. 2 cases for China and 2 cases for Eastern Asia in the 20-24 age group. 2 cases for China and 2 cases for Eastern Asia in the 25-29 age group. 0 cases for China and 1 cases for Eastern Asia in the 30-34 age group. 13 cases for China and 14 cases for Eastern Asia in the 35-39 age group.

Data Sources:

Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2020). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: https://gco.iarc.fr/today, accessed [27 January 2021].

Figure 111: Comparison of age-specific anal cancer mortality rates among men by age in China, within the region, and the rest of world



Data accessed on 27 Jan 2021

For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods

[a] Rates per 100,000 men per year.

Data Sources:

Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2020). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: https://gco.iarc.fr/today, accessed [27 January 2021].

Figure 112: Comparison of age-specific anal cancer mortality rates among women by age in China, within the region, and the rest of world



Data accessed on 27 Jan 2021

For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods

[a] Rates per 100,000 women per year.

Data Sources:

Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2020). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: https://gco.iarc.fr/today, accessed [27 January 2021].

9.2.3 Vulva cancer mortality in China across Eastern Asia

Figure 113: Age-standardised mortality rates of vulva cancer of China (estimates for 2020)



Data accessed on 27 Jan 2021
For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods
[a] Rates per 100,000 women per year.
Data Sources:
Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2020). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: https://gco.iarc.fr/today, accessed [27 January 2021].

Figure 114: Annual number of deaths of vulva cancer by age group in China (estimates for 2020)



Data accessed on 27 Jan 2021

For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods

[a] 0 cases for China and 0 cases for Eastern Asia in the 15-19 age group. 4 cases for China and 4 cases for Eastern Asia in the 20-24 age group. 3 cases for China and 3 cases for Eastern Asia in the 25-29 age group. 17 cases for China and 18 cases for Eastern Asia in the 30-34 age group. 17 cases for China and 19 cases for Eastern Asia in the 35-39 age group.

Data Sources:

Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2020). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: https://gco.iarc.fr/today, accessed [27 January 2021].

Figure 115: Comparison of age-specific vulva cancer mortality rates in China, within the region, and the rest of world



Data accessed on 27 Jan 2021
For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods
[a] Rates per 100,000 women per year.
Data Sources:
Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2020). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: https://gco.iarc.fr/today, accessed [27 January 2021].

9.2.4 Vaginal cancer mortality in China across Eastern Asia

Figure 116: Age-standardised mortality rates of vaginal cancer of China (estimates for 2020)



Data accessed on 27 Jan 2021
For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods
[a] Rates per 100,000 women per year.
Data Sources:
Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2020). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: https://gco.iarc.fr/today, accessed [27 January 2021].

Figure 117: Annual number of deaths of cervical cancer by age group in China (estimates for 2020)



Data accessed on 27 Jan 2021

For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods

[a] 0 cases for China and 0 cases for Eastern Asia in the 15-19 age group. 0 cases for China and 0 cases for Eastern Asia in the 20-24 age group. 2 cases for China and 2 cases for Eastern Asia in the 25-29 age group.

Data Sources:

Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2020). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: https://gco.iarc.fr/today, accessed [27 January 2021].

Figure 118: Comparison of age-specific vaginal cancer mortality rates in China, within the region, and the rest of world



Data accessed on 27 Jan 2021

For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods

[a] Rates per 100,000 women per year.

Data Sources:

Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2020). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: https://gco.iarc.fr/today, accessed [27 January 2021].

9.2.5 Penile cancer mortality in China across Eastern Asia

Figure 119: Age-standardised mortality rates of penile cancer of China (estimates for 2020)



Data accessed on 27 Jan 2021
For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods
[a] Rates per 100,000 men per year.
Data Sources:
Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2020). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: https://gco.iarc.fr/today, accessed [27 January 2021].

Figure 120: Annual number of new deaths of penile cancer by age group in China (estimates for 2020)



Data accessed on 27 Jan 2021

For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods

[a] 0 cases for China and 1 cases for Eastern Asia in the 15-19 age group. 0 cases for China and 2 cases for Eastern Asia in the 20-24 age group. 3 cases for China and 4 cases for Eastern Asia in the 25-29 age group.

Data Sources:

Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2020). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: https://gco.iarc.fr/today, accessed [27 January 2021].

Figure 121: Comparison of age-specific penile cancer mortality rates in China, within the region, and the rest of world



Data accessed on 27 Jan 2021
For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods
[a] Rates per 100,000 men per year.
Data Sources:
Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2020). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: https://gco.iarc.fr/today, accessed [27 January 2021].

9.2.6 Oropharyngeal cancer mortality in China across Eastern Asia

Figure 122: Age-standardised mortality rates of oropharyngeal cancer of China (estimates for 2020)



Data accessed on 27 Jan 2021

For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods

[a] Rates per 100,000 men per year.

[b] Rates per 100,000 women per year.

Data Sources:

Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2020). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: https://gco.iarc.fr/today, accessed [27 January 2021].

Figure 123: Annual number of deaths of oropharyngeal cancer among men by age group in China (estimates for 2020)



Data accessed on 27 Jan 2021

For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods

[a] 0 cases for China and 0 cases for Eastern Asia in the 15-19 age group. 3 cases for China and 3 cases for Eastern Asia in the 20-24 age group. 3 cases for China and 3 cases for Eastern Asia in the 25-29 age group. 7 cases for China and 8 cases for Eastern Asia in the 30-34 age group.

Data Sources:

Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2020). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: https://gco.iarc.fr/today, accessed [27 January 2021].

Figure 124: Annual number of deaths of oropharyngeal cancer among women by age group in China (estimates for 2020)



Data accessed on 27 Jan 2021

For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods

[a] 0 cases for China and 0 cases for Eastern Asia in the 15-19 age group. 0 cases for China and 0 cases for Eastern Asia in the 20-24 age group. 1 cases for China and 1 cases for Eastern Asia in the 25-29 age group. 4 cases for China and 4 cases for Eastern Asia in the 30-34 age group. 4 cases for China and 5 cases for Eastern Asia in the 35-39 age group.

Data Sources:

Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2020). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: https://gco.iarc.fr/today, accessed [27 January 2021].

Figure 125: Comparison of age-specific oropharyngeal cancer mortality rates among men by age in China, within the region, and the rest of world



Data accessed on 27 Jan 2021

For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods

[a] Rates per 100,000 men per year.

Data Sources:

Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2020). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: https://gco.iarc.fr/today, accessed [27 January 2021].

Figure 126: Comparison of age-specific oropharyngeal cancer mortality rates among women by age in China, within the region, and the rest of world



Data accessed on 27 Jan 2021

For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods

[a] Rates per 100,000 women per year.

Data Sources:

Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2020). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: https://gco.iarc.fr/today, accessed [27 January 2021].

9.2.7 Oral cavity cancer mortality in China across Eastern Asia

Figure 127: Age-standardised mortality rates of oral cavity cancer of China (estimates for 2020)



Data accessed on 27 Jan 2021

For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods

[a] Rates per 100,000 men per year.

[b] Rates per 100,000 women per year.

Data Sources:

Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2020). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: https://gco.iarc.fr/today, accessed [27 January 2021].

Figure 128: Annual number of deaths of oral cavity cancer among men by age group in China (estimates for 2020)



Data accessed on 27 Jan 2021

For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods

[a] 6 cases for China and 6 cases for Eastern Asia in the 15-19 age group. 4 cases for China and 7 cases for Eastern Asia in the 20-24 age group. 19 cases for China and 31 cases for Eastern Asia in the 25-29 age group. 34 cases for China and 101 cases for Eastern Asia in the 30-34 age group.

Data Sources:

Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2020). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: https://gco.iarc.fr/today, accessed [27 January 2021].

Figure 129: Annual number of deaths of oral cavity cancer among women by age group in China (estimates for 2020)



Data accessed on 27 Jan 2021

For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods

[a] 9 cases for China and 9 cases for Eastern Asia in the 15-19 age group. 10 cases for China and 11 cases for Eastern Asia in the 20-24 age group. 25 cases for China and 30 cases for Eastern Asia in the 25-29 age group. 43 cases for China and 50 cases for Eastern Asia in the 30-34 age group. 37 cases for China and 53 cases for Eastern Asia in the 35-39 age group.

Data Sources:

Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2020). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: https://gco.iarc.fr/today, accessed [27 January 2021].

Figure 130: Comparison of age-specific oral cavity cancer mortality rates among men by age in China, within the region, and the rest of world



Data accessed on 27 Jan 2021

For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods

[a] Rates per 100,000 men per year.

Data Sources:

Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2020). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: https://gco.iarc.fr/today, accessed [27 January 2021].

Figure 131: Comparison of age-specific oral cavity cancer mortality rates among women by age in China, within the region, and the rest of world



Data accessed on 27 Jan 2021

For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods

[a] Rates per 100,000 women per year.

Data Sources:

Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2020). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: https://gco.iarc.fr/today, accessed [27 January 2021].

9.2.8 Laryngeal cancer mortality in China across Eastern Asia

Figure 132: Age-standardised mortality rates of laryngeal cancer of China (estimates for 2020)



Data accessed on 27 Jan 2021

For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods

[a] Rates per 100,000 men per year.

[b] Rates per 100,000 women per year.

Data Sources:

Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2020). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: https://gco.iarc.fr/today, accessed [27 January 2021].

Figure 133: Annual number of deaths of laryngeal cancer among men by age group in China (estimates for 2020)



Data accessed on 27 Jan 2021

For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods

[a] 0 cases for China and 0 cases for Eastern Asia in the 15-19 age group. 3 cases for China and 3 cases for Eastern Asia in the 20-24 age group. 2 cases for China and 2 cases for Eastern Asia in the 25-29 age group. 25 cases for China and 27 cases for Eastern Asia in the 30-34 age group. 47 cases for China and 52 cases for Eastern Asia in the 35-39 age group.

Data Sources:

Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2020). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: https://gco.iarc.fr/today, accessed [27 January 2021].

Figure 134: Annual number of deaths of laryngeal cancer among women by age group in China (estimates for 2020)



Data accessed on 27 Jan 2021

For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods

[a] 3 cases for China and 3 cases for Eastern Asia in the 15-19 age group. 0 cases for China and 0 cases for Eastern Asia in the 20-24 age group. 6 cases for China and 6 cases for Eastern Asia in the 25-29 age group. 10 cases for China and 10 cases for Eastern Asia in the 30-34 age group. 14 cases for China and 14 cases for Eastern Asia in the 35-39 age group. 21 cases for China and 22 cases for Eastern Asia in the 40-44 age group.

Data Sources:

Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2020). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: https://gco.iarc.fr/today, accessed [27 January 2021].

Figure 135: Comparison of age-specific laryngeal cancer mortality rates among men by age in China, within the region, and the rest of world



Data accessed on 27 Jan 2021

For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods

[a] Rates per 100,000 men per year.

Data Sources:

Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2020). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: https://gco.iarc.fr/today, accessed [27 January 2021].

Figure 136: Comparison of age-specific laryngeal cancer mortality rates among women by age in China, within the region, and the rest of world



Data accessed on 27 Jan 2021

For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods

[a] Rates per 100,000 women per year.

Data Sources:

Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2020). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: https://gco.iarc.fr/today, accessed [27 January 2021].

10 Glossary

Table 49: Glossary

Term	Definition
Incidence	Incidence is the number of new cases arising in a given period in a specified population. This information is collected routinely by cancer registries. It can be expressed as an absolute number of cases per year or as a rate per 100,000 persons per year (see Crude rate and ASR below). The rate provides an approximation of the average risk of developing a cancer.
Mortality	Mortality is the number of deaths occurring in a given period in a specified population. It can be expressed as an absolute number of deaths per year or as a rate per 100,000 persons per year.
Prevalence	The prevalence of a particular cancer can be defined as the number of persons in a defined population who have been diagnosed with that type of cancer, and who are still alive at the end of a given year, the survivors. Complete prevalence represents the number of persons alive at certain point in time who previously had a diagnosis of the disease, regardless of how long ago the diagnosis was, or if the patient is still under treatment or is considered cured. Partial prevalence , which limits the number of patients to those diagnosed during a fixed time in the past, is a particularly useful measure of cancer burden. Prevalence of cancers based on cases diagnosed within one, three and five are presented as they are likely to be of relevance to the different stages of cancer therapy, namely, initial treatment (one year), clinical follow-up (three years) and cure (five years). Patients who are still alive five years after diagnosis are usually considered cured since the death rates of such patients are similar to those in the general population. There are exceptions, particularly breast cancer. Prevalence is presented for the adult population only (ages 15 and over), and is available both as numbers and as proportions per 100,000 persons.
Crude rate	Data on incidence or mortality are often presented as rates. For a specific tumour and population, a crude rate is calculated simply by dividing the number of new cancers or cancer deaths observed during a given time period by the corresponding number of person years in the population at risk. For cancer, the result is usually expressed as an annual rate per 100,000 persons at risk.
ASR (age-standardised rate)	An age-standardised rate (ASR) is a summary measure of the rate that a population would have if it had a standard age structure. Standardization is necessary when comparing several populations that differ with respect to age because age has a powerful influence on the risk of cancer. The ASR is a weighted mean of the age-specific rates; the weights are taken from population distribution of the standard population. The most frequently used standard population is the World Standard Population. The calculated incidence or mortality rate is then called age-standardised incidence or mortality rate (world). It is also expressed per 100,000. The world standard population used in GLOBOCAN is as proposed by Segi [1] and modified by Doll and al. [2]. The age-standardised rate is calculated using 10 age-groups. The result may be slightly different from that computed using the same data categorised using the traditional 5 year age bands.

Continued on next page

Table 49 – continued from previous page

Term	Definition
Cumulative risk	Cumulative incidence/mortality is the probability or risk of individuals getting/dying from the disease during a specified period. For cancer, it is expressed as the number of new born children (out of 100, or 1000) who would be expected to develop/die from a particular cancer before the age of 75 if they had the rates of cancer observed in the period in the absence of competing causes.
Cytologically normal women	No abnormal cells are observed on the surface of their cervix upon cytology.
Cervical Intraepithelial Neoplasia (CIN) / Squamous Intraepithelial Lesions (SIL)	SIL and CIN are two commonly used terms to describe precancerous lesions or the abnormal growth of squamous cells observed in the cervix. SIL is an abnormal result derived from cervical cytological screening or Pap smear testing. CIN is a histological diagnosis made upon analysis of cervical tissue obtained by biopsy or surgical excision. The condition is graded as CIN 1, 2 or 3, according to the thickness of the abnormal epithelium (1/3, 2/3 or the entire thickness).
Low-grade cervical lesions (LSIL/CIN-1)	Low-grade cervical lesions are defined by early changes in size, shape, and number of ab-normal cells formed on the surface of the cervix and may be referred to as mild dysplasia, LSIL, or CIN-1.
High-grade cervical lesions (HSIL / CIN-2 / CIN-3 / CIS)	High-grade cervical lesions are defined by a large number of precancerous cells on the sur-face of the cervix that are distinctly different from normal cells. They have the potential to become cancerous cells and invade deeper tissues of the cervix. These lesions may be referred to as moderate or severe dysplasia, HSIL, CIN-2, CIN-3 or cervical carcinoma in situ (CIS).
Carcinoma in situ (CIS)	Preinvasive malignancy limited to the epithelium without invasion of the basement membrane. CIN 3 encompasses the squamous carcinoma in situ.
Invasive cervical cancer (ICC) / Cervical cancer	If the high-grade precancerous cells invade the basement membrane is called ICC. ICC stages range from stage I (cancer is in the cervix or uterus only) to stage IV (the cancer has spread to distant organs, such as the liver).
Adenocarcinoma	Invasive tumour with glandular and squamous elements intermingled

Acknowledgments

This report has been developed by the Unit of Infections and Cancer, Cancer Epidemiology Research Program, at the Institut Català d'Oncologia (ICO, Catalan Institute of Oncology). This report was supported by a grant from the Instituto de Salud Carlos III (Spanish Government) through the projects PI18/01137, PI21/00982, PI22/00219 and CIBERESP CB06/02/0073, and the Secretariat for Universities and Research of the Department of Business and knowledge of the Government of Catalonia grants to support the activities of research groups (SGR 2017–2021) (Grant number 2017SRG1718 and 2021SGR01029). The report has also received funding from the European Union's Horizon 2020 research and innovation program under grant agreement No. 847845. We thank the CERCA Program / Generalitat de Catalunya for institutional support. The HPV Information Centre is being developed by the ICO. The Centre was originally launched by ICO with the collaboration of WHO's Immunisation, Vaccines and Biologicals (IVB) department and support from the Bill and Melinda Gates Foundation.

Cancer Epidemiology Research Program, Catalan Institute of Oncology (ICO), Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), in alphabetic order
Albero G, Amarilla S, Bosch FX, Bruni L, Collado JJ, de Sanjosé S, Gómez D, Mena M, Muñoz J, Ruiz FJ, Serrano B.
International Agency for Research on Cancer (IARC)

Note to the reader

Anyone who is aware of relevant published data that may not have been included in the present report is encouraged to contact the HPV Information Centre for potential contributions.
Although efforts have been made by the HPV Information Centre to prepare and include as accurately as possible the data presented, mistakes may occur. Readers are requested to communicate any errors to the HPV Information Centre, so that corrections can be made in future volumes.

Disclaimer

The information in this database is provided as a service to our users. Any digital or printed publication of the information provided in the web site should be accompanied by an acknowledgment of HPV Information Centre as the source. Systematic retrieval of data to create, directly or indirectly, a scientific publication, collection, database, directory or website requires a permission from HPV Information Centre.
The responsibility for the interpretation and use of the material contained in the HPV Information Centre lies on the user. In no event shall the HPV Information Centre be liable for any damages arising from the use of the information.

Licensed Logo Use

Use, reproduction, copying, or redistribution of HPV Information Centre logo is strictly prohibited without written explicit permission from the HPV Information Centre.

Contact information:
ICO/IARC HPV Information Centre
Institut Català d'Oncologia
Avda. Gran Via de l'Hospitalet, 199-203
08908 L'Hospitalet de Llobregat (Barcelona, Spain)
e-mail: info@hpvcentre.net
internet address: www.hpvcentre.net